{"transactions":[{"id":4633675,"issuer":{"id":183937,"kind":"organization","name":"ADARx Pharmaceuticals, Inc.","symbol":"ADRX"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35791,"kind":"organization","name":"OrbiMed Capital GP VII LLC","position":2,"cik":"0001760648","reported_name":"OrbiMed Capital GP VII LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53132,"kind":"organization","name":"OrbiMed Israel GP II, L.P.","position":3,"cik":"0001682090","reported_name":"OrbiMed Israel GP II, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53131,"kind":"organization","name":"OrbiMed Advisors Israel II Ltd","position":4,"cik":"0001682093","reported_name":"OrbiMed Advisors Israel II Ltd","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24740,"kind":"person","name":"OrbiMed Genesis GP LLC","position":5,"cik":"0001808744","reported_name":"OrbiMed Genesis GP LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series C Preferred Stock","published_at":"2026-10-01T01:23:22.000Z","date":"2026-09-28","kind":"exercise","planned":false,"acquired":false,"shares":256448,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series A Preferred Stock, Series B Preferred Stock, Series B-1 Preferred Stock, and Series C Preferred Stock (collectively, the \"Preferred Stock\") automatically converted on a 1-for-1.1717 basis into shares of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. Share numbers give effect to such conversion. The Preferred Stock has no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series A Preferred Stock, Series B Preferred Stock, Series B-1 Preferred Stock, and Series C Preferred Stock (collectively, the \"Preferred Stock\") automatically converted on a 1-for-1.1717 basis into shares of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. Share numbers give effect to such conversion. The Preferred Stock has no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series A Preferred Stock, Series B Preferred Stock, Series B-1 Preferred Stock, and Series C Preferred Stock (collectively, the \"Preferred Stock\") automatically converted on a 1-for-1.1717 basis into shares of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. Share numbers give effect to such conversion. The Preferred Stock has no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"These securities are held directly by OrbiMed Israel Partners II, L.P. (\"OIP II\"). OrbiMed Israel GP II, L.P. (\"Israel GP\") is the general partner of OIP II. OrbiMed Advisors Israel II Limited (\"Advisors Israel\") is the general partner of Israel GP. By virtue of such relationships, Israel GP and Advisors Israel may be deemed to have voting power and investment power over the securities held by OIP II and as a result, may be deemed to have beneficial ownership over such securities. Advisors Israel exercises this investment and voting power through a management committee comprised of Carl L. Gordon, David P. Bonita, and Erez Chimovits, each of whom disclaims beneficial ownership of the shares held by OIP II."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"This report on Form 4 is jointly filed by OrbiMed Advisors, GP VII, Israel GP, Advisors Israel, and Genesis GP. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. The Reporting Persons have designated Carl L. Gordon, a member of OrbiMed Advisors, and Erez Chimovits, an employee of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any of such entity or person is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":256448},"source":{"system":"sec-edgar","filing":"0000947871-26-000910","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":19,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787126000910/ownership.xml","form_type":"4"}},{"id":4633674,"issuer":{"id":183937,"kind":"organization","name":"ADARx Pharmaceuticals, Inc.","symbol":"ADRX"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35791,"kind":"organization","name":"OrbiMed Capital GP VII LLC","position":2,"cik":"0001760648","reported_name":"OrbiMed Capital GP VII LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53132,"kind":"organization","name":"OrbiMed Israel GP II, L.P.","position":3,"cik":"0001682090","reported_name":"OrbiMed Israel GP II, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53131,"kind":"organization","name":"OrbiMed Advisors Israel II Ltd","position":4,"cik":"0001682093","reported_name":"OrbiMed Advisors Israel II Ltd","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24740,"kind":"person","name":"OrbiMed Genesis GP LLC","position":5,"cik":"0001808744","reported_name":"OrbiMed Genesis GP LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B-1 Preferred Stock","published_at":"2026-10-01T01:23:22.000Z","date":"2026-09-28","kind":"exercise","planned":false,"acquired":false,"shares":513067,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series A Preferred Stock, Series B Preferred Stock, Series B-1 Preferred Stock, and Series C Preferred Stock (collectively, the \"Preferred Stock\") automatically converted on a 1-for-1.1717 basis into shares of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. Share numbers give effect to such conversion. The Preferred Stock has no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series A Preferred Stock, Series B Preferred Stock, Series B-1 Preferred Stock, and Series C Preferred Stock (collectively, the \"Preferred Stock\") automatically converted on a 1-for-1.1717 basis into shares of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. Share numbers give effect to such conversion. The Preferred Stock has no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series A Preferred Stock, Series B Preferred Stock, Series B-1 Preferred Stock, and Series C Preferred Stock (collectively, the \"Preferred Stock\") automatically converted on a 1-for-1.1717 basis into shares of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. Share numbers give effect to such conversion. The Preferred Stock has no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"These securities are held directly by OrbiMed Israel Partners II, L.P. (\"OIP II\"). OrbiMed Israel GP II, L.P. (\"Israel GP\") is the general partner of OIP II. OrbiMed Advisors Israel II Limited (\"Advisors Israel\") is the general partner of Israel GP. By virtue of such relationships, Israel GP and Advisors Israel may be deemed to have voting power and investment power over the securities held by OIP II and as a result, may be deemed to have beneficial ownership over such securities. Advisors Israel exercises this investment and voting power through a management committee comprised of Carl L. Gordon, David P. Bonita, and Erez Chimovits, each of whom disclaims beneficial ownership of the shares held by OIP II."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"This report on Form 4 is jointly filed by OrbiMed Advisors, GP VII, Israel GP, Advisors Israel, and Genesis GP. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. The Reporting Persons have designated Carl L. Gordon, a member of OrbiMed Advisors, and Erez Chimovits, an employee of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any of such entity or person is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":513067},"source":{"system":"sec-edgar","filing":"0000947871-26-000910","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":18,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787126000910/ownership.xml","form_type":"4"}},{"id":4633673,"issuer":{"id":183937,"kind":"organization","name":"ADARx Pharmaceuticals, Inc.","symbol":"ADRX"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35791,"kind":"organization","name":"OrbiMed Capital GP VII LLC","position":2,"cik":"0001760648","reported_name":"OrbiMed Capital GP VII LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53132,"kind":"organization","name":"OrbiMed Israel GP II, L.P.","position":3,"cik":"0001682090","reported_name":"OrbiMed Israel GP II, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53131,"kind":"organization","name":"OrbiMed Advisors Israel II Ltd","position":4,"cik":"0001682093","reported_name":"OrbiMed Advisors Israel II Ltd","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24740,"kind":"person","name":"OrbiMed Genesis GP LLC","position":5,"cik":"0001808744","reported_name":"OrbiMed Genesis GP LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Preferred Stock","published_at":"2026-10-01T01:23:22.000Z","date":"2026-09-28","kind":"exercise","planned":false,"acquired":false,"shares":1333975,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series A Preferred Stock, Series B Preferred Stock, Series B-1 Preferred Stock, and Series C Preferred Stock (collectively, the \"Preferred Stock\") automatically converted on a 1-for-1.1717 basis into shares of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. Share numbers give effect to such conversion. The Preferred Stock has no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series A Preferred Stock, Series B Preferred Stock, Series B-1 Preferred Stock, and Series C Preferred Stock (collectively, the \"Preferred Stock\") automatically converted on a 1-for-1.1717 basis into shares of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. Share numbers give effect to such conversion. The Preferred Stock has no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series A Preferred Stock, Series B Preferred Stock, Series B-1 Preferred Stock, and Series C Preferred Stock (collectively, the \"Preferred Stock\") automatically converted on a 1-for-1.1717 basis into shares of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. Share numbers give effect to such conversion. The Preferred Stock has no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"These securities are held directly by OrbiMed Israel Partners II, L.P. (\"OIP II\"). OrbiMed Israel GP II, L.P. (\"Israel GP\") is the general partner of OIP II. OrbiMed Advisors Israel II Limited (\"Advisors Israel\") is the general partner of Israel GP. By virtue of such relationships, Israel GP and Advisors Israel may be deemed to have voting power and investment power over the securities held by OIP II and as a result, may be deemed to have beneficial ownership over such securities. Advisors Israel exercises this investment and voting power through a management committee comprised of Carl L. Gordon, David P. Bonita, and Erez Chimovits, each of whom disclaims beneficial ownership of the shares held by OIP II."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"This report on Form 4 is jointly filed by OrbiMed Advisors, GP VII, Israel GP, Advisors Israel, and Genesis GP. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. The Reporting Persons have designated Carl L. Gordon, a member of OrbiMed Advisors, and Erez Chimovits, an employee of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any of such entity or person is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1333975},"source":{"system":"sec-edgar","filing":"0000947871-26-000910","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":17,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787126000910/ownership.xml","form_type":"4"}},{"id":4633672,"issuer":{"id":183937,"kind":"organization","name":"ADARx Pharmaceuticals, Inc.","symbol":"ADRX"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35791,"kind":"organization","name":"OrbiMed Capital GP VII LLC","position":2,"cik":"0001760648","reported_name":"OrbiMed Capital GP VII LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53132,"kind":"organization","name":"OrbiMed Israel GP II, L.P.","position":3,"cik":"0001682090","reported_name":"OrbiMed Israel GP II, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53131,"kind":"organization","name":"OrbiMed Advisors Israel II Ltd","position":4,"cik":"0001682093","reported_name":"OrbiMed Advisors Israel II Ltd","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24740,"kind":"person","name":"OrbiMed Genesis GP LLC","position":5,"cik":"0001808744","reported_name":"OrbiMed Genesis GP LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Preferred Stock","published_at":"2026-10-01T01:23:22.000Z","date":"2026-09-28","kind":"exercise","planned":false,"acquired":false,"shares":7127019,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series A Preferred Stock, Series B Preferred Stock, Series B-1 Preferred Stock, and Series C Preferred Stock (collectively, the \"Preferred Stock\") automatically converted on a 1-for-1.1717 basis into shares of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. Share numbers give effect to such conversion. The Preferred Stock has no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series A Preferred Stock, Series B Preferred Stock, Series B-1 Preferred Stock, and Series C Preferred Stock (collectively, the \"Preferred Stock\") automatically converted on a 1-for-1.1717 basis into shares of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. Share numbers give effect to such conversion. The Preferred Stock has no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series A Preferred Stock, Series B Preferred Stock, Series B-1 Preferred Stock, and Series C Preferred Stock (collectively, the \"Preferred Stock\") automatically converted on a 1-for-1.1717 basis into shares of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. Share numbers give effect to such conversion. The Preferred Stock has no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"These securities are held directly by OrbiMed Israel Partners II, L.P. (\"OIP II\"). OrbiMed Israel GP II, L.P. (\"Israel GP\") is the general partner of OIP II. OrbiMed Advisors Israel II Limited (\"Advisors Israel\") is the general partner of Israel GP. By virtue of such relationships, Israel GP and Advisors Israel may be deemed to have voting power and investment power over the securities held by OIP II and as a result, may be deemed to have beneficial ownership over such securities. Advisors Israel exercises this investment and voting power through a management committee comprised of Carl L. Gordon, David P. Bonita, and Erez Chimovits, each of whom disclaims beneficial ownership of the shares held by OIP II."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"This report on Form 4 is jointly filed by OrbiMed Advisors, GP VII, Israel GP, Advisors Israel, and Genesis GP. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. The Reporting Persons have designated Carl L. Gordon, a member of OrbiMed Advisors, and Erez Chimovits, an employee of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any of such entity or person is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":7127019},"source":{"system":"sec-edgar","filing":"0000947871-26-000910","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":16,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787126000910/ownership.xml","form_type":"4"}},{"id":4633671,"issuer":{"id":183937,"kind":"organization","name":"ADARx Pharmaceuticals, Inc.","symbol":"ADRX"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35791,"kind":"organization","name":"OrbiMed Capital GP VII LLC","position":2,"cik":"0001760648","reported_name":"OrbiMed Capital GP VII LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53132,"kind":"organization","name":"OrbiMed Israel GP II, L.P.","position":3,"cik":"0001682090","reported_name":"OrbiMed Israel GP II, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53131,"kind":"organization","name":"OrbiMed Advisors Israel II Ltd","position":4,"cik":"0001682093","reported_name":"OrbiMed Advisors Israel II Ltd","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24740,"kind":"person","name":"OrbiMed Genesis GP LLC","position":5,"cik":"0001808744","reported_name":"OrbiMed Genesis GP LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series C Preferred Stock","published_at":"2026-10-01T01:23:22.000Z","date":"2026-09-28","kind":"exercise","planned":false,"acquired":false,"shares":564187,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series A Preferred Stock, Series B Preferred Stock, Series B-1 Preferred Stock, and Series C Preferred Stock (collectively, the \"Preferred Stock\") automatically converted on a 1-for-1.1717 basis into shares of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. Share numbers give effect to such conversion. The Preferred Stock has no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series A Preferred Stock, Series B Preferred Stock, Series B-1 Preferred Stock, and Series C Preferred Stock (collectively, the \"Preferred Stock\") automatically converted on a 1-for-1.1717 basis into shares of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. Share numbers give effect to such conversion. The Preferred Stock has no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series A Preferred Stock, Series B Preferred Stock, Series B-1 Preferred Stock, and Series C Preferred Stock (collectively, the \"Preferred Stock\") automatically converted on a 1-for-1.1717 basis into shares of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. Share numbers give effect to such conversion. The Preferred Stock has no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These securities are held directly by OrbiMed Private Investments VII, LP (\"OPI VII\"). OrbiMed Capital GP VII LLC (\"GP VII\") is the general partner of OPI VII. OrbiMed Advisors LLC (\"OrbiMed Advisors\") is the managing member of GP VII. By virtue of such relationships, GP VII and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by OPI VII and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, W. Carter Neild, and Geoffrey C. Hsu, each of whom disclaims beneficial ownership of the shares held by OPI VII."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"This report on Form 4 is jointly filed by OrbiMed Advisors, GP VII, Israel GP, Advisors Israel, and Genesis GP. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. The Reporting Persons have designated Carl L. Gordon, a member of OrbiMed Advisors, and Erez Chimovits, an employee of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any of such entity or person is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":564187},"source":{"system":"sec-edgar","filing":"0000947871-26-000910","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":15,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787126000910/ownership.xml","form_type":"4"}},{"id":4633670,"issuer":{"id":183937,"kind":"organization","name":"ADARx Pharmaceuticals, Inc.","symbol":"ADRX"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35791,"kind":"organization","name":"OrbiMed Capital GP VII LLC","position":2,"cik":"0001760648","reported_name":"OrbiMed Capital GP VII LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53132,"kind":"organization","name":"OrbiMed Israel GP II, L.P.","position":3,"cik":"0001682090","reported_name":"OrbiMed Israel GP II, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53131,"kind":"organization","name":"OrbiMed Advisors Israel II Ltd","position":4,"cik":"0001682093","reported_name":"OrbiMed Advisors Israel II Ltd","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24740,"kind":"person","name":"OrbiMed Genesis GP LLC","position":5,"cik":"0001808744","reported_name":"OrbiMed Genesis GP LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B-1 Preferred Stock","published_at":"2026-10-01T01:23:22.000Z","date":"2026-09-28","kind":"exercise","planned":false,"acquired":false,"shares":769601,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series A Preferred Stock, Series B Preferred Stock, Series B-1 Preferred Stock, and Series C Preferred Stock (collectively, the \"Preferred Stock\") automatically converted on a 1-for-1.1717 basis into shares of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. Share numbers give effect to such conversion. The Preferred Stock has no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series A Preferred Stock, Series B Preferred Stock, Series B-1 Preferred Stock, and Series C Preferred Stock (collectively, the \"Preferred Stock\") automatically converted on a 1-for-1.1717 basis into shares of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. Share numbers give effect to such conversion. The Preferred Stock has no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series A Preferred Stock, Series B Preferred Stock, Series B-1 Preferred Stock, and Series C Preferred Stock (collectively, the \"Preferred Stock\") automatically converted on a 1-for-1.1717 basis into shares of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. Share numbers give effect to such conversion. The Preferred Stock has no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These securities are held directly by OrbiMed Private Investments VII, LP (\"OPI VII\"). OrbiMed Capital GP VII LLC (\"GP VII\") is the general partner of OPI VII. OrbiMed Advisors LLC (\"OrbiMed Advisors\") is the managing member of GP VII. By virtue of such relationships, GP VII and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by OPI VII and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, W. Carter Neild, and Geoffrey C. Hsu, each of whom disclaims beneficial ownership of the shares held by OPI VII."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"This report on Form 4 is jointly filed by OrbiMed Advisors, GP VII, Israel GP, Advisors Israel, and Genesis GP. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. The Reporting Persons have designated Carl L. Gordon, a member of OrbiMed Advisors, and Erez Chimovits, an employee of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any of such entity or person is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":769601},"source":{"system":"sec-edgar","filing":"0000947871-26-000910","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787126000910/ownership.xml","form_type":"4"}},{"id":4633669,"issuer":{"id":183937,"kind":"organization","name":"ADARx Pharmaceuticals, Inc.","symbol":"ADRX"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35791,"kind":"organization","name":"OrbiMed Capital GP VII LLC","position":2,"cik":"0001760648","reported_name":"OrbiMed Capital GP VII LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53132,"kind":"organization","name":"OrbiMed Israel GP II, L.P.","position":3,"cik":"0001682090","reported_name":"OrbiMed Israel GP II, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53131,"kind":"organization","name":"OrbiMed Advisors Israel II Ltd","position":4,"cik":"0001682093","reported_name":"OrbiMed Advisors Israel II Ltd","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24740,"kind":"person","name":"OrbiMed Genesis GP LLC","position":5,"cik":"0001808744","reported_name":"OrbiMed Genesis GP LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Preferred Stock","published_at":"2026-10-01T01:23:22.000Z","date":"2026-09-28","kind":"exercise","planned":false,"acquired":false,"shares":2000962,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series A Preferred Stock, Series B Preferred Stock, Series B-1 Preferred Stock, and Series C Preferred Stock (collectively, the \"Preferred Stock\") automatically converted on a 1-for-1.1717 basis into shares of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. Share numbers give effect to such conversion. The Preferred Stock has no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series A Preferred Stock, Series B Preferred Stock, Series B-1 Preferred Stock, and Series C Preferred Stock (collectively, the \"Preferred Stock\") automatically converted on a 1-for-1.1717 basis into shares of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. Share numbers give effect to such conversion. The Preferred Stock has no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series A Preferred Stock, Series B Preferred Stock, Series B-1 Preferred Stock, and Series C Preferred Stock (collectively, the \"Preferred Stock\") automatically converted on a 1-for-1.1717 basis into shares of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. Share numbers give effect to such conversion. The Preferred Stock has no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These securities are held directly by OrbiMed Private Investments VII, LP (\"OPI VII\"). OrbiMed Capital GP VII LLC (\"GP VII\") is the general partner of OPI VII. OrbiMed Advisors LLC (\"OrbiMed Advisors\") is the managing member of GP VII. By virtue of such relationships, GP VII and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by OPI VII and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, W. Carter Neild, and Geoffrey C. Hsu, each of whom disclaims beneficial ownership of the shares held by OPI VII."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"This report on Form 4 is jointly filed by OrbiMed Advisors, GP VII, Israel GP, Advisors Israel, and Genesis GP. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. The Reporting Persons have designated Carl L. Gordon, a member of OrbiMed Advisors, and Erez Chimovits, an employee of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any of such entity or person is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":2000962},"source":{"system":"sec-edgar","filing":"0000947871-26-000910","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787126000910/ownership.xml","form_type":"4"}},{"id":4633668,"issuer":{"id":183937,"kind":"organization","name":"ADARx Pharmaceuticals, Inc.","symbol":"ADRX"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35791,"kind":"organization","name":"OrbiMed Capital GP VII LLC","position":2,"cik":"0001760648","reported_name":"OrbiMed Capital GP VII LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53132,"kind":"organization","name":"OrbiMed Israel GP II, L.P.","position":3,"cik":"0001682090","reported_name":"OrbiMed Israel GP II, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53131,"kind":"organization","name":"OrbiMed Advisors Israel II Ltd","position":4,"cik":"0001682093","reported_name":"OrbiMed Advisors Israel II Ltd","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24740,"kind":"person","name":"OrbiMed Genesis GP LLC","position":5,"cik":"0001808744","reported_name":"OrbiMed Genesis GP LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Preferred Stock","published_at":"2026-10-01T01:23:22.000Z","date":"2026-09-28","kind":"exercise","planned":false,"acquired":false,"shares":10690530,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series A Preferred Stock, Series B Preferred Stock, Series B-1 Preferred Stock, and Series C Preferred Stock (collectively, the \"Preferred Stock\") automatically converted on a 1-for-1.1717 basis into shares of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. Share numbers give effect to such conversion. The Preferred Stock has no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series A Preferred Stock, Series B Preferred Stock, Series B-1 Preferred Stock, and Series C Preferred Stock (collectively, the \"Preferred Stock\") automatically converted on a 1-for-1.1717 basis into shares of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. Share numbers give effect to such conversion. The Preferred Stock has no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series A Preferred Stock, Series B Preferred Stock, Series B-1 Preferred Stock, and Series C Preferred Stock (collectively, the \"Preferred Stock\") automatically converted on a 1-for-1.1717 basis into shares of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. Share numbers give effect to such conversion. The Preferred Stock has no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These securities are held directly by OrbiMed Private Investments VII, LP (\"OPI VII\"). OrbiMed Capital GP VII LLC (\"GP VII\") is the general partner of OPI VII. OrbiMed Advisors LLC (\"OrbiMed Advisors\") is the managing member of GP VII. By virtue of such relationships, GP VII and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by OPI VII and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, W. Carter Neild, and Geoffrey C. Hsu, each of whom disclaims beneficial ownership of the shares held by OPI VII."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"This report on Form 4 is jointly filed by OrbiMed Advisors, GP VII, Israel GP, Advisors Israel, and Genesis GP. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. The Reporting Persons have designated Carl L. Gordon, a member of OrbiMed Advisors, and Erez Chimovits, an employee of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any of such entity or person is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":10690530},"source":{"system":"sec-edgar","filing":"0000947871-26-000910","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787126000910/ownership.xml","form_type":"4"}},{"id":4633667,"issuer":{"id":183937,"kind":"organization","name":"ADARx Pharmaceuticals, Inc.","symbol":"ADRX"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35791,"kind":"organization","name":"OrbiMed Capital GP VII LLC","position":2,"cik":"0001760648","reported_name":"OrbiMed Capital GP VII LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53132,"kind":"organization","name":"OrbiMed Israel GP II, L.P.","position":3,"cik":"0001682090","reported_name":"OrbiMed Israel GP II, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53131,"kind":"organization","name":"OrbiMed Advisors Israel II Ltd","position":4,"cik":"0001682093","reported_name":"OrbiMed Advisors Israel II Ltd","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24740,"kind":"person","name":"OrbiMed Genesis GP LLC","position":5,"cik":"0001808744","reported_name":"OrbiMed Genesis GP LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-10-01T01:23:22.000Z","date":"2026-09-28","kind":"purchase","planned":false,"acquired":true,"shares":588235,"price":17,"value":9999995.0,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Reflects shares of the Issuer's Common Stock purchased in the Issuer's initial public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"These securities are held directly by OrbiMed Genesis Master Fund, L.P. (\"OrbiMed Genesis\"). OrbiMed Genesis GP LLC (\"Genesis GP\") is the general partner of OrbiMed Genesis. OrbiMed Advisors is the managing member of Genesis GP. By virtue of such relationships, Genesis GP and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by OrbiMed Genesis and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, W. Carter Neild, and Geoffrey C. Hsu, each of whom disclaims beneficial ownership of the shares held by OrbiMed Genesis."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"This report on Form 4 is jointly filed by OrbiMed Advisors, GP VII, Israel GP, Advisors Israel, and Genesis GP. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. The Reporting Persons have designated Carl L. Gordon, a member of OrbiMed Advisors, and Erez Chimovits, an employee of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any of such entity or person is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":588235,"source":{"system":"sec-edgar","filing":"0000947871-26-000910","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787126000910/ownership.xml","form_type":"4"}},{"id":4633666,"issuer":{"id":183937,"kind":"organization","name":"ADARx Pharmaceuticals, Inc.","symbol":"ADRX"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35791,"kind":"organization","name":"OrbiMed Capital GP VII LLC","position":2,"cik":"0001760648","reported_name":"OrbiMed Capital GP VII LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53132,"kind":"organization","name":"OrbiMed Israel GP II, L.P.","position":3,"cik":"0001682090","reported_name":"OrbiMed Israel GP II, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53131,"kind":"organization","name":"OrbiMed Advisors Israel II Ltd","position":4,"cik":"0001682093","reported_name":"OrbiMed Advisors Israel II Ltd","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24740,"kind":"person","name":"OrbiMed Genesis GP LLC","position":5,"cik":"0001808744","reported_name":"OrbiMed Genesis GP LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-10-01T01:23:22.000Z","date":"2026-09-28","kind":"purchase","planned":false,"acquired":true,"shares":61516,"price":17,"value":1045772.0,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Reflects shares of the Issuer's Common Stock purchased in the Issuer's initial public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"These securities are held directly by OrbiMed Israel Partners II, L.P. (\"OIP II\"). OrbiMed Israel GP II, L.P. (\"Israel GP\") is the general partner of OIP II. OrbiMed Advisors Israel II Limited (\"Advisors Israel\") is the general partner of Israel GP. By virtue of such relationships, Israel GP and Advisors Israel may be deemed to have voting power and investment power over the securities held by OIP II and as a result, may be deemed to have beneficial ownership over such securities. Advisors Israel exercises this investment and voting power through a management committee comprised of Carl L. Gordon, David P. Bonita, and Erez Chimovits, each of whom disclaims beneficial ownership of the shares held by OIP II."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"This report on Form 4 is jointly filed by OrbiMed Advisors, GP VII, Israel GP, Advisors Israel, and Genesis GP. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. The Reporting Persons have designated Carl L. Gordon, a member of OrbiMed Advisors, and Erez Chimovits, an employee of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any of such entity or person is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":9292025,"source":{"system":"sec-edgar","filing":"0000947871-26-000910","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787126000910/ownership.xml","form_type":"4"}},{"id":4633665,"issuer":{"id":183937,"kind":"organization","name":"ADARx Pharmaceuticals, Inc.","symbol":"ADRX"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35791,"kind":"organization","name":"OrbiMed Capital GP VII LLC","position":2,"cik":"0001760648","reported_name":"OrbiMed Capital GP VII LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53132,"kind":"organization","name":"OrbiMed Israel GP II, L.P.","position":3,"cik":"0001682090","reported_name":"OrbiMed Israel GP II, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53131,"kind":"organization","name":"OrbiMed Advisors Israel II Ltd","position":4,"cik":"0001682093","reported_name":"OrbiMed Advisors Israel II Ltd","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24740,"kind":"person","name":"OrbiMed Genesis GP LLC","position":5,"cik":"0001808744","reported_name":"OrbiMed Genesis GP LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-10-01T01:23:22.000Z","date":"2026-09-28","kind":"exercise","planned":false,"acquired":true,"shares":256448,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series A Preferred Stock, Series B Preferred Stock, Series B-1 Preferred Stock, and Series C Preferred Stock (collectively, the \"Preferred Stock\") automatically converted on a 1-for-1.1717 basis into shares of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. Share numbers give effect to such conversion. The Preferred Stock has no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"These securities are held directly by OrbiMed Israel Partners II, L.P. (\"OIP II\"). OrbiMed Israel GP II, L.P. (\"Israel GP\") is the general partner of OIP II. OrbiMed Advisors Israel II Limited (\"Advisors Israel\") is the general partner of Israel GP. By virtue of such relationships, Israel GP and Advisors Israel may be deemed to have voting power and investment power over the securities held by OIP II and as a result, may be deemed to have beneficial ownership over such securities. Advisors Israel exercises this investment and voting power through a management committee comprised of Carl L. Gordon, David P. Bonita, and Erez Chimovits, each of whom disclaims beneficial ownership of the shares held by OIP II."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"This report on Form 4 is jointly filed by OrbiMed Advisors, GP VII, Israel GP, Advisors Israel, and Genesis GP. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. The Reporting Persons have designated Carl L. Gordon, a member of OrbiMed Advisors, and Erez Chimovits, an employee of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any of such entity or person is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":9230509,"source":{"system":"sec-edgar","filing":"0000947871-26-000910","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787126000910/ownership.xml","form_type":"4"}},{"id":4633664,"issuer":{"id":183937,"kind":"organization","name":"ADARx Pharmaceuticals, Inc.","symbol":"ADRX"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35791,"kind":"organization","name":"OrbiMed Capital GP VII LLC","position":2,"cik":"0001760648","reported_name":"OrbiMed Capital GP VII LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53132,"kind":"organization","name":"OrbiMed Israel GP II, L.P.","position":3,"cik":"0001682090","reported_name":"OrbiMed Israel GP II, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53131,"kind":"organization","name":"OrbiMed Advisors Israel II Ltd","position":4,"cik":"0001682093","reported_name":"OrbiMed Advisors Israel II Ltd","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24740,"kind":"person","name":"OrbiMed Genesis GP LLC","position":5,"cik":"0001808744","reported_name":"OrbiMed Genesis GP LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-10-01T01:23:22.000Z","date":"2026-09-28","kind":"exercise","planned":false,"acquired":true,"shares":513067,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series A Preferred Stock, Series B Preferred Stock, Series B-1 Preferred Stock, and Series C Preferred Stock (collectively, the \"Preferred Stock\") automatically converted on a 1-for-1.1717 basis into shares of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. Share numbers give effect to such conversion. The Preferred Stock has no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"These securities are held directly by OrbiMed Israel Partners II, L.P. (\"OIP II\"). OrbiMed Israel GP II, L.P. (\"Israel GP\") is the general partner of OIP II. OrbiMed Advisors Israel II Limited (\"Advisors Israel\") is the general partner of Israel GP. By virtue of such relationships, Israel GP and Advisors Israel may be deemed to have voting power and investment power over the securities held by OIP II and as a result, may be deemed to have beneficial ownership over such securities. Advisors Israel exercises this investment and voting power through a management committee comprised of Carl L. Gordon, David P. Bonita, and Erez Chimovits, each of whom disclaims beneficial ownership of the shares held by OIP II."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"This report on Form 4 is jointly filed by OrbiMed Advisors, GP VII, Israel GP, Advisors Israel, and Genesis GP. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. The Reporting Persons have designated Carl L. Gordon, a member of OrbiMed Advisors, and Erez Chimovits, an employee of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any of such entity or person is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":8974061,"source":{"system":"sec-edgar","filing":"0000947871-26-000910","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787126000910/ownership.xml","form_type":"4"}},{"id":4633663,"issuer":{"id":183937,"kind":"organization","name":"ADARx Pharmaceuticals, Inc.","symbol":"ADRX"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35791,"kind":"organization","name":"OrbiMed Capital GP VII LLC","position":2,"cik":"0001760648","reported_name":"OrbiMed Capital GP VII LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53132,"kind":"organization","name":"OrbiMed Israel GP II, L.P.","position":3,"cik":"0001682090","reported_name":"OrbiMed Israel GP II, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53131,"kind":"organization","name":"OrbiMed Advisors Israel II Ltd","position":4,"cik":"0001682093","reported_name":"OrbiMed Advisors Israel II Ltd","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24740,"kind":"person","name":"OrbiMed Genesis GP LLC","position":5,"cik":"0001808744","reported_name":"OrbiMed Genesis GP LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-10-01T01:23:22.000Z","date":"2026-09-28","kind":"exercise","planned":false,"acquired":true,"shares":1333975,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series A Preferred Stock, Series B Preferred Stock, Series B-1 Preferred Stock, and Series C Preferred Stock (collectively, the \"Preferred Stock\") automatically converted on a 1-for-1.1717 basis into shares of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. Share numbers give effect to such conversion. The Preferred Stock has no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"These securities are held directly by OrbiMed Israel Partners II, L.P. (\"OIP II\"). OrbiMed Israel GP II, L.P. (\"Israel GP\") is the general partner of OIP II. OrbiMed Advisors Israel II Limited (\"Advisors Israel\") is the general partner of Israel GP. By virtue of such relationships, Israel GP and Advisors Israel may be deemed to have voting power and investment power over the securities held by OIP II and as a result, may be deemed to have beneficial ownership over such securities. Advisors Israel exercises this investment and voting power through a management committee comprised of Carl L. Gordon, David P. Bonita, and Erez Chimovits, each of whom disclaims beneficial ownership of the shares held by OIP II."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"This report on Form 4 is jointly filed by OrbiMed Advisors, GP VII, Israel GP, Advisors Israel, and Genesis GP. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. The Reporting Persons have designated Carl L. Gordon, a member of OrbiMed Advisors, and Erez Chimovits, an employee of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any of such entity or person is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":8460994,"source":{"system":"sec-edgar","filing":"0000947871-26-000910","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787126000910/ownership.xml","form_type":"4"}},{"id":4633662,"issuer":{"id":183937,"kind":"organization","name":"ADARx Pharmaceuticals, Inc.","symbol":"ADRX"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35791,"kind":"organization","name":"OrbiMed Capital GP VII LLC","position":2,"cik":"0001760648","reported_name":"OrbiMed Capital GP VII LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53132,"kind":"organization","name":"OrbiMed Israel GP II, L.P.","position":3,"cik":"0001682090","reported_name":"OrbiMed Israel GP II, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53131,"kind":"organization","name":"OrbiMed Advisors Israel II Ltd","position":4,"cik":"0001682093","reported_name":"OrbiMed Advisors Israel II Ltd","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24740,"kind":"person","name":"OrbiMed Genesis GP LLC","position":5,"cik":"0001808744","reported_name":"OrbiMed Genesis GP LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-10-01T01:23:22.000Z","date":"2026-09-28","kind":"exercise","planned":false,"acquired":true,"shares":7127019,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series A Preferred Stock, Series B Preferred Stock, Series B-1 Preferred Stock, and Series C Preferred Stock (collectively, the \"Preferred Stock\") automatically converted on a 1-for-1.1717 basis into shares of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. Share numbers give effect to such conversion. The Preferred Stock has no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"These securities are held directly by OrbiMed Israel Partners II, L.P. (\"OIP II\"). OrbiMed Israel GP II, L.P. (\"Israel GP\") is the general partner of OIP II. OrbiMed Advisors Israel II Limited (\"Advisors Israel\") is the general partner of Israel GP. By virtue of such relationships, Israel GP and Advisors Israel may be deemed to have voting power and investment power over the securities held by OIP II and as a result, may be deemed to have beneficial ownership over such securities. Advisors Israel exercises this investment and voting power through a management committee comprised of Carl L. Gordon, David P. Bonita, and Erez Chimovits, each of whom disclaims beneficial ownership of the shares held by OIP II."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"This report on Form 4 is jointly filed by OrbiMed Advisors, GP VII, Israel GP, Advisors Israel, and Genesis GP. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. The Reporting Persons have designated Carl L. Gordon, a member of OrbiMed Advisors, and Erez Chimovits, an employee of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any of such entity or person is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":7127019,"source":{"system":"sec-edgar","filing":"0000947871-26-000910","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787126000910/ownership.xml","form_type":"4"}},{"id":4633661,"issuer":{"id":183937,"kind":"organization","name":"ADARx Pharmaceuticals, Inc.","symbol":"ADRX"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35791,"kind":"organization","name":"OrbiMed Capital GP VII LLC","position":2,"cik":"0001760648","reported_name":"OrbiMed Capital GP VII LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53132,"kind":"organization","name":"OrbiMed Israel GP II, L.P.","position":3,"cik":"0001682090","reported_name":"OrbiMed Israel GP II, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53131,"kind":"organization","name":"OrbiMed Advisors Israel II Ltd","position":4,"cik":"0001682093","reported_name":"OrbiMed Advisors Israel II Ltd","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24740,"kind":"person","name":"OrbiMed Genesis GP LLC","position":5,"cik":"0001808744","reported_name":"OrbiMed Genesis GP LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-10-01T01:23:22.000Z","date":"2026-09-28","kind":"purchase","planned":false,"acquired":true,"shares":300249,"price":17,"value":5104233.0,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Reflects shares of the Issuer's Common Stock purchased in the Issuer's initial public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These securities are held directly by OrbiMed Private Investments VII, LP (\"OPI VII\"). OrbiMed Capital GP VII LLC (\"GP VII\") is the general partner of OPI VII. OrbiMed Advisors LLC (\"OrbiMed Advisors\") is the managing member of GP VII. By virtue of such relationships, GP VII and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by OPI VII and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, W. Carter Neild, and Geoffrey C. Hsu, each of whom disclaims beneficial ownership of the shares held by OPI VII."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"This report on Form 4 is jointly filed by OrbiMed Advisors, GP VII, Israel GP, Advisors Israel, and Genesis GP. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. The Reporting Persons have designated Carl L. Gordon, a member of OrbiMed Advisors, and Erez Chimovits, an employee of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any of such entity or person is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":14325529,"source":{"system":"sec-edgar","filing":"0000947871-26-000910","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787126000910/ownership.xml","form_type":"4"}},{"id":4633660,"issuer":{"id":183937,"kind":"organization","name":"ADARx Pharmaceuticals, Inc.","symbol":"ADRX"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35791,"kind":"organization","name":"OrbiMed Capital GP VII LLC","position":2,"cik":"0001760648","reported_name":"OrbiMed Capital GP VII LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53132,"kind":"organization","name":"OrbiMed Israel GP II, L.P.","position":3,"cik":"0001682090","reported_name":"OrbiMed Israel GP II, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53131,"kind":"organization","name":"OrbiMed Advisors Israel II Ltd","position":4,"cik":"0001682093","reported_name":"OrbiMed Advisors Israel II Ltd","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24740,"kind":"person","name":"OrbiMed Genesis GP LLC","position":5,"cik":"0001808744","reported_name":"OrbiMed Genesis GP LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-10-01T01:23:22.000Z","date":"2026-09-28","kind":"exercise","planned":false,"acquired":true,"shares":564187,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series A Preferred Stock, Series B Preferred Stock, Series B-1 Preferred Stock, and Series C Preferred Stock (collectively, the \"Preferred Stock\") automatically converted on a 1-for-1.1717 basis into shares of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. Share numbers give effect to such conversion. The Preferred Stock has no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These securities are held directly by OrbiMed Private Investments VII, LP (\"OPI VII\"). OrbiMed Capital GP VII LLC (\"GP VII\") is the general partner of OPI VII. OrbiMed Advisors LLC (\"OrbiMed Advisors\") is the managing member of GP VII. By virtue of such relationships, GP VII and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by OPI VII and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, W. Carter Neild, and Geoffrey C. Hsu, each of whom disclaims beneficial ownership of the shares held by OPI VII."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"This report on Form 4 is jointly filed by OrbiMed Advisors, GP VII, Israel GP, Advisors Israel, and Genesis GP. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. The Reporting Persons have designated Carl L. Gordon, a member of OrbiMed Advisors, and Erez Chimovits, an employee of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any of such entity or person is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":14025280,"source":{"system":"sec-edgar","filing":"0000947871-26-000910","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787126000910/ownership.xml","form_type":"4"}},{"id":4633659,"issuer":{"id":183937,"kind":"organization","name":"ADARx Pharmaceuticals, Inc.","symbol":"ADRX"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35791,"kind":"organization","name":"OrbiMed Capital GP VII LLC","position":2,"cik":"0001760648","reported_name":"OrbiMed Capital GP VII LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53132,"kind":"organization","name":"OrbiMed Israel GP II, L.P.","position":3,"cik":"0001682090","reported_name":"OrbiMed Israel GP II, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53131,"kind":"organization","name":"OrbiMed Advisors Israel II Ltd","position":4,"cik":"0001682093","reported_name":"OrbiMed Advisors Israel II Ltd","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24740,"kind":"person","name":"OrbiMed Genesis GP LLC","position":5,"cik":"0001808744","reported_name":"OrbiMed Genesis GP LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-10-01T01:23:22.000Z","date":"2026-09-28","kind":"exercise","planned":false,"acquired":true,"shares":769601,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series A Preferred Stock, Series B Preferred Stock, Series B-1 Preferred Stock, and Series C Preferred Stock (collectively, the \"Preferred Stock\") automatically converted on a 1-for-1.1717 basis into shares of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. Share numbers give effect to such conversion. The Preferred Stock has no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These securities are held directly by OrbiMed Private Investments VII, LP (\"OPI VII\"). OrbiMed Capital GP VII LLC (\"GP VII\") is the general partner of OPI VII. OrbiMed Advisors LLC (\"OrbiMed Advisors\") is the managing member of GP VII. By virtue of such relationships, GP VII and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by OPI VII and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, W. Carter Neild, and Geoffrey C. Hsu, each of whom disclaims beneficial ownership of the shares held by OPI VII."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"This report on Form 4 is jointly filed by OrbiMed Advisors, GP VII, Israel GP, Advisors Israel, and Genesis GP. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. The Reporting Persons have designated Carl L. Gordon, a member of OrbiMed Advisors, and Erez Chimovits, an employee of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any of such entity or person is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":13461093,"source":{"system":"sec-edgar","filing":"0000947871-26-000910","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787126000910/ownership.xml","form_type":"4"}},{"id":4633658,"issuer":{"id":183937,"kind":"organization","name":"ADARx Pharmaceuticals, Inc.","symbol":"ADRX"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35791,"kind":"organization","name":"OrbiMed Capital GP VII LLC","position":2,"cik":"0001760648","reported_name":"OrbiMed Capital GP VII LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53132,"kind":"organization","name":"OrbiMed Israel GP II, L.P.","position":3,"cik":"0001682090","reported_name":"OrbiMed Israel GP II, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53131,"kind":"organization","name":"OrbiMed Advisors Israel II Ltd","position":4,"cik":"0001682093","reported_name":"OrbiMed Advisors Israel II Ltd","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24740,"kind":"person","name":"OrbiMed Genesis GP LLC","position":5,"cik":"0001808744","reported_name":"OrbiMed Genesis GP LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-10-01T01:23:22.000Z","date":"2026-09-28","kind":"exercise","planned":false,"acquired":true,"shares":2000962,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series A Preferred Stock, Series B Preferred Stock, Series B-1 Preferred Stock, and Series C Preferred Stock (collectively, the \"Preferred Stock\") automatically converted on a 1-for-1.1717 basis into shares of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. Share numbers give effect to such conversion. The Preferred Stock has no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These securities are held directly by OrbiMed Private Investments VII, LP (\"OPI VII\"). OrbiMed Capital GP VII LLC (\"GP VII\") is the general partner of OPI VII. OrbiMed Advisors LLC (\"OrbiMed Advisors\") is the managing member of GP VII. By virtue of such relationships, GP VII and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by OPI VII and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, W. Carter Neild, and Geoffrey C. Hsu, each of whom disclaims beneficial ownership of the shares held by OPI VII."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"This report on Form 4 is jointly filed by OrbiMed Advisors, GP VII, Israel GP, Advisors Israel, and Genesis GP. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. The Reporting Persons have designated Carl L. Gordon, a member of OrbiMed Advisors, and Erez Chimovits, an employee of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any of such entity or person is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":12691492,"source":{"system":"sec-edgar","filing":"0000947871-26-000910","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787126000910/ownership.xml","form_type":"4"}},{"id":4633657,"issuer":{"id":183937,"kind":"organization","name":"ADARx Pharmaceuticals, Inc.","symbol":"ADRX"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35791,"kind":"organization","name":"OrbiMed Capital GP VII LLC","position":2,"cik":"0001760648","reported_name":"OrbiMed Capital GP VII LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53132,"kind":"organization","name":"OrbiMed Israel GP II, L.P.","position":3,"cik":"0001682090","reported_name":"OrbiMed Israel GP II, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53131,"kind":"organization","name":"OrbiMed Advisors Israel II Ltd","position":4,"cik":"0001682093","reported_name":"OrbiMed Advisors Israel II Ltd","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24740,"kind":"person","name":"OrbiMed Genesis GP LLC","position":5,"cik":"0001808744","reported_name":"OrbiMed Genesis GP LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-10-01T01:23:22.000Z","date":"2026-09-28","kind":"exercise","planned":false,"acquired":true,"shares":10690530,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series A Preferred Stock, Series B Preferred Stock, Series B-1 Preferred Stock, and Series C Preferred Stock (collectively, the \"Preferred Stock\") automatically converted on a 1-for-1.1717 basis into shares of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. Share numbers give effect to such conversion. The Preferred Stock has no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These securities are held directly by OrbiMed Private Investments VII, LP (\"OPI VII\"). OrbiMed Capital GP VII LLC (\"GP VII\") is the general partner of OPI VII. OrbiMed Advisors LLC (\"OrbiMed Advisors\") is the managing member of GP VII. By virtue of such relationships, GP VII and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by OPI VII and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, W. Carter Neild, and Geoffrey C. Hsu, each of whom disclaims beneficial ownership of the shares held by OPI VII."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"This report on Form 4 is jointly filed by OrbiMed Advisors, GP VII, Israel GP, Advisors Israel, and Genesis GP. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. The Reporting Persons have designated Carl L. Gordon, a member of OrbiMed Advisors, and Erez Chimovits, an employee of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any of such entity or person is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":10690530,"source":{"system":"sec-edgar","filing":"0000947871-26-000910","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787126000910/ownership.xml","form_type":"4"}},{"id":811786,"issuer":{"id":6860,"kind":"organization","name":"Adicet Bio, Inc."},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53130,"kind":"organization","name":"OrbiMed Capital GP V LLC","position":2,"cik":"0001615374","reported_name":"OrbiMed Capital GP V LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51517,"kind":"person","name":"OrbiMed Capital GP VI LLC","position":3,"cik":"0001682115","reported_name":"OrbiMed Capital GP VI LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24740,"kind":"person","name":"OrbiMed Genesis GP LLC","position":4,"cik":"0001808744","reported_name":"OrbiMed Genesis GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53131,"kind":"organization","name":"OrbiMed Advisors Israel II Ltd","position":5,"cik":"0001682093","reported_name":"OrbiMed Advisors Israel II Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53132,"kind":"organization","name":"OrbiMed Israel GP II, L.P.","position":6,"cik":"0001682090","reported_name":"OrbiMed Israel GP II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53133,"kind":"organization","name":"OrbiMed Israel GP Ltd.","position":7,"cik":"0001569590","reported_name":"OrbiMed Israel GP Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53134,"kind":"organization","name":"OrbiMed Israel BioFund GP Limited Partnership","position":8,"cik":"0001569821","reported_name":"OrbiMed Israel BioFund GP Limited Partnership","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-04-09T21:38:36.000Z","date":"2026-04-08","kind":"sale","planned":false,"acquired":false,"shares":40416,"price":6.52,"value":263512.32,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held of record by OrbiMed Israel Partners II, L.P. (\"OIP II\"). OrbiMed Israel GP II, L.P. (\"OrbiMed Israel GP II\") is the general partner of OIP II, and OrbiMed Advisors Israel II Limited (\"OrbiMed Israel II\") is the general partner of OrbiMed Israel GP II. By virtue of such relationships, OrbiMed Israel GP II and OrbiMed Israel II may be deemed to have voting and investment power over the shares of common stock held by OIP II and, as a result, may be deemed to have beneficial ownership over such shares of common stock. OrbiMed Israel II exercises this investment and voting power through an investment committee comprised of Carl L. Gordon, David Bonita, and Erez Chimovits, each of whom disclaims beneficial ownership over the shares of common stock held by OIP II."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"Each of OrbiMed Advisors, OrbiMed BioFund, OrbiMed Israel GP, OrbiMed Israel GP II, OrbiMed Israel II, Genesis GP, GP V, and GP VI disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of his or its pecuniary interest therein, if any. This report shall not be deemed an admission that any such person or entity is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000947871-26-000421","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787126000421/ownership.xml","form_type":"4"}},{"id":811785,"issuer":{"id":6860,"kind":"organization","name":"Adicet Bio, Inc."},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53130,"kind":"organization","name":"OrbiMed Capital GP V LLC","position":2,"cik":"0001615374","reported_name":"OrbiMed Capital GP V LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51517,"kind":"person","name":"OrbiMed Capital GP VI LLC","position":3,"cik":"0001682115","reported_name":"OrbiMed Capital GP VI LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24740,"kind":"person","name":"OrbiMed Genesis GP LLC","position":4,"cik":"0001808744","reported_name":"OrbiMed Genesis GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53131,"kind":"organization","name":"OrbiMed Advisors Israel II Ltd","position":5,"cik":"0001682093","reported_name":"OrbiMed Advisors Israel II Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53132,"kind":"organization","name":"OrbiMed Israel GP II, L.P.","position":6,"cik":"0001682090","reported_name":"OrbiMed Israel GP II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53133,"kind":"organization","name":"OrbiMed Israel GP Ltd.","position":7,"cik":"0001569590","reported_name":"OrbiMed Israel GP Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53134,"kind":"organization","name":"OrbiMed Israel BioFund GP Limited Partnership","position":8,"cik":"0001569821","reported_name":"OrbiMed Israel BioFund GP Limited Partnership","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-04-09T21:38:36.000Z","date":"2026-04-08","kind":"sale","planned":false,"acquired":false,"shares":32523,"price":6.29,"value":204569.67,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"These securities are held of record by OrbiMed Israel Partners Limited Partnership (\"OIP\"). OrbiMed Israel BioFund GP Limited Partnership (\"OrbiMed BioFund\") is the general partner of OIP, and OrbiMed Israel GP Ltd. (\"OrbiMed Israel GP\") is the general partner of OrbiMed BioFund. By virtue of such relationships, OrbiMed BioFund and OrbiMed Israel GP may be deemed to have voting and investment power over the shares of common stock held by OIP and, as a result, may be deemed to have beneficial ownership over such shares of common stock. OrbiMed Israel GP exercises this investment and voting power through an investment committee comprised of Carl L. Gordon and Erez Chimovits, each of whom disclaims beneficial ownership over the shares of common stock held by OIP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"Each of OrbiMed Advisors, OrbiMed BioFund, OrbiMed Israel GP, OrbiMed Israel GP II, OrbiMed Israel II, Genesis GP, GP V, and GP VI disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of his or its pecuniary interest therein, if any. This report shall not be deemed an admission that any such person or entity is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000947871-26-000421","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787126000421/ownership.xml","form_type":"4"}},{"id":811784,"issuer":{"id":6860,"kind":"organization","name":"Adicet Bio, Inc."},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53130,"kind":"organization","name":"OrbiMed Capital GP V LLC","position":2,"cik":"0001615374","reported_name":"OrbiMed Capital GP V LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51517,"kind":"person","name":"OrbiMed Capital GP VI LLC","position":3,"cik":"0001682115","reported_name":"OrbiMed Capital GP VI LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24740,"kind":"person","name":"OrbiMed Genesis GP LLC","position":4,"cik":"0001808744","reported_name":"OrbiMed Genesis GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53131,"kind":"organization","name":"OrbiMed Advisors Israel II Ltd","position":5,"cik":"0001682093","reported_name":"OrbiMed Advisors Israel II Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53132,"kind":"organization","name":"OrbiMed Israel GP II, L.P.","position":6,"cik":"0001682090","reported_name":"OrbiMed Israel GP II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53133,"kind":"organization","name":"OrbiMed Israel GP Ltd.","position":7,"cik":"0001569590","reported_name":"OrbiMed Israel GP Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53134,"kind":"organization","name":"OrbiMed Israel BioFund GP Limited Partnership","position":8,"cik":"0001569821","reported_name":"OrbiMed Israel BioFund GP Limited Partnership","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-04-09T21:38:36.000Z","date":"2026-04-07","kind":"sale","planned":false,"acquired":false,"shares":2400,"price":6.38,"value":15312.0,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"These securities are held of record by OrbiMed Israel Partners Limited Partnership (\"OIP\"). OrbiMed Israel BioFund GP Limited Partnership (\"OrbiMed BioFund\") is the general partner of OIP, and OrbiMed Israel GP Ltd. (\"OrbiMed Israel GP\") is the general partner of OrbiMed BioFund. By virtue of such relationships, OrbiMed BioFund and OrbiMed Israel GP may be deemed to have voting and investment power over the shares of common stock held by OIP and, as a result, may be deemed to have beneficial ownership over such shares of common stock. OrbiMed Israel GP exercises this investment and voting power through an investment committee comprised of Carl L. Gordon and Erez Chimovits, each of whom disclaims beneficial ownership over the shares of common stock held by OIP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"Each of OrbiMed Advisors, OrbiMed BioFund, OrbiMed Israel GP, OrbiMed Israel GP II, OrbiMed Israel II, Genesis GP, GP V, and GP VI disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of his or its pecuniary interest therein, if any. This report shall not be deemed an admission that any such person or entity is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":32523,"source":{"system":"sec-edgar","filing":"0000947871-26-000421","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787126000421/ownership.xml","form_type":"4"}},{"id":811783,"issuer":{"id":6860,"kind":"organization","name":"Adicet Bio, Inc."},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53130,"kind":"organization","name":"OrbiMed Capital GP V LLC","position":2,"cik":"0001615374","reported_name":"OrbiMed Capital GP V LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51517,"kind":"person","name":"OrbiMed Capital GP VI LLC","position":3,"cik":"0001682115","reported_name":"OrbiMed Capital GP VI LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24740,"kind":"person","name":"OrbiMed Genesis GP LLC","position":4,"cik":"0001808744","reported_name":"OrbiMed Genesis GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53131,"kind":"organization","name":"OrbiMed Advisors Israel II Ltd","position":5,"cik":"0001682093","reported_name":"OrbiMed Advisors Israel II Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53132,"kind":"organization","name":"OrbiMed Israel GP II, L.P.","position":6,"cik":"0001682090","reported_name":"OrbiMed Israel GP II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53133,"kind":"organization","name":"OrbiMed Israel GP Ltd.","position":7,"cik":"0001569590","reported_name":"OrbiMed Israel GP Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53134,"kind":"organization","name":"OrbiMed Israel BioFund GP Limited Partnership","position":8,"cik":"0001569821","reported_name":"OrbiMed Israel BioFund GP Limited Partnership","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-04-09T21:38:36.000Z","date":"2026-04-07","kind":"sale","planned":false,"acquired":false,"shares":29319,"price":6.53,"value":191453.07,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"These securities are held of record by OrbiMed Israel Partners Limited Partnership (\"OIP\"). OrbiMed Israel BioFund GP Limited Partnership (\"OrbiMed BioFund\") is the general partner of OIP, and OrbiMed Israel GP Ltd. (\"OrbiMed Israel GP\") is the general partner of OrbiMed BioFund. By virtue of such relationships, OrbiMed BioFund and OrbiMed Israel GP may be deemed to have voting and investment power over the shares of common stock held by OIP and, as a result, may be deemed to have beneficial ownership over such shares of common stock. OrbiMed Israel GP exercises this investment and voting power through an investment committee comprised of Carl L. Gordon and Erez Chimovits, each of whom disclaims beneficial ownership over the shares of common stock held by OIP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"Each of OrbiMed Advisors, OrbiMed BioFund, OrbiMed Israel GP, OrbiMed Israel GP II, OrbiMed Israel II, Genesis GP, GP V, and GP VI disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of his or its pecuniary interest therein, if any. This report shall not be deemed an admission that any such person or entity is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":34923,"source":{"system":"sec-edgar","filing":"0000947871-26-000421","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787126000421/ownership.xml","form_type":"4"}},{"id":1020454,"issuer":{"id":6860,"kind":"organization","name":"Adicet Bio, Inc."},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53130,"kind":"organization","name":"OrbiMed Capital GP V LLC","position":2,"cik":"0001615374","reported_name":"OrbiMed Capital GP V LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51517,"kind":"person","name":"OrbiMed Capital GP VI LLC","position":3,"cik":"0001682115","reported_name":"OrbiMed Capital GP VI LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24740,"kind":"person","name":"OrbiMed Genesis GP LLC","position":4,"cik":"0001808744","reported_name":"OrbiMed Genesis GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53131,"kind":"organization","name":"OrbiMed Advisors Israel II Ltd","position":5,"cik":"0001682093","reported_name":"OrbiMed Advisors Israel II Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53132,"kind":"organization","name":"OrbiMed Israel GP II, L.P.","position":6,"cik":"0001682090","reported_name":"OrbiMed Israel GP II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53133,"kind":"organization","name":"OrbiMed Israel GP Ltd.","position":7,"cik":"0001569590","reported_name":"OrbiMed Israel GP Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53134,"kind":"organization","name":"OrbiMed Israel BioFund GP Limited Partnership","position":8,"cik":"0001569821","reported_name":"OrbiMed Israel BioFund GP Limited Partnership","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-10-11T00:06:01.000Z","date":"2025-10-08","kind":"purchase","planned":false,"acquired":true,"shares":3500000,"price":1,"value":3500000.0,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These securities were purchased in an underwritten registered direct offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"These securities are held of record by OrbiMed Private Investments VI, LP (\"OPI VI\"). OrbiMed Capital GP VI LLC (\"GP VI\") is the general partner of OPI VI, and OrbiMed Advisors is the managing member of GP VI. By virtue of such relationships, GP VI and OrbiMed Advisors may be deemed to have voting and investment power over the shares of common stock held by OPI VI and, as a result, may be deemed to have beneficial ownership over such shares of common stock. OrbiMed Advisors exercises this investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership over the shares of common stock held by OPI VI."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"Each of OrbiMed Advisors, OrbiMed BioFund, OrbiMed Israel GP, OrbiMed Israel GP II, OrbiMed Israel II, GP V, GP VI, and Genesis GP disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of his or its pecuniary interest therein, if any. This report shall not be deemed an admission that any such person or entity is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":4490254,"source":{"system":"sec-edgar","filing":"0000947871-25-000898","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787125000898/ownership.xml","form_type":"4"}},{"id":1020453,"issuer":{"id":6860,"kind":"organization","name":"Adicet Bio, Inc."},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53130,"kind":"organization","name":"OrbiMed Capital GP V LLC","position":2,"cik":"0001615374","reported_name":"OrbiMed Capital GP V LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51517,"kind":"person","name":"OrbiMed Capital GP VI LLC","position":3,"cik":"0001682115","reported_name":"OrbiMed Capital GP VI LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24740,"kind":"person","name":"OrbiMed Genesis GP LLC","position":4,"cik":"0001808744","reported_name":"OrbiMed Genesis GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53131,"kind":"organization","name":"OrbiMed Advisors Israel II Ltd","position":5,"cik":"0001682093","reported_name":"OrbiMed Advisors Israel II Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53132,"kind":"organization","name":"OrbiMed Israel GP II, L.P.","position":6,"cik":"0001682090","reported_name":"OrbiMed Israel GP II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53133,"kind":"organization","name":"OrbiMed Israel GP Ltd.","position":7,"cik":"0001569590","reported_name":"OrbiMed Israel GP Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53134,"kind":"organization","name":"OrbiMed Israel BioFund GP Limited Partnership","position":8,"cik":"0001569821","reported_name":"OrbiMed Israel BioFund GP Limited Partnership","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-10-11T00:06:01.000Z","date":"2025-10-08","kind":"purchase","planned":false,"acquired":true,"shares":1500000,"price":1,"value":1500000.0,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These securities were purchased in an underwritten registered direct offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"These securities are held of record by OrbiMed Private Investments V, LP (\"OPI V\"). OrbiMed Capital GP V LLC (\"GP V\") is the general partner of OPI V, and OrbiMed Advisors LLC (\"OrbiMed Advisors\"), a registered investment adviser under the Investment Advisors Act of 1940, as amended, is the managing member of GP V. By virtue of such relationships, GP V and OrbiMed Advisors may be deemed to have voting and investment power over the shares of common stock held by OPI V and, as a result, may be deemed to have beneficial ownership over such shares of common stock. OrbiMed Advisors exercises this investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership over the shares of common stock held by OPI V."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"Each of OrbiMed Advisors, OrbiMed BioFund, OrbiMed Israel GP, OrbiMed Israel GP II, OrbiMed Israel II, GP V, GP VI, and Genesis GP disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of his or its pecuniary interest therein, if any. This report shall not be deemed an admission that any such person or entity is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":9026359,"source":{"system":"sec-edgar","filing":"0000947871-25-000898","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787125000898/ownership.xml","form_type":"4"}},{"id":1385168,"issuer":{"id":5743,"kind":"organization","name":"Upstream Bio, Inc.","symbol":"UPB"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24291,"kind":"person","name":"OrbiMed Capital GP VIII LLC","position":2,"cik":"0001845804","reported_name":"OrbiMed Capital GP VIII LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53131,"kind":"organization","name":"OrbiMed Advisors Israel II Ltd","position":3,"cik":"0001682093","reported_name":"OrbiMed Advisors Israel II Ltd","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53132,"kind":"organization","name":"OrbiMed Israel GP II, L.P.","position":4,"cik":"0001682090","reported_name":"OrbiMed Israel GP II, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B redeemable convertible preferred stock","published_at":"2024-10-17T20:17:52.000Z","date":"2024-10-15","kind":"exercise","planned":false,"acquired":false,"shares":789833,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series A redeemable convertible preferred stock and Series B redeemable convertible preferred stock automatically converted into shares of the Issuer's common stock on a one-for-1.049 basis immediately prior to the closing of the Issuer's initial public offering and have no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series A redeemable convertible preferred stock and Series B redeemable convertible preferred stock automatically converted into shares of the Issuer's common stock on a one-for-1.049 basis immediately prior to the closing of the Issuer's initial public offering and have no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series A redeemable convertible preferred stock and Series B redeemable convertible preferred stock automatically converted into shares of the Issuer's common stock on a one-for-1.049 basis immediately prior to the closing of the Issuer's initial public offering and have no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series A redeemable convertible preferred stock and Series B redeemable convertible preferred stock automatically converted into shares of the Issuer's common stock on a one-for-1.049 basis immediately prior to the closing of the Issuer's initial public offering and have no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These securities are held of record by OrbiMed Private Investments VIII, LP (\"OPI VIII\"). OrbiMed Capital GP VIII LLC (\"GP VIII\") is the general partner of OPI VIII, and OrbiMed Advisors LLC (\"OrbiMed Advisors\") is the managing member of GP VIII. By virtue of such relationships, GP VIII and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by OPI VIII and, as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the securities held by OPI VIII."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Each of Advisors II, Israel GP, OrbiMed Advisors, and GP VIII disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. OrbiMed Advisors, GP VIII. Advisors II, and Israel GP have designated a representative, Chimovits, an employee of OrbiMed Advisors and a director of Advisors II, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any such person or entity is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":789833},"source":{"system":"sec-edgar","filing":"0000947871-24-000806","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787124000806/ownership.xml","form_type":"4"}},{"id":1385167,"issuer":{"id":5743,"kind":"organization","name":"Upstream Bio, Inc.","symbol":"UPB"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24291,"kind":"person","name":"OrbiMed Capital GP VIII LLC","position":2,"cik":"0001845804","reported_name":"OrbiMed Capital GP VIII LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53131,"kind":"organization","name":"OrbiMed Advisors Israel II Ltd","position":3,"cik":"0001682093","reported_name":"OrbiMed Advisors Israel II Ltd","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53132,"kind":"organization","name":"OrbiMed Israel GP II, L.P.","position":4,"cik":"0001682090","reported_name":"OrbiMed Israel GP II, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B redeemable convertible preferred stock","published_at":"2024-10-17T20:17:52.000Z","date":"2024-10-15","kind":"exercise","planned":false,"acquired":false,"shares":197456,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series A redeemable convertible preferred stock and Series B redeemable convertible preferred stock automatically converted into shares of the Issuer's common stock on a one-for-1.049 basis immediately prior to the closing of the Issuer's initial public offering and have no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series A redeemable convertible preferred stock and Series B redeemable convertible preferred stock automatically converted into shares of the Issuer's common stock on a one-for-1.049 basis immediately prior to the closing of the Issuer's initial public offering and have no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series A redeemable convertible preferred stock and Series B redeemable convertible preferred stock automatically converted into shares of the Issuer's common stock on a one-for-1.049 basis immediately prior to the closing of the Issuer's initial public offering and have no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series A redeemable convertible preferred stock and Series B redeemable convertible preferred stock automatically converted into shares of the Issuer's common stock on a one-for-1.049 basis immediately prior to the closing of the Issuer's initial public offering and have no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held of record by OrbiMed Israel Partners II, L.P. (\"OIP II\"). OrbiMed Israel GP II, L.P. (\"Israel GP\") is the general partner of OIP II, and OrbiMed Advisors Israel II Limited (\"Advisors II\") is the general partner of Israel GP. By virtue of such relationships, Israel GP and Advisors II may be deemed to have voting and investment power over the securities held by OIP II and, as a result, may be deemed to have beneficial ownership over such securities. Advisors II exercises voting and investment power through an investment committee comprised of Carl L. Gordon, David P. Bonita, and Erez Chimovits (\"Chimovits\"), each of whom disclaims beneficial ownership of the securities held by OIP II."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Each of Advisors II, Israel GP, OrbiMed Advisors, and GP VIII disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. OrbiMed Advisors, GP VIII. Advisors II, and Israel GP have designated a representative, Chimovits, an employee of OrbiMed Advisors and a director of Advisors II, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any such person or entity is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":197456},"source":{"system":"sec-edgar","filing":"0000947871-24-000806","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787124000806/ownership.xml","form_type":"4"}},{"id":1385166,"issuer":{"id":5743,"kind":"organization","name":"Upstream Bio, Inc.","symbol":"UPB"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24291,"kind":"person","name":"OrbiMed Capital GP VIII LLC","position":2,"cik":"0001845804","reported_name":"OrbiMed Capital GP VIII LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53131,"kind":"organization","name":"OrbiMed Advisors Israel II Ltd","position":3,"cik":"0001682093","reported_name":"OrbiMed Advisors Israel II Ltd","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53132,"kind":"organization","name":"OrbiMed Israel GP II, L.P.","position":4,"cik":"0001682090","reported_name":"OrbiMed Israel GP II, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A redeemable convertible preferred stock","published_at":"2024-10-17T20:17:52.000Z","date":"2024-10-15","kind":"exercise","planned":false,"acquired":false,"shares":2098000,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series A redeemable convertible preferred stock and Series B redeemable convertible preferred stock automatically converted into shares of the Issuer's common stock on a one-for-1.049 basis immediately prior to the closing of the Issuer's initial public offering and have no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series A redeemable convertible preferred stock and Series B redeemable convertible preferred stock automatically converted into shares of the Issuer's common stock on a one-for-1.049 basis immediately prior to the closing of the Issuer's initial public offering and have no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series A redeemable convertible preferred stock and Series B redeemable convertible preferred stock automatically converted into shares of the Issuer's common stock on a one-for-1.049 basis immediately prior to the closing of the Issuer's initial public offering and have no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series A redeemable convertible preferred stock and Series B redeemable convertible preferred stock automatically converted into shares of the Issuer's common stock on a one-for-1.049 basis immediately prior to the closing of the Issuer's initial public offering and have no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These securities are held of record by OrbiMed Private Investments VIII, LP (\"OPI VIII\"). OrbiMed Capital GP VIII LLC (\"GP VIII\") is the general partner of OPI VIII, and OrbiMed Advisors LLC (\"OrbiMed Advisors\") is the managing member of GP VIII. By virtue of such relationships, GP VIII and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by OPI VIII and, as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the securities held by OPI VIII."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Each of Advisors II, Israel GP, OrbiMed Advisors, and GP VIII disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. OrbiMed Advisors, GP VIII. Advisors II, and Israel GP have designated a representative, Chimovits, an employee of OrbiMed Advisors and a director of Advisors II, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any such person or entity is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":2098000},"source":{"system":"sec-edgar","filing":"0000947871-24-000806","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787124000806/ownership.xml","form_type":"4"}},{"id":1385165,"issuer":{"id":5743,"kind":"organization","name":"Upstream Bio, Inc.","symbol":"UPB"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24291,"kind":"person","name":"OrbiMed Capital GP VIII LLC","position":2,"cik":"0001845804","reported_name":"OrbiMed Capital GP VIII LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53131,"kind":"organization","name":"OrbiMed Advisors Israel II Ltd","position":3,"cik":"0001682093","reported_name":"OrbiMed Advisors Israel II Ltd","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53132,"kind":"organization","name":"OrbiMed Israel GP II, L.P.","position":4,"cik":"0001682090","reported_name":"OrbiMed Israel GP II, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A redeemable convertible preferred stock","published_at":"2024-10-17T20:17:52.000Z","date":"2024-10-15","kind":"exercise","planned":false,"acquired":false,"shares":524500,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series A redeemable convertible preferred stock and Series B redeemable convertible preferred stock automatically converted into shares of the Issuer's common stock on a one-for-1.049 basis immediately prior to the closing of the Issuer's initial public offering and have no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series A redeemable convertible preferred stock and Series B redeemable convertible preferred stock automatically converted into shares of the Issuer's common stock on a one-for-1.049 basis immediately prior to the closing of the Issuer's initial public offering and have no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series A redeemable convertible preferred stock and Series B redeemable convertible preferred stock automatically converted into shares of the Issuer's common stock on a one-for-1.049 basis immediately prior to the closing of the Issuer's initial public offering and have no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series A redeemable convertible preferred stock and Series B redeemable convertible preferred stock automatically converted into shares of the Issuer's common stock on a one-for-1.049 basis immediately prior to the closing of the Issuer's initial public offering and have no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held of record by OrbiMed Israel Partners II, L.P. (\"OIP II\"). OrbiMed Israel GP II, L.P. (\"Israel GP\") is the general partner of OIP II, and OrbiMed Advisors Israel II Limited (\"Advisors II\") is the general partner of Israel GP. By virtue of such relationships, Israel GP and Advisors II may be deemed to have voting and investment power over the securities held by OIP II and, as a result, may be deemed to have beneficial ownership over such securities. Advisors II exercises voting and investment power through an investment committee comprised of Carl L. Gordon, David P. Bonita, and Erez Chimovits (\"Chimovits\"), each of whom disclaims beneficial ownership of the securities held by OIP II."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Each of Advisors II, Israel GP, OrbiMed Advisors, and GP VIII disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. OrbiMed Advisors, GP VIII. Advisors II, and Israel GP have designated a representative, Chimovits, an employee of OrbiMed Advisors and a director of Advisors II, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any such person or entity is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":524500},"source":{"system":"sec-edgar","filing":"0000947871-24-000806","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787124000806/ownership.xml","form_type":"4"}},{"id":1385164,"issuer":{"id":5743,"kind":"organization","name":"Upstream Bio, Inc.","symbol":"UPB"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24291,"kind":"person","name":"OrbiMed Capital GP VIII LLC","position":2,"cik":"0001845804","reported_name":"OrbiMed Capital GP VIII LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53131,"kind":"organization","name":"OrbiMed Advisors Israel II Ltd","position":3,"cik":"0001682093","reported_name":"OrbiMed Advisors Israel II Ltd","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53132,"kind":"organization","name":"OrbiMed Israel GP II, L.P.","position":4,"cik":"0001682090","reported_name":"OrbiMed Israel GP II, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-10-17T20:17:52.000Z","date":"2024-10-15","kind":"purchase","planned":false,"acquired":true,"shares":660000,"price":17,"value":11220000.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These securities are held of record by OrbiMed Private Investments VIII, LP (\"OPI VIII\"). OrbiMed Capital GP VIII LLC (\"GP VIII\") is the general partner of OPI VIII, and OrbiMed Advisors LLC (\"OrbiMed Advisors\") is the managing member of GP VIII. By virtue of such relationships, GP VIII and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by OPI VIII and, as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the securities held by OPI VIII."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Each of Advisors II, Israel GP, OrbiMed Advisors, and GP VIII disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. OrbiMed Advisors, GP VIII. Advisors II, and Israel GP have designated a representative, Chimovits, an employee of OrbiMed Advisors and a director of Advisors II, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any such person or entity is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":4554873,"source":{"system":"sec-edgar","filing":"0000947871-24-000806","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787124000806/ownership.xml","form_type":"4"}},{"id":1385163,"issuer":{"id":5743,"kind":"organization","name":"Upstream Bio, Inc.","symbol":"UPB"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24291,"kind":"person","name":"OrbiMed Capital GP VIII LLC","position":2,"cik":"0001845804","reported_name":"OrbiMed Capital GP VIII LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53131,"kind":"organization","name":"OrbiMed Advisors Israel II Ltd","position":3,"cik":"0001682093","reported_name":"OrbiMed Advisors Israel II Ltd","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53132,"kind":"organization","name":"OrbiMed Israel GP II, L.P.","position":4,"cik":"0001682090","reported_name":"OrbiMed Israel GP II, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-10-17T20:17:52.000Z","date":"2024-10-15","kind":"exercise","planned":false,"acquired":true,"shares":2887833,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series A redeemable convertible preferred stock and Series B redeemable convertible preferred stock automatically converted into shares of the Issuer's common stock on a one-for-1.049 basis immediately prior to the closing of the Issuer's initial public offering and have no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These securities are held of record by OrbiMed Private Investments VIII, LP (\"OPI VIII\"). OrbiMed Capital GP VIII LLC (\"GP VIII\") is the general partner of OPI VIII, and OrbiMed Advisors LLC (\"OrbiMed Advisors\") is the managing member of GP VIII. By virtue of such relationships, GP VIII and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by OPI VIII and, as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the securities held by OPI VIII."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Each of Advisors II, Israel GP, OrbiMed Advisors, and GP VIII disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. OrbiMed Advisors, GP VIII. Advisors II, and Israel GP have designated a representative, Chimovits, an employee of OrbiMed Advisors and a director of Advisors II, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any such person or entity is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":3894873,"source":{"system":"sec-edgar","filing":"0000947871-24-000806","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787124000806/ownership.xml","form_type":"4"}},{"id":1385162,"issuer":{"id":5743,"kind":"organization","name":"Upstream Bio, Inc.","symbol":"UPB"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24291,"kind":"person","name":"OrbiMed Capital GP VIII LLC","position":2,"cik":"0001845804","reported_name":"OrbiMed Capital GP VIII LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53131,"kind":"organization","name":"OrbiMed Advisors Israel II Ltd","position":3,"cik":"0001682093","reported_name":"OrbiMed Advisors Israel II Ltd","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53132,"kind":"organization","name":"OrbiMed Israel GP II, L.P.","position":4,"cik":"0001682090","reported_name":"OrbiMed Israel GP II, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-10-17T20:17:52.000Z","date":"2024-10-15","kind":"purchase","planned":false,"acquired":true,"shares":165000,"price":17,"value":2805000.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held of record by OrbiMed Israel Partners II, L.P. (\"OIP II\"). OrbiMed Israel GP II, L.P. (\"Israel GP\") is the general partner of OIP II, and OrbiMed Advisors Israel II Limited (\"Advisors II\") is the general partner of Israel GP. By virtue of such relationships, Israel GP and Advisors II may be deemed to have voting and investment power over the securities held by OIP II and, as a result, may be deemed to have beneficial ownership over such securities. Advisors II exercises voting and investment power through an investment committee comprised of Carl L. Gordon, David P. Bonita, and Erez Chimovits (\"Chimovits\"), each of whom disclaims beneficial ownership of the securities held by OIP II."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Each of Advisors II, Israel GP, OrbiMed Advisors, and GP VIII disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. OrbiMed Advisors, GP VIII. Advisors II, and Israel GP have designated a representative, Chimovits, an employee of OrbiMed Advisors and a director of Advisors II, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any such person or entity is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":1138716,"source":{"system":"sec-edgar","filing":"0000947871-24-000806","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787124000806/ownership.xml","form_type":"4"}},{"id":1385161,"issuer":{"id":5743,"kind":"organization","name":"Upstream Bio, Inc.","symbol":"UPB"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24291,"kind":"person","name":"OrbiMed Capital GP VIII LLC","position":2,"cik":"0001845804","reported_name":"OrbiMed Capital GP VIII LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53131,"kind":"organization","name":"OrbiMed Advisors Israel II Ltd","position":3,"cik":"0001682093","reported_name":"OrbiMed Advisors Israel II Ltd","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53132,"kind":"organization","name":"OrbiMed Israel GP II, L.P.","position":4,"cik":"0001682090","reported_name":"OrbiMed Israel GP II, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-10-17T20:17:52.000Z","date":"2024-10-15","kind":"exercise","planned":false,"acquired":true,"shares":721956,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series A redeemable convertible preferred stock and Series B redeemable convertible preferred stock automatically converted into shares of the Issuer's common stock on a one-for-1.049 basis immediately prior to the closing of the Issuer's initial public offering and have no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held of record by OrbiMed Israel Partners II, L.P. (\"OIP II\"). OrbiMed Israel GP II, L.P. (\"Israel GP\") is the general partner of OIP II, and OrbiMed Advisors Israel II Limited (\"Advisors II\") is the general partner of Israel GP. By virtue of such relationships, Israel GP and Advisors II may be deemed to have voting and investment power over the securities held by OIP II and, as a result, may be deemed to have beneficial ownership over such securities. Advisors II exercises voting and investment power through an investment committee comprised of Carl L. Gordon, David P. Bonita, and Erez Chimovits (\"Chimovits\"), each of whom disclaims beneficial ownership of the securities held by OIP II."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Each of Advisors II, Israel GP, OrbiMed Advisors, and GP VIII disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. OrbiMed Advisors, GP VIII. Advisors II, and Israel GP have designated a representative, Chimovits, an employee of OrbiMed Advisors and a director of Advisors II, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any such person or entity is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":973716,"source":{"system":"sec-edgar","filing":"0000947871-24-000806","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787124000806/ownership.xml","form_type":"4"}},{"id":1669923,"issuer":{"id":6860,"kind":"organization","name":"Adicet Bio, Inc."},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53130,"kind":"organization","name":"OrbiMed Capital GP V LLC","position":2,"cik":"0001615374","reported_name":"OrbiMed Capital GP V LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51517,"kind":"person","name":"OrbiMed Capital GP VI LLC","position":3,"cik":"0001682115","reported_name":"OrbiMed Capital GP VI LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24740,"kind":"person","name":"OrbiMed Genesis GP LLC","position":4,"cik":"0001808744","reported_name":"OrbiMed Genesis GP LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53131,"kind":"organization","name":"OrbiMed Advisors Israel II Ltd","position":5,"cik":"0001682093","reported_name":"OrbiMed Advisors Israel II Ltd","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53132,"kind":"organization","name":"OrbiMed Israel GP II, L.P.","position":6,"cik":"0001682090","reported_name":"OrbiMed Israel GP II, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53133,"kind":"organization","name":"OrbiMed Israel GP Ltd.","position":7,"cik":"0001569590","reported_name":"OrbiMed Israel GP Ltd.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53134,"kind":"organization","name":"OrbiMed Israel BioFund GP Limited Partnership","position":8,"cik":"0001569821","reported_name":"OrbiMed Israel BioFund GP Limited Partnership","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-01-27T00:14:22.000Z","date":"2024-01-25","kind":"purchase","planned":false,"acquired":true,"shares":1041700,"price":2.4,"value":2500080.0,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares of the Issuer's common stock were purchased in the Issuer's underwritten public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"This report is being jointly filed by OrbiMed Advisors, GP V, GP VI, Genesis GP, OrbiMed Israel GP II, OrbiMed Israel II, OrbiMed BioFund, and OrbiMed Israel GP. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Exchange Act, except to the extent of its pecuniary interest therein, if any. OrbiMed Advisors, GP V, GP VI, OrbiMed Israel GP II, OrbiMed Israel II, OrbiMed BioFund, and OrbiMed Israel GP have designated Carl L. Gordon (\"Gordon\") to serve on the Issuer's board of directors. This report shall not be deemed an admission that any of the Reporting Persons or Gordon is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"These shares of the Issuer's common stock are held of record by OrbiMed Genesis Master Fund, L.P. (\"Genesis\"). OrbiMed Genesis GP LLC (\"Genesis GP\") is the general partner of Genesis, and OrbiMed Advisors is the managing member of Genesis. By virtue of such relationships, Genesis GP and OrbiMed Advisors may be deemed to have voting and investment power with respect to the securities held by Genesis noted above and as a result may be deemed to beneficially own such securities for purposes of Rule 13d-3 under the Exchange Act. OrbiMed Advisors exercises this investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the Shares held by Genesis."}],"balance_after":1255985,"source":{"system":"sec-edgar","filing":"0000950170-24-008053","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000095017024008053/ownership.xml","form_type":"4"}},{"id":1669922,"issuer":{"id":6860,"kind":"organization","name":"Adicet Bio, Inc."},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53130,"kind":"organization","name":"OrbiMed Capital GP V LLC","position":2,"cik":"0001615374","reported_name":"OrbiMed Capital GP V LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51517,"kind":"person","name":"OrbiMed Capital GP VI LLC","position":3,"cik":"0001682115","reported_name":"OrbiMed Capital GP VI LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24740,"kind":"person","name":"OrbiMed Genesis GP LLC","position":4,"cik":"0001808744","reported_name":"OrbiMed Genesis GP LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53131,"kind":"organization","name":"OrbiMed Advisors Israel II Ltd","position":5,"cik":"0001682093","reported_name":"OrbiMed Advisors Israel II Ltd","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53132,"kind":"organization","name":"OrbiMed Israel GP II, L.P.","position":6,"cik":"0001682090","reported_name":"OrbiMed Israel GP II, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53133,"kind":"organization","name":"OrbiMed Israel GP Ltd.","position":7,"cik":"0001569590","reported_name":"OrbiMed Israel GP Ltd.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53134,"kind":"organization","name":"OrbiMed Israel BioFund GP Limited Partnership","position":8,"cik":"0001569821","reported_name":"OrbiMed Israel BioFund GP Limited Partnership","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-01-27T00:14:22.000Z","date":"2024-01-25","kind":"purchase","planned":false,"acquired":true,"shares":242200,"price":2.4,"value":581280.0,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares of the Issuer's common stock were purchased in the Issuer's underwritten public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"This report is being jointly filed by OrbiMed Advisors, GP V, GP VI, Genesis GP, OrbiMed Israel GP II, OrbiMed Israel II, OrbiMed BioFund, and OrbiMed Israel GP. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Exchange Act, except to the extent of its pecuniary interest therein, if any. OrbiMed Advisors, GP V, GP VI, OrbiMed Israel GP II, OrbiMed Israel II, OrbiMed BioFund, and OrbiMed Israel GP have designated Carl L. Gordon (\"Gordon\") to serve on the Issuer's board of directors. This report shall not be deemed an admission that any of the Reporting Persons or Gordon is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"These shares of the Issuer's common stock are held of record by OrbiMed Private Investments VI, LP (\"OPI VI\"). OrbiMed Capital GP VI LLC (\"GP VI\") is the general partner of OPI VI, and OrbiMed Advisors is the managing member of GP VI. By virtue of such relationships, GP VI and OrbiMed Advisors may be deemed to have voting and investment power with respect to the securities held by OPI VI noted above and as a result may be deemed to beneficially own such securities for purposes of Rule 13d-3 under the Exchange Act. OrbiMed Advisors exercises this investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the Shares held by OPI VI."}],"balance_after":990254,"source":{"system":"sec-edgar","filing":"0000950170-24-008053","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000095017024008053/ownership.xml","form_type":"4"}},{"id":1669921,"issuer":{"id":6860,"kind":"organization","name":"Adicet Bio, Inc."},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53130,"kind":"organization","name":"OrbiMed Capital GP V LLC","position":2,"cik":"0001615374","reported_name":"OrbiMed Capital GP V LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51517,"kind":"person","name":"OrbiMed Capital GP VI LLC","position":3,"cik":"0001682115","reported_name":"OrbiMed Capital GP VI LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24740,"kind":"person","name":"OrbiMed Genesis GP LLC","position":4,"cik":"0001808744","reported_name":"OrbiMed Genesis GP LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53131,"kind":"organization","name":"OrbiMed Advisors Israel II Ltd","position":5,"cik":"0001682093","reported_name":"OrbiMed Advisors Israel II Ltd","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53132,"kind":"organization","name":"OrbiMed Israel GP II, L.P.","position":6,"cik":"0001682090","reported_name":"OrbiMed Israel GP II, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53133,"kind":"organization","name":"OrbiMed Israel GP Ltd.","position":7,"cik":"0001569590","reported_name":"OrbiMed Israel GP Ltd.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53134,"kind":"organization","name":"OrbiMed Israel BioFund GP Limited Partnership","position":8,"cik":"0001569821","reported_name":"OrbiMed Israel BioFund GP Limited Partnership","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-01-27T00:14:22.000Z","date":"2024-01-25","kind":"purchase","planned":false,"acquired":true,"shares":1841100,"price":2.4,"value":4418640.0,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares of the Issuer's common stock were purchased in the Issuer's underwritten public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares of the Issuer's common stock are held of record by OrbiMed Private Investments V, LP (\"OPI V\"). OrbiMed Capital GP V LLC (\"GP V\") is the general partner of OPI V, and OrbiMed Advisors LLC (\"OrbiMed Advisors\"), a registered investment adviser under the Investment Advisors Act of 1940, as amended, is the managing member of GP V. By virtue of such relationships, GP V and OrbiMed Advisors may be deemed to have voting and investment power with respect to the securities held by OPI V noted above and as a result may be deemed to beneficially own such securities for purposes of Rule 13d-3 under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"). OrbiMed Advisors exercises this investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI V."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"This report is being jointly filed by OrbiMed Advisors, GP V, GP VI, Genesis GP, OrbiMed Israel GP II, OrbiMed Israel II, OrbiMed BioFund, and OrbiMed Israel GP. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Exchange Act, except to the extent of its pecuniary interest therein, if any. OrbiMed Advisors, GP V, GP VI, OrbiMed Israel GP II, OrbiMed Israel II, OrbiMed BioFund, and OrbiMed Israel GP have designated Carl L. Gordon (\"Gordon\") to serve on the Issuer's board of directors. This report shall not be deemed an admission that any of the Reporting Persons or Gordon is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":7526359,"source":{"system":"sec-edgar","filing":"0000950170-24-008053","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000095017024008053/ownership.xml","form_type":"4"}},{"id":1804183,"issuer":{"id":4602,"kind":"organization","name":"Damora Therapeutics, Inc.","symbol":"DMRA"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24740,"kind":"person","name":"OrbiMed Genesis GP LLC","position":2,"cik":"0001808744","reported_name":"OrbiMed Genesis GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53132,"kind":"organization","name":"OrbiMed Israel GP II, L.P.","position":3,"cik":"0001682090","reported_name":"OrbiMed Israel GP II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53131,"kind":"organization","name":"OrbiMed Advisors Israel II Ltd","position":4,"cik":"0001682093","reported_name":"OrbiMed Advisors Israel II Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35791,"kind":"organization","name":"OrbiMed Capital GP VII LLC","position":5,"cik":"0001760648","reported_name":"OrbiMed Capital GP VII LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-08-17T20:40:30.000Z","date":"2023-08-15","kind":"sale","planned":false,"acquired":false,"shares":535534,"price":0.75,"value":401650.5,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These securities are held of record by OrbiMed Private Investments VII, LP (\"OPI VII\"). OrbiMed Capital GP VII LLC (\"GP VII\") is the general partner of OPI VII and OrbiMed Advisors is the managing member of GP VII. By virtue of such relationships, OrbiMed Advisors and GP VII may be deemed to have voting power and investment power over the securities held by OPI VII and, as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the securities held by OPI VII."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Each of OrbiMed Advisors, Genesis GP, OrbiMed Israel, OrbiMed Limited, and GP VII disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any such person or entity, including the Reporting Persons, is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":1510375,"source":{"system":"sec-edgar","filing":"0000947871-23-000873","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787123000873/ownership.xml","form_type":"4"}},{"id":1804182,"issuer":{"id":4602,"kind":"organization","name":"Damora Therapeutics, Inc.","symbol":"DMRA"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24740,"kind":"person","name":"OrbiMed Genesis GP LLC","position":2,"cik":"0001808744","reported_name":"OrbiMed Genesis GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53132,"kind":"organization","name":"OrbiMed Israel GP II, L.P.","position":3,"cik":"0001682090","reported_name":"OrbiMed Israel GP II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53131,"kind":"organization","name":"OrbiMed Advisors Israel II Ltd","position":4,"cik":"0001682093","reported_name":"OrbiMed Advisors Israel II Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35791,"kind":"organization","name":"OrbiMed Capital GP VII LLC","position":5,"cik":"0001760648","reported_name":"OrbiMed Capital GP VII LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-08-17T20:40:30.000Z","date":"2023-08-15","kind":"sale","planned":false,"acquired":false,"shares":248819,"price":0.75,"value":186614.25,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held of record by OrbiMed Israel Partners II, L.P. (\"OIP II\"). OrbiMed Israel GP II, L.P. (\"OrbiMed Israel\") is the general partner of OIP II and OrbiMed Advisors Israel II Limited (\"OrbiMed Limited\") is the general partner of OrbiMed Israel. By virtue of such relationships, OrbiMed Limited and OrbiMed Israel may be deemed to have voting power and investment power over the securities held by OIP II and, as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Limited exercises voting and investment power through a management committee comprised of Carl L. Gordon, David P. Bonita, and Erez Chimovits, each of whom disclaims beneficial ownership of the securities held by OIP II."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Each of OrbiMed Advisors, Genesis GP, OrbiMed Israel, OrbiMed Limited, and GP VII disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any such person or entity, including the Reporting Persons, is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":631048,"source":{"system":"sec-edgar","filing":"0000947871-23-000873","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787123000873/ownership.xml","form_type":"4"}},{"id":1804181,"issuer":{"id":4602,"kind":"organization","name":"Damora Therapeutics, Inc.","symbol":"DMRA"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24740,"kind":"person","name":"OrbiMed Genesis GP LLC","position":2,"cik":"0001808744","reported_name":"OrbiMed Genesis GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53132,"kind":"organization","name":"OrbiMed Israel GP II, L.P.","position":3,"cik":"0001682090","reported_name":"OrbiMed Israel GP II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53131,"kind":"organization","name":"OrbiMed Advisors Israel II Ltd","position":4,"cik":"0001682093","reported_name":"OrbiMed Advisors Israel II Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35791,"kind":"organization","name":"OrbiMed Capital GP VII LLC","position":5,"cik":"0001760648","reported_name":"OrbiMed Capital GP VII LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-08-17T20:40:30.000Z","date":"2023-08-15","kind":"sale","planned":false,"acquired":false,"shares":38327,"price":0.75,"value":28745.25,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"These securities are held of record by OrbiMed Genesis Master Fund, L.P. (\"OrbiMed Genesis\"). OrbiMed Genesis GP LLC (\"Genesis GP\") is the general partner of OrbiMed Genesis and OrbiMed Advisors LLC (\"OrbiMed Advisors\") is the managing member of Genesis GP. By virtue of such relationships, OrbiMed Advisors and Genesis GP may be deemed to have voting power and investment power over the securities held by OrbiMed Genesis and, as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the securities held by OrbiMed Genesis."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Each of OrbiMed Advisors, Genesis GP, OrbiMed Israel, OrbiMed Limited, and GP VII disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any such person or entity, including the Reporting Persons, is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":97204,"source":{"system":"sec-edgar","filing":"0000947871-23-000873","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787123000873/ownership.xml","form_type":"4"}},{"id":1818267,"issuer":{"id":4602,"kind":"organization","name":"Damora Therapeutics, Inc.","symbol":"DMRA"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24740,"kind":"person","name":"OrbiMed Genesis GP LLC","position":2,"cik":"0001808744","reported_name":"OrbiMed Genesis GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53132,"kind":"organization","name":"OrbiMed Israel GP II, L.P.","position":3,"cik":"0001682090","reported_name":"OrbiMed Israel GP II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53131,"kind":"organization","name":"OrbiMed Advisors Israel II Ltd","position":4,"cik":"0001682093","reported_name":"OrbiMed Advisors Israel II Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35791,"kind":"organization","name":"OrbiMed Capital GP VII LLC","position":5,"cik":"0001760648","reported_name":"OrbiMed Capital GP VII LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-08-02T21:05:38.000Z","date":"2023-07-31","kind":"sale","planned":false,"acquired":false,"shares":153078,"price":3,"value":459234.0,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These securities are held of record by OrbiMed Private Investments VII, LP (\"OPI VII\"). OrbiMed Capital GP VII LLC (\"GP VII\") is the general partner of OPI VII and OrbiMed Advisors is the managing member of GP VII. By virtue of such relationships, OrbiMed Advisors and GP VII may be deemed to have voting power and investment power over the securities held by OPI VII and, as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the securities held by OPI VII."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Each of OrbiMed Advisors, Genesis GP, OrbiMed Israel, OrbiMed Limited, and GP VII disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any such person or entity, including the Reporting Persons, is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":2105909,"source":{"system":"sec-edgar","filing":"0000947871-23-000809","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787123000809/ownership.xml","form_type":"4"}},{"id":1818266,"issuer":{"id":4602,"kind":"organization","name":"Damora Therapeutics, Inc.","symbol":"DMRA"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24740,"kind":"person","name":"OrbiMed Genesis GP LLC","position":2,"cik":"0001808744","reported_name":"OrbiMed Genesis GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53132,"kind":"organization","name":"OrbiMed Israel GP II, L.P.","position":3,"cik":"0001682090","reported_name":"OrbiMed Israel GP II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53131,"kind":"organization","name":"OrbiMed Advisors Israel II Ltd","position":4,"cik":"0001682093","reported_name":"OrbiMed Advisors Israel II Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35791,"kind":"organization","name":"OrbiMed Capital GP VII LLC","position":5,"cik":"0001760648","reported_name":"OrbiMed Capital GP VII LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-08-02T21:05:38.000Z","date":"2023-07-31","kind":"sale","planned":false,"acquired":false,"shares":29700,"price":3,"value":89100.0,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held of record by OrbiMed Israel Partners II, L.P. (\"OIP II\"). OrbiMed Israel GP II, L.P. (\"OrbiMed Israel\") is the general partner of OIP II and OrbiMed Advisors Israel II Limited (\"OrbiMed Limited\") is the general partner of OrbiMed Israel. By virtue of such relationships, OrbiMed Limited and OrbiMed Israel may be deemed to have voting power and investment power over the securities held by OIP II and, as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Limited exercises voting and investment power through a management committee comprised of Carl L. Gordon, David P. Bonita, and Erez Chimovits, each of whom disclaims beneficial ownership of the securities held by OIP II."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Each of OrbiMed Advisors, Genesis GP, OrbiMed Israel, OrbiMed Limited, and GP VII disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any such person or entity, including the Reporting Persons, is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":879867,"source":{"system":"sec-edgar","filing":"0000947871-23-000809","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787123000809/ownership.xml","form_type":"4"}},{"id":1818265,"issuer":{"id":4602,"kind":"organization","name":"Damora Therapeutics, Inc.","symbol":"DMRA"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24740,"kind":"person","name":"OrbiMed Genesis GP LLC","position":2,"cik":"0001808744","reported_name":"OrbiMed Genesis GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53132,"kind":"organization","name":"OrbiMed Israel GP II, L.P.","position":3,"cik":"0001682090","reported_name":"OrbiMed Israel GP II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53131,"kind":"organization","name":"OrbiMed Advisors Israel II Ltd","position":4,"cik":"0001682093","reported_name":"OrbiMed Advisors Israel II Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35791,"kind":"organization","name":"OrbiMed Capital GP VII LLC","position":5,"cik":"0001760648","reported_name":"OrbiMed Capital GP VII LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-08-02T21:05:38.000Z","date":"2023-07-31","kind":"sale","planned":false,"acquired":false,"shares":26622,"price":3,"value":79866.0,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"These securities are held of record by OrbiMed Genesis Master Fund, L.P. (\"OrbiMed Genesis\"). OrbiMed Genesis GP LLC (\"Genesis GP\") is the general partner of OrbiMed Genesis and OrbiMed Advisors LLC (\"OrbiMed Advisors\") is the managing member of Genesis GP. By virtue of such relationships, OrbiMed Advisors and Genesis GP may be deemed to have voting power and investment power over the securities held by OrbiMed Genesis and, as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the securities held by OrbiMed Genesis."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Each of OrbiMed Advisors, Genesis GP, OrbiMed Israel, OrbiMed Limited, and GP VII disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any such person or entity, including the Reporting Persons, is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":135531,"source":{"system":"sec-edgar","filing":"0000947871-23-000809","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787123000809/ownership.xml","form_type":"4"}},{"id":1822349,"issuer":{"id":4602,"kind":"organization","name":"Damora Therapeutics, Inc.","symbol":"DMRA"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24740,"kind":"person","name":"OrbiMed Genesis GP LLC","position":2,"cik":"0001808744","reported_name":"OrbiMed Genesis GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53132,"kind":"organization","name":"OrbiMed Israel GP II, L.P.","position":3,"cik":"0001682090","reported_name":"OrbiMed Israel GP II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53131,"kind":"organization","name":"OrbiMed Advisors Israel II Ltd","position":4,"cik":"0001682093","reported_name":"OrbiMed Advisors Israel II Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35791,"kind":"organization","name":"OrbiMed Capital GP VII LLC","position":5,"cik":"0001760648","reported_name":"OrbiMed Capital GP VII LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-07-27T20:28:17.000Z","date":"2023-07-25","kind":"sale","planned":false,"acquired":false,"shares":26700,"price":2.92,"value":77964.0,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents the weighted average sale price of the shares of the Issuer's common stock sold, ranging from a low of $2.81 to a high of $3.12 per share. The Reporting Persons undertake, upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, to provide full information regarding the number of shares sold at each separate price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"These securities are held of record by OrbiMed Private Investments VII, LP (\"OPI VII\"). OrbiMed Capital GP VII LLC (\"GP VII\") is the general partner of OPI VII and OrbiMed Advisors is the managing member of GP VII. By virtue of such relationships, OrbiMed Advisors and GP VII may be deemed to have voting power and investment power over the securities held by OPI VII and, as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the securities held by OPI VII."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Each of OrbiMed Advisors, Genesis GP, OrbiMed Israel, OrbiMed Limited, and GP VII disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any such person or entity, including the Reporting Persons, is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":2258987,"source":{"system":"sec-edgar","filing":"0000947871-23-000789","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787123000789/ownership.xml","form_type":"4"}},{"id":1822348,"issuer":{"id":4602,"kind":"organization","name":"Damora Therapeutics, Inc.","symbol":"DMRA"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24740,"kind":"person","name":"OrbiMed Genesis GP LLC","position":2,"cik":"0001808744","reported_name":"OrbiMed Genesis GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53132,"kind":"organization","name":"OrbiMed Israel GP II, L.P.","position":3,"cik":"0001682090","reported_name":"OrbiMed Israel GP II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53131,"kind":"organization","name":"OrbiMed Advisors Israel II Ltd","position":4,"cik":"0001682093","reported_name":"OrbiMed Advisors Israel II Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35791,"kind":"organization","name":"OrbiMed Capital GP VII LLC","position":5,"cik":"0001760648","reported_name":"OrbiMed Capital GP VII LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-07-27T20:28:17.000Z","date":"2023-07-25","kind":"sale","planned":false,"acquired":false,"shares":4700,"price":2.92,"value":13724.0,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents the weighted average sale price of the shares of the Issuer's common stock sold, ranging from a low of $2.81 to a high of $3.12 per share. The Reporting Persons undertake, upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, to provide full information regarding the number of shares sold at each separate price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These securities are held of record by OrbiMed Israel Partners II, L.P. (\"OIP II\"). OrbiMed Israel GP II, L.P. (\"OrbiMed Israel\") is the general partner of OIP II and OrbiMed Advisors Israel II Limited (\"OrbiMed Limited\") is the general partner of OrbiMed Israel. By virtue of such relationships, OrbiMed Limited and OrbiMed Israel may be deemed to have voting power and investment power over the securities held by OIP II and, as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Limited exercises voting and investment power through a management committee comprised of Carl L. Gordon, David P. Bonita, and Erez Chimovits, each of whom disclaims beneficial ownership of the securities held by OIP II."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Each of OrbiMed Advisors, Genesis GP, OrbiMed Israel, OrbiMed Limited, and GP VII disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any such person or entity, including the Reporting Persons, is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":909567,"source":{"system":"sec-edgar","filing":"0000947871-23-000789","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787123000789/ownership.xml","form_type":"4"}},{"id":1822347,"issuer":{"id":4602,"kind":"organization","name":"Damora Therapeutics, Inc.","symbol":"DMRA"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24740,"kind":"person","name":"OrbiMed Genesis GP LLC","position":2,"cik":"0001808744","reported_name":"OrbiMed Genesis GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53132,"kind":"organization","name":"OrbiMed Israel GP II, L.P.","position":3,"cik":"0001682090","reported_name":"OrbiMed Israel GP II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53131,"kind":"organization","name":"OrbiMed Advisors Israel II Ltd","position":4,"cik":"0001682093","reported_name":"OrbiMed Advisors Israel II Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35791,"kind":"organization","name":"OrbiMed Capital GP VII LLC","position":5,"cik":"0001760648","reported_name":"OrbiMed Capital GP VII LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-07-27T20:28:17.000Z","date":"2023-07-25","kind":"sale","planned":false,"acquired":false,"shares":7800,"price":2.92,"value":22776.0,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents the weighted average sale price of the shares of the Issuer's common stock sold, ranging from a low of $2.81 to a high of $3.12 per share. The Reporting Persons undertake, upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, to provide full information regarding the number of shares sold at each separate price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held of record by OrbiMed Genesis Master Fund, L.P. (\"OrbiMed Genesis\"). OrbiMed Genesis GP LLC (\"Genesis GP\") is the general partner of OrbiMed Genesis and OrbiMed Advisors LLC (\"OrbiMed Advisors\") is the managing member of Genesis GP. By virtue of such relationships, OrbiMed Advisors and Genesis GP may be deemed to have voting power and investment power over the securities held by OrbiMed Genesis and, as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the securities held by OrbiMed Genesis."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Each of OrbiMed Advisors, Genesis GP, OrbiMed Israel, OrbiMed Limited, and GP VII disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any such person or entity, including the Reporting Persons, is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":162153,"source":{"system":"sec-edgar","filing":"0000947871-23-000789","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787123000789/ownership.xml","form_type":"4"}},{"id":1828938,"issuer":{"id":4602,"kind":"organization","name":"Damora Therapeutics, Inc.","symbol":"DMRA"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24740,"kind":"person","name":"OrbiMed Genesis GP LLC","position":2,"cik":"0001808744","reported_name":"OrbiMed Genesis GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53132,"kind":"organization","name":"OrbiMed Israel GP II, L.P.","position":3,"cik":"0001682090","reported_name":"OrbiMed Israel GP II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53131,"kind":"organization","name":"OrbiMed Advisors Israel II Ltd","position":4,"cik":"0001682093","reported_name":"OrbiMed Advisors Israel II Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35791,"kind":"organization","name":"OrbiMed Capital GP VII LLC","position":5,"cik":"0001760648","reported_name":"OrbiMed Capital GP VII LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-07-17T20:13:17.000Z","date":"2023-07-13","kind":"sale","planned":false,"acquired":false,"shares":132100,"price":2.4,"value":317040.0,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These securities are held of record by OrbiMed Private Investments VII, LP (\"OPI VII\"). OrbiMed Capital GP VII LLC (\"GP VII\") is the general partner of OPI VII and OrbiMed Advisors is the managing member of GP VII. By virtue of such relationships, OrbiMed Advisors and GP VII may be deemed to have voting power and investment power over the securities held by OPI VII and, as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the securities held by OPI VII."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Each of OrbiMed Advisors, Genesis GP, OrbiMed Israel, OrbiMed Limited, and GP VII disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any such person or entity, including the Reporting Persons, is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":2285687,"source":{"system":"sec-edgar","filing":"0000947871-23-000753","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787123000753/ownership.xml","form_type":"4"}},{"id":1828937,"issuer":{"id":4602,"kind":"organization","name":"Damora Therapeutics, Inc.","symbol":"DMRA"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24740,"kind":"person","name":"OrbiMed Genesis GP LLC","position":2,"cik":"0001808744","reported_name":"OrbiMed Genesis GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53132,"kind":"organization","name":"OrbiMed Israel GP II, L.P.","position":3,"cik":"0001682090","reported_name":"OrbiMed Israel GP II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53131,"kind":"organization","name":"OrbiMed Advisors Israel II Ltd","position":4,"cik":"0001682093","reported_name":"OrbiMed Advisors Israel II Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35791,"kind":"organization","name":"OrbiMed Capital GP VII LLC","position":5,"cik":"0001760648","reported_name":"OrbiMed Capital GP VII LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-07-17T20:13:17.000Z","date":"2023-07-13","kind":"sale","planned":false,"acquired":false,"shares":52800,"price":2.4,"value":126720.0,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held of record by OrbiMed Israel Partners II, L.P. (\"OIP II\"). OrbiMed Israel GP II, L.P. (\"OrbiMed Israel\") is the general partner of OIP II and OrbiMed Advisors Israel II Limited (\"OrbiMed Limited\") is the general partner of OrbiMed Israel. By virtue of such relationships, OrbiMed Limited and OrbiMed Israel may be deemed to have voting power and investment power over the securities held by OIP II and, as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Limited exercises voting and investment power through a management committee comprised of Carl L. Gordon, David P. Bonita, and Erez Chimovits, each of whom disclaims beneficial ownership of the securities held by OIP II."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Each of OrbiMed Advisors, Genesis GP, OrbiMed Israel, OrbiMed Limited, and GP VII disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any such person or entity, including the Reporting Persons, is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":914267,"source":{"system":"sec-edgar","filing":"0000947871-23-000753","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787123000753/ownership.xml","form_type":"4"}},{"id":1828936,"issuer":{"id":4602,"kind":"organization","name":"Damora Therapeutics, Inc.","symbol":"DMRA"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24740,"kind":"person","name":"OrbiMed Genesis GP LLC","position":2,"cik":"0001808744","reported_name":"OrbiMed Genesis GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53132,"kind":"organization","name":"OrbiMed Israel GP II, L.P.","position":3,"cik":"0001682090","reported_name":"OrbiMed Israel GP II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53131,"kind":"organization","name":"OrbiMed Advisors Israel II Ltd","position":4,"cik":"0001682093","reported_name":"OrbiMed Advisors Israel II Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35791,"kind":"organization","name":"OrbiMed Capital GP VII LLC","position":5,"cik":"0001760648","reported_name":"OrbiMed Capital GP VII LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-07-17T20:13:17.000Z","date":"2023-07-13","kind":"sale","planned":false,"acquired":false,"shares":9800,"price":2.4,"value":23520.0,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"These securities are held of record by OrbiMed Genesis Master Fund, L.P. (\"OrbiMed Genesis\"). OrbiMed Genesis GP LLC (\"Genesis GP\") is the general partner of OrbiMed Genesis and OrbiMed Advisors LLC (\"OrbiMed Advisors\") is the managing member of Genesis GP. By virtue of such relationships, OrbiMed Advisors and Genesis GP may be deemed to have voting power and investment power over the securities held by OrbiMed Genesis and, as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the securities held by OrbiMed Genesis."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Each of OrbiMed Advisors, Genesis GP, OrbiMed Israel, OrbiMed Limited, and GP VII disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any such person or entity, including the Reporting Persons, is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":169953,"source":{"system":"sec-edgar","filing":"0000947871-23-000753","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787123000753/ownership.xml","form_type":"4"}},{"id":1842241,"issuer":{"id":6860,"kind":"organization","name":"Adicet Bio, Inc."},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53130,"kind":"organization","name":"OrbiMed Capital GP V LLC","position":2,"cik":"0001615374","reported_name":"OrbiMed Capital GP V LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51517,"kind":"person","name":"OrbiMed Capital GP VI LLC","position":3,"cik":"0001682115","reported_name":"OrbiMed Capital GP VI LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24740,"kind":"person","name":"OrbiMed Genesis GP LLC","position":4,"cik":"0001808744","reported_name":"OrbiMed Genesis GP LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53131,"kind":"organization","name":"OrbiMed Advisors Israel II Ltd","position":5,"cik":"0001682093","reported_name":"OrbiMed Advisors Israel II Ltd","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53132,"kind":"organization","name":"OrbiMed Israel GP II, L.P.","position":6,"cik":"0001682090","reported_name":"OrbiMed Israel GP II, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53133,"kind":"organization","name":"OrbiMed Israel GP Ltd.","position":7,"cik":"0001569590","reported_name":"OrbiMed Israel GP Ltd.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53134,"kind":"organization","name":"OrbiMed Israel BioFund GP Limited Partnership","position":8,"cik":"0001569821","reported_name":"OrbiMed Israel BioFund GP Limited Partnership","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24622,"kind":"person","name":"Chimovits Erez","position":9,"cik":"0001706399","reported_name":"Chimovits Erez","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-06-29T20:46:01.000Z","date":"2023-06-27","kind":"purchase","planned":false,"acquired":true,"shares":58000,"price":2.09,"value":121220.0,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents the weighted average purchase price of the shares of common stock purchased, ranging from a low of $2.08 to a high of $2.12 per share. The Reporting Persons undertake, upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, to provide full information regarding the number of shares purchased at each separate price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"These shares of the Issuer's common stock are held of record by OrbiMed Private Investments VI, LP (\"OPI VI\"). OrbiMed Capital GP VI LLC (\"GP VI\") is the general partner of OPI VI, and OrbiMed Advisors is the managing member of GP VI. By virtue of such relationships, GP VI and OrbiMed Advisors may be deemed to have voting and investment power over the shares of common stock held by OPI VI and, as a result, may be deemed to have beneficial ownership over such shares of common stock. OrbiMed Advisors exercises this investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership over the shares of common stock held by OPI VI."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"Each of OrbiMed Advisors, OrbiMed BioFund, OrbiMed Israel GP, OrbiMed Israel GP II, OrbiMed Israel II, GP V, GP VI, Genesis GP, and Erez Chimovits disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of his or its pecuniary interest therein, if any. OrbiMed Advisors, GP V and GP VI have designated a representative, Carl L. Gordon, a member of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any such person or entity is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":748054,"source":{"system":"sec-edgar","filing":"0000947871-23-000713","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787123000713/ownership.xml","form_type":"4"}},{"id":1842240,"issuer":{"id":6860,"kind":"organization","name":"Adicet Bio, Inc."},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53130,"kind":"organization","name":"OrbiMed Capital GP V LLC","position":2,"cik":"0001615374","reported_name":"OrbiMed Capital GP V LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51517,"kind":"person","name":"OrbiMed Capital GP VI LLC","position":3,"cik":"0001682115","reported_name":"OrbiMed Capital GP VI LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24740,"kind":"person","name":"OrbiMed Genesis GP LLC","position":4,"cik":"0001808744","reported_name":"OrbiMed Genesis GP LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53131,"kind":"organization","name":"OrbiMed Advisors Israel II Ltd","position":5,"cik":"0001682093","reported_name":"OrbiMed Advisors Israel II Ltd","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53132,"kind":"organization","name":"OrbiMed Israel GP II, L.P.","position":6,"cik":"0001682090","reported_name":"OrbiMed Israel GP II, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53133,"kind":"organization","name":"OrbiMed Israel GP Ltd.","position":7,"cik":"0001569590","reported_name":"OrbiMed Israel GP Ltd.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53134,"kind":"organization","name":"OrbiMed Israel BioFund GP Limited Partnership","position":8,"cik":"0001569821","reported_name":"OrbiMed Israel BioFund GP Limited Partnership","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24622,"kind":"person","name":"Chimovits Erez","position":9,"cik":"0001706399","reported_name":"Chimovits Erez","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-06-29T20:46:01.000Z","date":"2023-06-27","kind":"purchase","planned":false,"acquired":true,"shares":442000,"price":2.09,"value":923780.0,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents the weighted average purchase price of the shares of common stock purchased, ranging from a low of $2.08 to a high of $2.12 per share. The Reporting Persons undertake, upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, to provide full information regarding the number of shares purchased at each separate price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"These shares of the Issuer's common stock are held of record by OrbiMed Private Investments V, LP (\"OPI V\"). OrbiMed Capital GP V LLC (\"GP V\") is the general partner of OPI V, and OrbiMed Advisors LLC (\"OrbiMed Advisors\"), a registered investment adviser under the Investment Advisors Act of 1940, as amended, is the managing member of GP V. By virtue of such relationships, GP V and OrbiMed Advisors may be deemed to have voting and investment power over the shares of common stock held by OPI V and, as a result, may be deemed to have beneficial ownership over such shares of common stock. OrbiMed Advisors exercises this investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership over the shares of common stock held by OPI V."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"Each of OrbiMed Advisors, OrbiMed BioFund, OrbiMed Israel GP, OrbiMed Israel GP II, OrbiMed Israel II, GP V, GP VI, Genesis GP, and Erez Chimovits disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of his or its pecuniary interest therein, if any. OrbiMed Advisors, GP V and GP VI have designated a representative, Carl L. Gordon, a member of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any such person or entity is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":5685259,"source":{"system":"sec-edgar","filing":"0000947871-23-000713","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787123000713/ownership.xml","form_type":"4"}},{"id":1842239,"issuer":{"id":6860,"kind":"organization","name":"Adicet Bio, Inc."},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53130,"kind":"organization","name":"OrbiMed Capital GP V LLC","position":2,"cik":"0001615374","reported_name":"OrbiMed Capital GP V LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51517,"kind":"person","name":"OrbiMed Capital GP VI LLC","position":3,"cik":"0001682115","reported_name":"OrbiMed Capital GP VI LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24740,"kind":"person","name":"OrbiMed Genesis GP LLC","position":4,"cik":"0001808744","reported_name":"OrbiMed Genesis GP LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53131,"kind":"organization","name":"OrbiMed Advisors Israel II Ltd","position":5,"cik":"0001682093","reported_name":"OrbiMed Advisors Israel II Ltd","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53132,"kind":"organization","name":"OrbiMed Israel GP II, L.P.","position":6,"cik":"0001682090","reported_name":"OrbiMed Israel GP II, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53133,"kind":"organization","name":"OrbiMed Israel GP Ltd.","position":7,"cik":"0001569590","reported_name":"OrbiMed Israel GP Ltd.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53134,"kind":"organization","name":"OrbiMed Israel BioFund GP Limited Partnership","position":8,"cik":"0001569821","reported_name":"OrbiMed Israel BioFund GP Limited Partnership","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24622,"kind":"person","name":"Chimovits Erez","position":9,"cik":"0001706399","reported_name":"Chimovits Erez","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-06-29T20:46:01.000Z","date":"2023-06-27","kind":"purchase","planned":false,"acquired":true,"shares":250000,"price":2.09,"value":522500.0,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents the weighted average purchase price of the shares of common stock purchased, ranging from a low of $2.08 to a high of $2.12 per share. The Reporting Persons undertake, upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, to provide full information regarding the number of shares purchased at each separate price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These shares of the Issuer's common stock are held of record by OrbiMed Israel Partners II, L.P. (\"OIP II\"). OrbiMed Israel GP II, L.P. (\"OrbiMed Israel GP II\") is the general partner of OIP II, and OrbiMed Advisors Israel II Limited (\"OrbiMed Israel II\") is the general partner of OrbiMed Israel GP II. By virtue of such relationships, OrbiMed Israel GP II and OrbiMed Israel II may be deemed to have voting and investment power over the shares of common stock held by OIP II and, as a result, may be deemed to have beneficial ownership over such shares of common stock. OrbiMed Israel II exercises this investment and voting power through an investment committee comprised of Carl L. Gordon, David Bonita, and Erez Chimovits, each of whom disclaims beneficial ownership over the shares of common stock held by OIP II."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"Each of OrbiMed Advisors, OrbiMed BioFund, OrbiMed Israel GP, OrbiMed Israel GP II, OrbiMed Israel II, GP V, GP VI, Genesis GP, and Erez Chimovits disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of his or its pecuniary interest therein, if any. OrbiMed Advisors, GP V and GP VI have designated a representative, Carl L. Gordon, a member of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any such person or entity is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":646657,"source":{"system":"sec-edgar","filing":"0000947871-23-000713","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787123000713/ownership.xml","form_type":"4"}},{"id":1842238,"issuer":{"id":6860,"kind":"organization","name":"Adicet Bio, Inc."},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53130,"kind":"organization","name":"OrbiMed Capital GP V LLC","position":2,"cik":"0001615374","reported_name":"OrbiMed Capital GP V LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51517,"kind":"person","name":"OrbiMed Capital GP VI LLC","position":3,"cik":"0001682115","reported_name":"OrbiMed Capital GP VI LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24740,"kind":"person","name":"OrbiMed Genesis GP LLC","position":4,"cik":"0001808744","reported_name":"OrbiMed Genesis GP LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53131,"kind":"organization","name":"OrbiMed Advisors Israel II Ltd","position":5,"cik":"0001682093","reported_name":"OrbiMed Advisors Israel II Ltd","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53132,"kind":"organization","name":"OrbiMed Israel GP II, L.P.","position":6,"cik":"0001682090","reported_name":"OrbiMed Israel GP II, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53133,"kind":"organization","name":"OrbiMed Israel GP Ltd.","position":7,"cik":"0001569590","reported_name":"OrbiMed Israel GP Ltd.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53134,"kind":"organization","name":"OrbiMed Israel BioFund GP Limited Partnership","position":8,"cik":"0001569821","reported_name":"OrbiMed Israel BioFund GP Limited Partnership","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24622,"kind":"person","name":"Chimovits Erez","position":9,"cik":"0001706399","reported_name":"Chimovits Erez","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-06-29T20:46:01.000Z","date":"2023-06-27","kind":"purchase","planned":false,"acquired":true,"shares":125000,"price":2.09,"value":261250.0,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents the weighted average purchase price of the shares of common stock purchased, ranging from a low of $2.08 to a high of $2.12 per share. The Reporting Persons undertake, upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, to provide full information regarding the number of shares purchased at each separate price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares of the Issuer's common stock are held of record by OrbiMed Israel Partners Limited Partnership (\"OIP\"). OrbiMed Israel BioFund GP Limited Partnership (\"OrbiMed BioFund\") is the general partner of OIP, and OrbiMed Israel GP Ltd. (\"OrbiMed Israel GP\") is the general partner of OrbiMed BioFund. By virtue of such relationships, OrbiMed BioFund and OrbiMed Israel GP may be deemed to have voting and investment power over the shares of common stock held by OIP and, as a result, may be deemed to have beneficial ownership over such shares of common stock. OrbiMed Israel GP exercises this investment and voting power through an investment committee comprised of Carl L. Gordon and Erez Chimovits, each of whom disclaims beneficial ownership over the shares of common stock held by OIP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"Each of OrbiMed Advisors, OrbiMed BioFund, OrbiMed Israel GP, OrbiMed Israel GP II, OrbiMed Israel II, GP V, GP VI, Genesis GP, and Erez Chimovits disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of his or its pecuniary interest therein, if any. OrbiMed Advisors, GP V and GP VI have designated a representative, Carl L. Gordon, a member of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any such person or entity is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":1027885,"source":{"system":"sec-edgar","filing":"0000947871-23-000713","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787123000713/ownership.xml","form_type":"4"}},{"id":1919101,"issuer":{"id":4602,"kind":"organization","name":"Damora Therapeutics, Inc.","symbol":"DMRA"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24740,"kind":"person","name":"OrbiMed Genesis GP LLC","position":2,"cik":"0001808744","reported_name":"OrbiMed Genesis GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53132,"kind":"organization","name":"OrbiMed Israel GP II, L.P.","position":3,"cik":"0001682090","reported_name":"OrbiMed Israel GP II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53131,"kind":"organization","name":"OrbiMed Advisors Israel II Ltd","position":4,"cik":"0001682093","reported_name":"OrbiMed Advisors Israel II Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35791,"kind":"organization","name":"OrbiMed Capital GP VII LLC","position":5,"cik":"0001760648","reported_name":"OrbiMed Capital GP VII LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-04-17T21:28:01.000Z","date":"2023-04-17","kind":"sale","planned":false,"acquired":false,"shares":8878,"price":1.97,"value":17489.66,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These securities are held of record by OrbiMed Private Investments VII, LP (\"OPI VII\"). OrbiMed Capital GP VII LLC (\"GP VII\") is the general partner of OPI VII and OrbiMed Advisors is the managing member of GP VII. By virtue of such relationships, OrbiMed Advisors and GP VII may be deemed to have voting power and investment power over the securities held by OPI VII and, as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the securities held by OPI VII."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Each of OrbiMed Advisors, Genesis GP, OrbiMed Israel, OrbiMed Limited, and GP VII disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any such person or entity, including the Reporting Persons, is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":2417787,"source":{"system":"sec-edgar","filing":"0000947871-23-000472","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787123000472/ownership.xml","form_type":"4"}},{"id":1919100,"issuer":{"id":4602,"kind":"organization","name":"Damora Therapeutics, Inc.","symbol":"DMRA"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24740,"kind":"person","name":"OrbiMed Genesis GP LLC","position":2,"cik":"0001808744","reported_name":"OrbiMed Genesis GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53132,"kind":"organization","name":"OrbiMed Israel GP II, L.P.","position":3,"cik":"0001682090","reported_name":"OrbiMed Israel GP II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53131,"kind":"organization","name":"OrbiMed Advisors Israel II Ltd","position":4,"cik":"0001682093","reported_name":"OrbiMed Advisors Israel II Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35791,"kind":"organization","name":"OrbiMed Capital GP VII LLC","position":5,"cik":"0001760648","reported_name":"OrbiMed Capital GP VII LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-04-17T21:28:01.000Z","date":"2023-04-17","kind":"sale","planned":false,"acquired":false,"shares":3551,"price":1.97,"value":6995.47,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held of record by OrbiMed Israel Partners II, L.P. (\"OIP II\"). OrbiMed Israel GP II, L.P. (\"OrbiMed Israel\") is the general partner of OIP II and OrbiMed Advisors Israel II Limited (\"OrbiMed Limited\") is the general partner of OrbiMed Israel. By virtue of such relationships, OrbiMed Limited and OrbiMed Israel may be deemed to have voting power and investment power over the securities held by OIP II and, as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Limited exercises voting and investment power through a management committee comprised of Carl L. Gordon, David P. Bonita, and Erez Chimovits, each of whom disclaims beneficial ownership of the securities held by OIP II."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Each of OrbiMed Advisors, Genesis GP, OrbiMed Israel, OrbiMed Limited, and GP VII disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any such person or entity, including the Reporting Persons, is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":967067,"source":{"system":"sec-edgar","filing":"0000947871-23-000472","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787123000472/ownership.xml","form_type":"4"}},{"id":1919099,"issuer":{"id":4602,"kind":"organization","name":"Damora Therapeutics, Inc.","symbol":"DMRA"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24740,"kind":"person","name":"OrbiMed Genesis GP LLC","position":2,"cik":"0001808744","reported_name":"OrbiMed Genesis GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53132,"kind":"organization","name":"OrbiMed Israel GP II, L.P.","position":3,"cik":"0001682090","reported_name":"OrbiMed Israel GP II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53131,"kind":"organization","name":"OrbiMed Advisors Israel II Ltd","position":4,"cik":"0001682093","reported_name":"OrbiMed Advisors Israel II Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35791,"kind":"organization","name":"OrbiMed Capital GP VII LLC","position":5,"cik":"0001760648","reported_name":"OrbiMed Capital GP VII LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-04-17T21:28:01.000Z","date":"2023-04-17","kind":"sale","planned":false,"acquired":false,"shares":660,"price":1.97,"value":1300.2,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"These securities are held of record by OrbiMed Genesis Master Fund, L.P. (\"OrbiMed Genesis\"). OrbiMed Genesis GP LLC (\"Genesis GP\") is the general partner of OrbiMed Genesis and OrbiMed Advisors LLC (\"OrbiMed Advisors\") is the managing member of Genesis GP. By virtue of such relationships, OrbiMed Advisors and Genesis GP may be deemed to have voting power and investment power over the securities held by OrbiMed Genesis and, as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the securities held by OrbiMed Genesis."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Each of OrbiMed Advisors, Genesis GP, OrbiMed Israel, OrbiMed Limited, and GP VII disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any such person or entity, including the Reporting Persons, is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":179753,"source":{"system":"sec-edgar","filing":"0000947871-23-000472","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787123000472/ownership.xml","form_type":"4"}},{"id":1919098,"issuer":{"id":4602,"kind":"organization","name":"Damora Therapeutics, Inc.","symbol":"DMRA"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24740,"kind":"person","name":"OrbiMed Genesis GP LLC","position":2,"cik":"0001808744","reported_name":"OrbiMed Genesis GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53132,"kind":"organization","name":"OrbiMed Israel GP II, L.P.","position":3,"cik":"0001682090","reported_name":"OrbiMed Israel GP II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53131,"kind":"organization","name":"OrbiMed Advisors Israel II Ltd","position":4,"cik":"0001682093","reported_name":"OrbiMed Advisors Israel II Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35791,"kind":"organization","name":"OrbiMed Capital GP VII LLC","position":5,"cik":"0001760648","reported_name":"OrbiMed Capital GP VII LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-04-17T21:28:01.000Z","date":"2023-04-14","kind":"sale","planned":false,"acquired":false,"shares":28110,"price":1.86,"value":52284.6,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These securities are held of record by OrbiMed Private Investments VII, LP (\"OPI VII\"). OrbiMed Capital GP VII LLC (\"GP VII\") is the general partner of OPI VII and OrbiMed Advisors is the managing member of GP VII. By virtue of such relationships, OrbiMed Advisors and GP VII may be deemed to have voting power and investment power over the securities held by OPI VII and, as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the securities held by OPI VII."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Each of OrbiMed Advisors, Genesis GP, OrbiMed Israel, OrbiMed Limited, and GP VII disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any such person or entity, including the Reporting Persons, is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":2426665,"source":{"system":"sec-edgar","filing":"0000947871-23-000472","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787123000472/ownership.xml","form_type":"4"}},{"id":1919097,"issuer":{"id":4602,"kind":"organization","name":"Damora Therapeutics, Inc.","symbol":"DMRA"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24740,"kind":"person","name":"OrbiMed Genesis GP LLC","position":2,"cik":"0001808744","reported_name":"OrbiMed Genesis GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53132,"kind":"organization","name":"OrbiMed Israel GP II, L.P.","position":3,"cik":"0001682090","reported_name":"OrbiMed Israel GP II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53131,"kind":"organization","name":"OrbiMed Advisors Israel II Ltd","position":4,"cik":"0001682093","reported_name":"OrbiMed Advisors Israel II Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35791,"kind":"organization","name":"OrbiMed Capital GP VII LLC","position":5,"cik":"0001760648","reported_name":"OrbiMed Capital GP VII LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-04-17T21:28:01.000Z","date":"2023-04-14","kind":"sale","planned":false,"acquired":false,"shares":11245,"price":1.86,"value":20915.7,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held of record by OrbiMed Israel Partners II, L.P. (\"OIP II\"). OrbiMed Israel GP II, L.P. (\"OrbiMed Israel\") is the general partner of OIP II and OrbiMed Advisors Israel II Limited (\"OrbiMed Limited\") is the general partner of OrbiMed Israel. By virtue of such relationships, OrbiMed Limited and OrbiMed Israel may be deemed to have voting power and investment power over the securities held by OIP II and, as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Limited exercises voting and investment power through a management committee comprised of Carl L. Gordon, David P. Bonita, and Erez Chimovits, each of whom disclaims beneficial ownership of the securities held by OIP II."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Each of OrbiMed Advisors, Genesis GP, OrbiMed Israel, OrbiMed Limited, and GP VII disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any such person or entity, including the Reporting Persons, is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":970618,"source":{"system":"sec-edgar","filing":"0000947871-23-000472","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787123000472/ownership.xml","form_type":"4"}},{"id":1919096,"issuer":{"id":4602,"kind":"organization","name":"Damora Therapeutics, Inc.","symbol":"DMRA"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24740,"kind":"person","name":"OrbiMed Genesis GP LLC","position":2,"cik":"0001808744","reported_name":"OrbiMed Genesis GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53132,"kind":"organization","name":"OrbiMed Israel GP II, L.P.","position":3,"cik":"0001682090","reported_name":"OrbiMed Israel GP II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53131,"kind":"organization","name":"OrbiMed Advisors Israel II Ltd","position":4,"cik":"0001682093","reported_name":"OrbiMed Advisors Israel II Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35791,"kind":"organization","name":"OrbiMed Capital GP VII LLC","position":5,"cik":"0001760648","reported_name":"OrbiMed Capital GP VII LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-04-17T21:28:01.000Z","date":"2023-04-14","kind":"sale","planned":false,"acquired":false,"shares":2091,"price":1.86,"value":3889.26,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"These securities are held of record by OrbiMed Genesis Master Fund, L.P. (\"OrbiMed Genesis\"). OrbiMed Genesis GP LLC (\"Genesis GP\") is the general partner of OrbiMed Genesis and OrbiMed Advisors LLC (\"OrbiMed Advisors\") is the managing member of Genesis GP. By virtue of such relationships, OrbiMed Advisors and Genesis GP may be deemed to have voting power and investment power over the securities held by OrbiMed Genesis and, as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the securities held by OrbiMed Genesis."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Each of OrbiMed Advisors, Genesis GP, OrbiMed Israel, OrbiMed Limited, and GP VII disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any such person or entity, including the Reporting Persons, is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":180413,"source":{"system":"sec-edgar","filing":"0000947871-23-000472","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787123000472/ownership.xml","form_type":"4"}},{"id":1919095,"issuer":{"id":4602,"kind":"organization","name":"Damora Therapeutics, Inc.","symbol":"DMRA"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24740,"kind":"person","name":"OrbiMed Genesis GP LLC","position":2,"cik":"0001808744","reported_name":"OrbiMed Genesis GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53132,"kind":"organization","name":"OrbiMed Israel GP II, L.P.","position":3,"cik":"0001682090","reported_name":"OrbiMed Israel GP II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53131,"kind":"organization","name":"OrbiMed Advisors Israel II Ltd","position":4,"cik":"0001682093","reported_name":"OrbiMed Advisors Israel II Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35791,"kind":"organization","name":"OrbiMed Capital GP VII LLC","position":5,"cik":"0001760648","reported_name":"OrbiMed Capital GP VII LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-04-17T21:28:01.000Z","date":"2023-04-13","kind":"sale","planned":false,"acquired":false,"shares":9459,"price":1.82,"value":17215.38,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These securities are held of record by OrbiMed Private Investments VII, LP (\"OPI VII\"). OrbiMed Capital GP VII LLC (\"GP VII\") is the general partner of OPI VII and OrbiMed Advisors is the managing member of GP VII. By virtue of such relationships, OrbiMed Advisors and GP VII may be deemed to have voting power and investment power over the securities held by OPI VII and, as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the securities held by OPI VII."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Each of OrbiMed Advisors, Genesis GP, OrbiMed Israel, OrbiMed Limited, and GP VII disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any such person or entity, including the Reporting Persons, is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":2454775,"source":{"system":"sec-edgar","filing":"0000947871-23-000472","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787123000472/ownership.xml","form_type":"4"}},{"id":1919094,"issuer":{"id":4602,"kind":"organization","name":"Damora Therapeutics, Inc.","symbol":"DMRA"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24740,"kind":"person","name":"OrbiMed Genesis GP LLC","position":2,"cik":"0001808744","reported_name":"OrbiMed Genesis GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53132,"kind":"organization","name":"OrbiMed Israel GP II, L.P.","position":3,"cik":"0001682090","reported_name":"OrbiMed Israel GP II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53131,"kind":"organization","name":"OrbiMed Advisors Israel II Ltd","position":4,"cik":"0001682093","reported_name":"OrbiMed Advisors Israel II Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35791,"kind":"organization","name":"OrbiMed Capital GP VII LLC","position":5,"cik":"0001760648","reported_name":"OrbiMed Capital GP VII LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-04-17T21:28:01.000Z","date":"2023-04-13","kind":"sale","planned":false,"acquired":false,"shares":3784,"price":1.82,"value":6886.88,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held of record by OrbiMed Israel Partners II, L.P. (\"OIP II\"). OrbiMed Israel GP II, L.P. (\"OrbiMed Israel\") is the general partner of OIP II and OrbiMed Advisors Israel II Limited (\"OrbiMed Limited\") is the general partner of OrbiMed Israel. By virtue of such relationships, OrbiMed Limited and OrbiMed Israel may be deemed to have voting power and investment power over the securities held by OIP II and, as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Limited exercises voting and investment power through a management committee comprised of Carl L. Gordon, David P. Bonita, and Erez Chimovits, each of whom disclaims beneficial ownership of the securities held by OIP II."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Each of OrbiMed Advisors, Genesis GP, OrbiMed Israel, OrbiMed Limited, and GP VII disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any such person or entity, including the Reporting Persons, is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":981863,"source":{"system":"sec-edgar","filing":"0000947871-23-000472","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787123000472/ownership.xml","form_type":"4"}},{"id":1919093,"issuer":{"id":4602,"kind":"organization","name":"Damora Therapeutics, Inc.","symbol":"DMRA"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24740,"kind":"person","name":"OrbiMed Genesis GP LLC","position":2,"cik":"0001808744","reported_name":"OrbiMed Genesis GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53132,"kind":"organization","name":"OrbiMed Israel GP II, L.P.","position":3,"cik":"0001682090","reported_name":"OrbiMed Israel GP II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53131,"kind":"organization","name":"OrbiMed Advisors Israel II Ltd","position":4,"cik":"0001682093","reported_name":"OrbiMed Advisors Israel II Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35791,"kind":"organization","name":"OrbiMed Capital GP VII LLC","position":5,"cik":"0001760648","reported_name":"OrbiMed Capital GP VII LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-04-17T21:28:01.000Z","date":"2023-04-13","kind":"sale","planned":false,"acquired":false,"shares":703,"price":1.82,"value":1279.46,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"These securities are held of record by OrbiMed Genesis Master Fund, L.P. (\"OrbiMed Genesis\"). OrbiMed Genesis GP LLC (\"Genesis GP\") is the general partner of OrbiMed Genesis and OrbiMed Advisors LLC (\"OrbiMed Advisors\") is the managing member of Genesis GP. By virtue of such relationships, OrbiMed Advisors and Genesis GP may be deemed to have voting power and investment power over the securities held by OrbiMed Genesis and, as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the securities held by OrbiMed Genesis."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Each of OrbiMed Advisors, Genesis GP, OrbiMed Israel, OrbiMed Limited, and GP VII disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any such person or entity, including the Reporting Persons, is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":182504,"source":{"system":"sec-edgar","filing":"0000947871-23-000472","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787123000472/ownership.xml","form_type":"4"}},{"id":1921259,"issuer":{"id":4602,"kind":"organization","name":"Damora Therapeutics, Inc.","symbol":"DMRA"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24740,"kind":"person","name":"OrbiMed Genesis GP LLC","position":2,"cik":"0001808744","reported_name":"OrbiMed Genesis GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53132,"kind":"organization","name":"OrbiMed Israel GP II, L.P.","position":3,"cik":"0001682090","reported_name":"OrbiMed Israel GP II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53131,"kind":"organization","name":"OrbiMed Advisors Israel II Ltd","position":4,"cik":"0001682093","reported_name":"OrbiMed Advisors Israel II Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35791,"kind":"organization","name":"OrbiMed Capital GP VII LLC","position":5,"cik":"0001760648","reported_name":"OrbiMed Capital GP VII LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-04-12T22:44:50.000Z","date":"2023-04-12","kind":"sale","planned":false,"acquired":false,"shares":1603,"price":1.81,"value":2901.43,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These securities are held of record by OrbiMed Private Investments VII, LP (\"OPI VII\"). OrbiMed Capital GP VII LLC (\"GP VII\") is the general partner of OPI VII and OrbiMed Advisors is the managing member of GP VII. By virtue of such relationships, OrbiMed Advisors and GP VII may be deemed to have voting power and investment power over the securities held by OPI VII and, as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the securities held by OPI VII."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Each of OrbiMed Advisors, Genesis GP, OrbiMed Israel, OrbiMed Limited, and GP VII disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any such person or entity, including the Reporting Persons, is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":2464234,"source":{"system":"sec-edgar","filing":"0000947871-23-000452","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787123000452/ownership.xml","form_type":"4"}},{"id":1921258,"issuer":{"id":4602,"kind":"organization","name":"Damora Therapeutics, Inc.","symbol":"DMRA"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24740,"kind":"person","name":"OrbiMed Genesis GP LLC","position":2,"cik":"0001808744","reported_name":"OrbiMed Genesis GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53132,"kind":"organization","name":"OrbiMed Israel GP II, L.P.","position":3,"cik":"0001682090","reported_name":"OrbiMed Israel GP II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53131,"kind":"organization","name":"OrbiMed Advisors Israel II Ltd","position":4,"cik":"0001682093","reported_name":"OrbiMed Advisors Israel II Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35791,"kind":"organization","name":"OrbiMed Capital GP VII LLC","position":5,"cik":"0001760648","reported_name":"OrbiMed Capital GP VII LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-04-12T22:44:50.000Z","date":"2023-04-12","kind":"sale","planned":false,"acquired":false,"shares":641,"price":1.81,"value":1160.21,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held of record by OrbiMed Israel Partners II, L.P. (\"OIP II\"). OrbiMed Israel GP II, L.P. (\"OrbiMed Israel\") is the general partner of OIP II and OrbiMed Advisors Israel II Limited (\"OrbiMed Limited\") is the general partner of OrbiMed Israel. By virtue of such relationships, OrbiMed Limited and OrbiMed Israel may be deemed to have voting power and investment power over the securities held by OIP II and, as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Limited exercises voting and investment power through a management committee comprised of Carl L. Gordon, David P. Bonita, and Erez Chimovits, each of whom disclaims beneficial ownership of the securities held by OIP II."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Each of OrbiMed Advisors, Genesis GP, OrbiMed Israel, OrbiMed Limited, and GP VII disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any such person or entity, including the Reporting Persons, is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":985647,"source":{"system":"sec-edgar","filing":"0000947871-23-000452","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787123000452/ownership.xml","form_type":"4"}},{"id":1921257,"issuer":{"id":4602,"kind":"organization","name":"Damora Therapeutics, Inc.","symbol":"DMRA"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24740,"kind":"person","name":"OrbiMed Genesis GP LLC","position":2,"cik":"0001808744","reported_name":"OrbiMed Genesis GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53132,"kind":"organization","name":"OrbiMed Israel GP II, L.P.","position":3,"cik":"0001682090","reported_name":"OrbiMed Israel GP II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53131,"kind":"organization","name":"OrbiMed Advisors Israel II Ltd","position":4,"cik":"0001682093","reported_name":"OrbiMed Advisors Israel II Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35791,"kind":"organization","name":"OrbiMed Capital GP VII LLC","position":5,"cik":"0001760648","reported_name":"OrbiMed Capital GP VII LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-04-12T22:44:50.000Z","date":"2023-04-12","kind":"sale","planned":false,"acquired":false,"shares":119,"price":1.81,"value":215.39,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"These securities are held of record by OrbiMed Genesis Master Fund, L.P. (\"OrbiMed Genesis\"). OrbiMed Genesis GP LLC (\"Genesis GP\") is the general partner of OrbiMed Genesis and OrbiMed Advisors LLC (\"OrbiMed Advisors\") is the managing member of Genesis GP. By virtue of such relationships, OrbiMed Advisors and Genesis GP may be deemed to have voting power and investment power over the securities held by OrbiMed Genesis and, as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the securities held by OrbiMed Genesis."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Each of OrbiMed Advisors, Genesis GP, OrbiMed Israel, OrbiMed Limited, and GP VII disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any such person or entity, including the Reporting Persons, is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":183207,"source":{"system":"sec-edgar","filing":"0000947871-23-000452","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787123000452/ownership.xml","form_type":"4"}},{"id":1921256,"issuer":{"id":4602,"kind":"organization","name":"Damora Therapeutics, Inc.","symbol":"DMRA"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24740,"kind":"person","name":"OrbiMed Genesis GP LLC","position":2,"cik":"0001808744","reported_name":"OrbiMed Genesis GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53132,"kind":"organization","name":"OrbiMed Israel GP II, L.P.","position":3,"cik":"0001682090","reported_name":"OrbiMed Israel GP II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53131,"kind":"organization","name":"OrbiMed Advisors Israel II Ltd","position":4,"cik":"0001682093","reported_name":"OrbiMed Advisors Israel II Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35791,"kind":"organization","name":"OrbiMed Capital GP VII LLC","position":5,"cik":"0001760648","reported_name":"OrbiMed Capital GP VII LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-04-12T22:44:50.000Z","date":"2023-04-11","kind":"sale","planned":false,"acquired":false,"shares":9459,"price":1.82,"value":17215.38,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These securities are held of record by OrbiMed Private Investments VII, LP (\"OPI VII\"). OrbiMed Capital GP VII LLC (\"GP VII\") is the general partner of OPI VII and OrbiMed Advisors is the managing member of GP VII. By virtue of such relationships, OrbiMed Advisors and GP VII may be deemed to have voting power and investment power over the securities held by OPI VII and, as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the securities held by OPI VII."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Each of OrbiMed Advisors, Genesis GP, OrbiMed Israel, OrbiMed Limited, and GP VII disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any such person or entity, including the Reporting Persons, is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":2465837,"source":{"system":"sec-edgar","filing":"0000947871-23-000452","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787123000452/ownership.xml","form_type":"4"}},{"id":1921255,"issuer":{"id":4602,"kind":"organization","name":"Damora Therapeutics, Inc.","symbol":"DMRA"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24740,"kind":"person","name":"OrbiMed Genesis GP LLC","position":2,"cik":"0001808744","reported_name":"OrbiMed Genesis GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53132,"kind":"organization","name":"OrbiMed Israel GP II, L.P.","position":3,"cik":"0001682090","reported_name":"OrbiMed Israel GP II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53131,"kind":"organization","name":"OrbiMed Advisors Israel II Ltd","position":4,"cik":"0001682093","reported_name":"OrbiMed Advisors Israel II Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35791,"kind":"organization","name":"OrbiMed Capital GP VII LLC","position":5,"cik":"0001760648","reported_name":"OrbiMed Capital GP VII LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-04-12T22:44:50.000Z","date":"2023-04-11","kind":"sale","planned":false,"acquired":false,"shares":3784,"price":1.82,"value":6886.88,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held of record by OrbiMed Israel Partners II, L.P. (\"OIP II\"). OrbiMed Israel GP II, L.P. (\"OrbiMed Israel\") is the general partner of OIP II and OrbiMed Advisors Israel II Limited (\"OrbiMed Limited\") is the general partner of OrbiMed Israel. By virtue of such relationships, OrbiMed Limited and OrbiMed Israel may be deemed to have voting power and investment power over the securities held by OIP II and, as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Limited exercises voting and investment power through a management committee comprised of Carl L. Gordon, David P. Bonita, and Erez Chimovits, each of whom disclaims beneficial ownership of the securities held by OIP II."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Each of OrbiMed Advisors, Genesis GP, OrbiMed Israel, OrbiMed Limited, and GP VII disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any such person or entity, including the Reporting Persons, is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":986288,"source":{"system":"sec-edgar","filing":"0000947871-23-000452","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787123000452/ownership.xml","form_type":"4"}},{"id":1921254,"issuer":{"id":4602,"kind":"organization","name":"Damora Therapeutics, Inc.","symbol":"DMRA"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24740,"kind":"person","name":"OrbiMed Genesis GP LLC","position":2,"cik":"0001808744","reported_name":"OrbiMed Genesis GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53132,"kind":"organization","name":"OrbiMed Israel GP II, L.P.","position":3,"cik":"0001682090","reported_name":"OrbiMed Israel GP II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53131,"kind":"organization","name":"OrbiMed Advisors Israel II Ltd","position":4,"cik":"0001682093","reported_name":"OrbiMed Advisors Israel II Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35791,"kind":"organization","name":"OrbiMed Capital GP VII LLC","position":5,"cik":"0001760648","reported_name":"OrbiMed Capital GP VII LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-04-12T22:44:50.000Z","date":"2023-04-11","kind":"sale","planned":false,"acquired":false,"shares":703,"price":1.82,"value":1279.46,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"These securities are held of record by OrbiMed Genesis Master Fund, L.P. (\"OrbiMed Genesis\"). OrbiMed Genesis GP LLC (\"Genesis GP\") is the general partner of OrbiMed Genesis and OrbiMed Advisors LLC (\"OrbiMed Advisors\") is the managing member of Genesis GP. By virtue of such relationships, OrbiMed Advisors and Genesis GP may be deemed to have voting power and investment power over the securities held by OrbiMed Genesis and, as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the securities held by OrbiMed Genesis."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Each of OrbiMed Advisors, Genesis GP, OrbiMed Israel, OrbiMed Limited, and GP VII disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any such person or entity, including the Reporting Persons, is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":183326,"source":{"system":"sec-edgar","filing":"0000947871-23-000452","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787123000452/ownership.xml","form_type":"4"}},{"id":1921253,"issuer":{"id":4602,"kind":"organization","name":"Damora Therapeutics, Inc.","symbol":"DMRA"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24740,"kind":"person","name":"OrbiMed Genesis GP LLC","position":2,"cik":"0001808744","reported_name":"OrbiMed Genesis GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53132,"kind":"organization","name":"OrbiMed Israel GP II, L.P.","position":3,"cik":"0001682090","reported_name":"OrbiMed Israel GP II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53131,"kind":"organization","name":"OrbiMed Advisors Israel II Ltd","position":4,"cik":"0001682093","reported_name":"OrbiMed Advisors Israel II Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35791,"kind":"organization","name":"OrbiMed Capital GP VII LLC","position":5,"cik":"0001760648","reported_name":"OrbiMed Capital GP VII LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-04-12T22:44:50.000Z","date":"2023-04-10","kind":"sale","planned":false,"acquired":false,"shares":34745,"price":1.79,"value":62193.55,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These securities are held of record by OrbiMed Private Investments VII, LP (\"OPI VII\"). OrbiMed Capital GP VII LLC (\"GP VII\") is the general partner of OPI VII and OrbiMed Advisors is the managing member of GP VII. By virtue of such relationships, OrbiMed Advisors and GP VII may be deemed to have voting power and investment power over the securities held by OPI VII and, as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the securities held by OPI VII."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Each of OrbiMed Advisors, Genesis GP, OrbiMed Israel, OrbiMed Limited, and GP VII disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any such person or entity, including the Reporting Persons, is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":2500582,"source":{"system":"sec-edgar","filing":"0000947871-23-000452","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787123000452/ownership.xml","form_type":"4"}},{"id":1921252,"issuer":{"id":4602,"kind":"organization","name":"Damora Therapeutics, Inc.","symbol":"DMRA"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24740,"kind":"person","name":"OrbiMed Genesis GP LLC","position":2,"cik":"0001808744","reported_name":"OrbiMed Genesis GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53132,"kind":"organization","name":"OrbiMed Israel GP II, L.P.","position":3,"cik":"0001682090","reported_name":"OrbiMed Israel GP II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53131,"kind":"organization","name":"OrbiMed Advisors Israel II Ltd","position":4,"cik":"0001682093","reported_name":"OrbiMed Advisors Israel II Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35791,"kind":"organization","name":"OrbiMed Capital GP VII LLC","position":5,"cik":"0001760648","reported_name":"OrbiMed Capital GP VII LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-04-12T22:44:50.000Z","date":"2023-04-10","kind":"sale","planned":false,"acquired":false,"shares":13899,"price":1.79,"value":24879.21,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held of record by OrbiMed Israel Partners II, L.P. (\"OIP II\"). OrbiMed Israel GP II, L.P. (\"OrbiMed Israel\") is the general partner of OIP II and OrbiMed Advisors Israel II Limited (\"OrbiMed Limited\") is the general partner of OrbiMed Israel. By virtue of such relationships, OrbiMed Limited and OrbiMed Israel may be deemed to have voting power and investment power over the securities held by OIP II and, as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Limited exercises voting and investment power through a management committee comprised of Carl L. Gordon, David P. Bonita, and Erez Chimovits, each of whom disclaims beneficial ownership of the securities held by OIP II."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Each of OrbiMed Advisors, Genesis GP, OrbiMed Israel, OrbiMed Limited, and GP VII disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any such person or entity, including the Reporting Persons, is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":1000187,"source":{"system":"sec-edgar","filing":"0000947871-23-000452","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787123000452/ownership.xml","form_type":"4"}},{"id":1921251,"issuer":{"id":4602,"kind":"organization","name":"Damora Therapeutics, Inc.","symbol":"DMRA"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24740,"kind":"person","name":"OrbiMed Genesis GP LLC","position":2,"cik":"0001808744","reported_name":"OrbiMed Genesis GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53132,"kind":"organization","name":"OrbiMed Israel GP II, L.P.","position":3,"cik":"0001682090","reported_name":"OrbiMed Israel GP II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53131,"kind":"organization","name":"OrbiMed Advisors Israel II Ltd","position":4,"cik":"0001682093","reported_name":"OrbiMed Advisors Israel II Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35791,"kind":"organization","name":"OrbiMed Capital GP VII LLC","position":5,"cik":"0001760648","reported_name":"OrbiMed Capital GP VII LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-04-12T22:44:50.000Z","date":"2023-04-10","kind":"sale","planned":false,"acquired":false,"shares":2584,"price":1.79,"value":4625.36,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"These securities are held of record by OrbiMed Genesis Master Fund, L.P. (\"OrbiMed Genesis\"). OrbiMed Genesis GP LLC (\"Genesis GP\") is the general partner of OrbiMed Genesis and OrbiMed Advisors LLC (\"OrbiMed Advisors\") is the managing member of Genesis GP. By virtue of such relationships, OrbiMed Advisors and Genesis GP may be deemed to have voting power and investment power over the securities held by OrbiMed Genesis and, as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the securities held by OrbiMed Genesis."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Each of OrbiMed Advisors, Genesis GP, OrbiMed Israel, OrbiMed Limited, and GP VII disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any such person or entity, including the Reporting Persons, is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":185910,"source":{"system":"sec-edgar","filing":"0000947871-23-000452","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787123000452/ownership.xml","form_type":"4"}},{"id":1923172,"issuer":{"id":4602,"kind":"organization","name":"Damora Therapeutics, Inc.","symbol":"DMRA"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24740,"kind":"person","name":"OrbiMed Genesis GP LLC","position":2,"cik":"0001808744","reported_name":"OrbiMed Genesis GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53132,"kind":"organization","name":"OrbiMed Israel GP II, L.P.","position":3,"cik":"0001682090","reported_name":"OrbiMed Israel GP II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53131,"kind":"organization","name":"OrbiMed Advisors Israel II Ltd","position":4,"cik":"0001682093","reported_name":"OrbiMed Advisors Israel II Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35791,"kind":"organization","name":"OrbiMed Capital GP VII LLC","position":5,"cik":"0001760648","reported_name":"OrbiMed Capital GP VII LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-04-07T20:42:12.000Z","date":"2023-04-06","kind":"sale","planned":false,"acquired":false,"shares":6558,"price":2,"value":13116.0,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These securities are held of record by OrbiMed Private Investments VII, LP (\"OPI VII\"). OrbiMed Capital GP VII LLC (\"GP VII\") is the general partner of OPI VII and OrbiMed Advisors is the managing member of GP VII. By virtue of such relationships, OrbiMed Advisors and GP VII may be deemed to have voting power and investment power over the securities held by OPI VII and, as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the securities held by OPI VII."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Each of OrbiMed Advisors, Genesis GP, OrbiMed Israel, OrbiMed Limited, and GP VII disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any such person or entity, including the Reporting Persons, is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":2510041,"source":{"system":"sec-edgar","filing":"0000947871-23-000438","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787123000438/ownership.xml","form_type":"4"}},{"id":1923171,"issuer":{"id":4602,"kind":"organization","name":"Damora Therapeutics, Inc.","symbol":"DMRA"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24740,"kind":"person","name":"OrbiMed Genesis GP LLC","position":2,"cik":"0001808744","reported_name":"OrbiMed Genesis GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53132,"kind":"organization","name":"OrbiMed Israel GP II, L.P.","position":3,"cik":"0001682090","reported_name":"OrbiMed Israel GP II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53131,"kind":"organization","name":"OrbiMed Advisors Israel II Ltd","position":4,"cik":"0001682093","reported_name":"OrbiMed Advisors Israel II Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35791,"kind":"organization","name":"OrbiMed Capital GP VII LLC","position":5,"cik":"0001760648","reported_name":"OrbiMed Capital GP VII LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-04-07T20:42:12.000Z","date":"2023-04-06","kind":"sale","planned":false,"acquired":false,"shares":2620,"price":2,"value":5240.0,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held of record by OrbiMed Israel Partners II, L.P. (\"OIP II\"). OrbiMed Israel GP II, L.P. (\"OrbiMed Israel\") is the general partner of OIP II and OrbiMed Advisors Israel II Limited (\"OrbiMed Limited\") is the general partner of OrbiMed Israel. By virtue of such relationships, OrbiMed Limited and OrbiMed Israel may be deemed to have voting power and investment power over the securities held by OIP II and, as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Limited exercises voting and investment power through a management committee comprised of Carl L. Gordon, David P. Bonita, and Erez Chimovits, each of whom disclaims beneficial ownership of the securities held by OIP II."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Each of OrbiMed Advisors, Genesis GP, OrbiMed Israel, OrbiMed Limited, and GP VII disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any such person or entity, including the Reporting Persons, is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":1003971,"source":{"system":"sec-edgar","filing":"0000947871-23-000438","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787123000438/ownership.xml","form_type":"4"}},{"id":1923170,"issuer":{"id":4602,"kind":"organization","name":"Damora Therapeutics, Inc.","symbol":"DMRA"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24740,"kind":"person","name":"OrbiMed Genesis GP LLC","position":2,"cik":"0001808744","reported_name":"OrbiMed Genesis GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53132,"kind":"organization","name":"OrbiMed Israel GP II, L.P.","position":3,"cik":"0001682090","reported_name":"OrbiMed Israel GP II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53131,"kind":"organization","name":"OrbiMed Advisors Israel II Ltd","position":4,"cik":"0001682093","reported_name":"OrbiMed Advisors Israel II Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35791,"kind":"organization","name":"OrbiMed Capital GP VII LLC","position":5,"cik":"0001760648","reported_name":"OrbiMed Capital GP VII LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-04-07T20:42:12.000Z","date":"2023-04-06","kind":"sale","planned":false,"acquired":false,"shares":487,"price":2,"value":974.0,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"These securities are held of record by OrbiMed Genesis Master Fund, L.P. (\"OrbiMed Genesis\"). OrbiMed Genesis GP LLC (\"Genesis GP\") is the general partner of OrbiMed Genesis and OrbiMed Advisors LLC (\"OrbiMed Advisors\") is the managing member of Genesis GP. By virtue of such relationships, OrbiMed Advisors and Genesis GP may be deemed to have voting power and investment power over the securities held by OrbiMed Genesis and, as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the securities held by OrbiMed Genesis."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Each of OrbiMed Advisors, Genesis GP, OrbiMed Israel, OrbiMed Limited, and GP VII disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any such person or entity, including the Reporting Persons, is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":186613,"source":{"system":"sec-edgar","filing":"0000947871-23-000438","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787123000438/ownership.xml","form_type":"4"}},{"id":1923169,"issuer":{"id":4602,"kind":"organization","name":"Damora Therapeutics, Inc.","symbol":"DMRA"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24740,"kind":"person","name":"OrbiMed Genesis GP LLC","position":2,"cik":"0001808744","reported_name":"OrbiMed Genesis GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53132,"kind":"organization","name":"OrbiMed Israel GP II, L.P.","position":3,"cik":"0001682090","reported_name":"OrbiMed Israel GP II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53131,"kind":"organization","name":"OrbiMed Advisors Israel II Ltd","position":4,"cik":"0001682093","reported_name":"OrbiMed Advisors Israel II Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35791,"kind":"organization","name":"OrbiMed Capital GP VII LLC","position":5,"cik":"0001760648","reported_name":"OrbiMed Capital GP VII LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-04-07T20:42:12.000Z","date":"2023-04-05","kind":"sale","planned":false,"acquired":false,"shares":63058,"price":2.18,"value":137466.44,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These securities are held of record by OrbiMed Private Investments VII, LP (\"OPI VII\"). OrbiMed Capital GP VII LLC (\"GP VII\") is the general partner of OPI VII and OrbiMed Advisors is the managing member of GP VII. By virtue of such relationships, OrbiMed Advisors and GP VII may be deemed to have voting power and investment power over the securities held by OPI VII and, as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the securities held by OPI VII."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Each of OrbiMed Advisors, Genesis GP, OrbiMed Israel, OrbiMed Limited, and GP VII disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any such person or entity, including the Reporting Persons, is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":2516599,"source":{"system":"sec-edgar","filing":"0000947871-23-000438","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787123000438/ownership.xml","form_type":"4"}},{"id":1923168,"issuer":{"id":4602,"kind":"organization","name":"Damora Therapeutics, Inc.","symbol":"DMRA"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24740,"kind":"person","name":"OrbiMed Genesis GP LLC","position":2,"cik":"0001808744","reported_name":"OrbiMed Genesis GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53132,"kind":"organization","name":"OrbiMed Israel GP II, L.P.","position":3,"cik":"0001682090","reported_name":"OrbiMed Israel GP II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53131,"kind":"organization","name":"OrbiMed Advisors Israel II Ltd","position":4,"cik":"0001682093","reported_name":"OrbiMed Advisors Israel II Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35791,"kind":"organization","name":"OrbiMed Capital GP VII LLC","position":5,"cik":"0001760648","reported_name":"OrbiMed Capital GP VII LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-04-07T20:42:12.000Z","date":"2023-04-05","kind":"sale","planned":false,"acquired":false,"shares":25220,"price":2.18,"value":54979.6,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held of record by OrbiMed Israel Partners II, L.P. (\"OIP II\"). OrbiMed Israel GP II, L.P. (\"OrbiMed Israel\") is the general partner of OIP II and OrbiMed Advisors Israel II Limited (\"OrbiMed Limited\") is the general partner of OrbiMed Israel. By virtue of such relationships, OrbiMed Limited and OrbiMed Israel may be deemed to have voting power and investment power over the securities held by OIP II and, as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Limited exercises voting and investment power through a management committee comprised of Carl L. Gordon, David P. Bonita, and Erez Chimovits, each of whom disclaims beneficial ownership of the securities held by OIP II."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Each of OrbiMed Advisors, Genesis GP, OrbiMed Israel, OrbiMed Limited, and GP VII disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any such person or entity, including the Reporting Persons, is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":1006591,"source":{"system":"sec-edgar","filing":"0000947871-23-000438","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787123000438/ownership.xml","form_type":"4"}},{"id":1923167,"issuer":{"id":4602,"kind":"organization","name":"Damora Therapeutics, Inc.","symbol":"DMRA"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24740,"kind":"person","name":"OrbiMed Genesis GP LLC","position":2,"cik":"0001808744","reported_name":"OrbiMed Genesis GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53132,"kind":"organization","name":"OrbiMed Israel GP II, L.P.","position":3,"cik":"0001682090","reported_name":"OrbiMed Israel GP II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53131,"kind":"organization","name":"OrbiMed Advisors Israel II Ltd","position":4,"cik":"0001682093","reported_name":"OrbiMed Advisors Israel II Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35791,"kind":"organization","name":"OrbiMed Capital GP VII LLC","position":5,"cik":"0001760648","reported_name":"OrbiMed Capital GP VII LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-04-07T20:42:12.000Z","date":"2023-04-05","kind":"sale","planned":false,"acquired":false,"shares":4687,"price":2.18,"value":10217.66,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"These securities are held of record by OrbiMed Genesis Master Fund, L.P. (\"OrbiMed Genesis\"). OrbiMed Genesis GP LLC (\"Genesis GP\") is the general partner of OrbiMed Genesis and OrbiMed Advisors LLC (\"OrbiMed Advisors\") is the managing member of Genesis GP. By virtue of such relationships, OrbiMed Advisors and Genesis GP may be deemed to have voting power and investment power over the securities held by OrbiMed Genesis and, as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the securities held by OrbiMed Genesis."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Each of OrbiMed Advisors, Genesis GP, OrbiMed Israel, OrbiMed Limited, and GP VII disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any such person or entity, including the Reporting Persons, is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":187100,"source":{"system":"sec-edgar","filing":"0000947871-23-000438","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787123000438/ownership.xml","form_type":"4"}},{"id":2424382,"issuer":{"id":73682,"kind":"organization","name":"89bio, Inc.","symbol":"ETNB"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51517,"kind":"person","name":"OrbiMed Capital GP VI LLC","position":2,"cik":"0001682115","reported_name":"OrbiMed Capital GP VI LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53131,"kind":"organization","name":"OrbiMed Advisors Israel II Ltd","position":3,"cik":"0001682093","reported_name":"OrbiMed Advisors Israel II Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53132,"kind":"organization","name":"OrbiMed Israel GP II, L.P.","position":4,"cik":"0001682090","reported_name":"OrbiMed Israel GP II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-01-27T22:22:20.000Z","date":"2022-01-26","kind":"sale","acquired":false,"shares":10740,"price":8.38,"value":90001.2,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The Shares were sold in block sale at a price of $8.38."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"These Shares are held of record by OrbiMed Israel Partners II, L.P. (\"OIP II\"). OrbiMed Israel GP II, L.P. (\"Israel GP II\") is the general partner of OIP II, and OrbiMed Advisors Israel II Limited (\"Advisors Israel II\") is the general partner of Israel GP II. By virtue of such relationships, Israel GP II and Advisors Israel II may be deemed to have voting and investment power with respect to the securities held directly by OIP II noted above and, as a result, may be deemed to have beneficial ownership over such securities. Advisors Israel II exercises this investment and voting power through a management committee comprised of Carl L. Gordon, David P. Bonita, and Erez Chimovits, each of whom disclaims beneficial ownership of the shares held by OIP II."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"This report is being jointly filed by OrbiMed Advisors, OrbiMed GP VI, Israel GP II, and Advisors Israel II. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Persons is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":1829436,"source":{"system":"sec-edgar","filing":"0000947871-22-000113","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787122000113/ownership.xml","form_type":"4"}},{"id":2424381,"issuer":{"id":73682,"kind":"organization","name":"89bio, Inc.","symbol":"ETNB"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51517,"kind":"person","name":"OrbiMed Capital GP VI LLC","position":2,"cik":"0001682115","reported_name":"OrbiMed Capital GP VI LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53131,"kind":"organization","name":"OrbiMed Advisors Israel II Ltd","position":3,"cik":"0001682093","reported_name":"OrbiMed Advisors Israel II Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53132,"kind":"organization","name":"OrbiMed Israel GP II, L.P.","position":4,"cik":"0001682090","reported_name":"OrbiMed Israel GP II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-01-27T22:22:20.000Z","date":"2022-01-26","kind":"sale","acquired":false,"shares":10742,"price":8.38,"value":90017.96,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The Shares were sold in block sale at a price of $8.38."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These Shares are held of record by OrbiMed Private Investments VI, LP (\"OPI VI\"). OrbiMed Capital GP VI LLC (\"OrbiMed GP VI\") is the general partner of OPI VI and OrbiMed Advisors LLC (\"OrbiMed Advisors\"), a registered investment adviser under the Investment Advisors Act of 1940, as amended, is the managing member of OrbiMed GP VI. By virtue of such relationships, OrbiMed GP VI and OrbiMed Advisors may be deemed to have voting and investment power with respect to the securities held by OPI VI noted above and, as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises this investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI VI."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"These Shares are held of record by OrbiMed Israel Partners II, L.P. (\"OIP II\"). OrbiMed Israel GP II, L.P. (\"Israel GP II\") is the general partner of OIP II, and OrbiMed Advisors Israel II Limited (\"Advisors Israel II\") is the general partner of Israel GP II. By virtue of such relationships, Israel GP II and Advisors Israel II may be deemed to have voting and investment power with respect to the securities held directly by OIP II noted above and, as a result, may be deemed to have beneficial ownership over such securities. Advisors Israel II exercises this investment and voting power through a management committee comprised of Carl L. Gordon, David P. Bonita, and Erez Chimovits, each of whom disclaims beneficial ownership of the shares held by OIP II."}],"balance_after":1829433,"source":{"system":"sec-edgar","filing":"0000947871-22-000113","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787122000113/ownership.xml","form_type":"4"}},{"id":2424380,"issuer":{"id":73682,"kind":"organization","name":"89bio, Inc.","symbol":"ETNB"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51517,"kind":"person","name":"OrbiMed Capital GP VI LLC","position":2,"cik":"0001682115","reported_name":"OrbiMed Capital GP VI LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53131,"kind":"organization","name":"OrbiMed Advisors Israel II Ltd","position":3,"cik":"0001682093","reported_name":"OrbiMed Advisors Israel II Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53132,"kind":"organization","name":"OrbiMed Israel GP II, L.P.","position":4,"cik":"0001682090","reported_name":"OrbiMed Israel GP II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-01-27T22:22:20.000Z","date":"2022-01-25","kind":"sale","acquired":false,"shares":24545,"price":8.4,"value":206178.0,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents the weighted average sale price of the shares of the Issuer's common stock (\"Shares\") sold ranging from a low of $8.40 to a high of $8.58 per Share. The Reporting Person undertakes, upon request by the Commission staff, the Issuer or a security holder of the Issuer, to provide full information regarding the number of Shares purchased at each separate price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"These Shares are held of record by OrbiMed Israel Partners II, L.P. (\"OIP II\"). OrbiMed Israel GP II, L.P. (\"Israel GP II\") is the general partner of OIP II, and OrbiMed Advisors Israel II Limited (\"Advisors Israel II\") is the general partner of Israel GP II. By virtue of such relationships, Israel GP II and Advisors Israel II may be deemed to have voting and investment power with respect to the securities held directly by OIP II noted above and, as a result, may be deemed to have beneficial ownership over such securities. Advisors Israel II exercises this investment and voting power through a management committee comprised of Carl L. Gordon, David P. Bonita, and Erez Chimovits, each of whom disclaims beneficial ownership of the shares held by OIP II."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"This report is being jointly filed by OrbiMed Advisors, OrbiMed GP VI, Israel GP II, and Advisors Israel II. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Persons is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":1840176,"source":{"system":"sec-edgar","filing":"0000947871-22-000113","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787122000113/ownership.xml","form_type":"4"}},{"id":2424379,"issuer":{"id":73682,"kind":"organization","name":"89bio, Inc.","symbol":"ETNB"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51517,"kind":"person","name":"OrbiMed Capital GP VI LLC","position":2,"cik":"0001682115","reported_name":"OrbiMed Capital GP VI LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53131,"kind":"organization","name":"OrbiMed Advisors Israel II Ltd","position":3,"cik":"0001682093","reported_name":"OrbiMed Advisors Israel II Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53132,"kind":"organization","name":"OrbiMed Israel GP II, L.P.","position":4,"cik":"0001682090","reported_name":"OrbiMed Israel GP II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-01-27T22:22:20.000Z","date":"2022-01-25","kind":"sale","acquired":false,"shares":24546,"price":8.4,"value":206186.4,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents the weighted average sale price of the shares of the Issuer's common stock (\"Shares\") sold ranging from a low of $8.40 to a high of $8.58 per Share. The Reporting Person undertakes, upon request by the Commission staff, the Issuer or a security holder of the Issuer, to provide full information regarding the number of Shares purchased at each separate price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These Shares are held of record by OrbiMed Private Investments VI, LP (\"OPI VI\"). OrbiMed Capital GP VI LLC (\"OrbiMed GP VI\") is the general partner of OPI VI and OrbiMed Advisors LLC (\"OrbiMed Advisors\"), a registered investment adviser under the Investment Advisors Act of 1940, as amended, is the managing member of OrbiMed GP VI. By virtue of such relationships, OrbiMed GP VI and OrbiMed Advisors may be deemed to have voting and investment power with respect to the securities held by OPI VI noted above and, as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises this investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI VI."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"These Shares are held of record by OrbiMed Israel Partners II, L.P. (\"OIP II\"). OrbiMed Israel GP II, L.P. (\"Israel GP II\") is the general partner of OIP II, and OrbiMed Advisors Israel II Limited (\"Advisors Israel II\") is the general partner of Israel GP II. By virtue of such relationships, Israel GP II and Advisors Israel II may be deemed to have voting and investment power with respect to the securities held directly by OIP II noted above and, as a result, may be deemed to have beneficial ownership over such securities. Advisors Israel II exercises this investment and voting power through a management committee comprised of Carl L. Gordon, David P. Bonita, and Erez Chimovits, each of whom disclaims beneficial ownership of the shares held by OIP II."}],"balance_after":1840175,"source":{"system":"sec-edgar","filing":"0000947871-22-000113","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787122000113/ownership.xml","form_type":"4"}},{"id":2474025,"issuer":{"id":6860,"kind":"organization","name":"Adicet Bio, Inc."},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53130,"kind":"organization","name":"OrbiMed Capital GP V LLC","position":2,"cik":"0001615374","reported_name":"OrbiMed Capital GP V LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51517,"kind":"person","name":"OrbiMed Capital GP VI LLC","position":3,"cik":"0001682115","reported_name":"OrbiMed Capital GP VI LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24740,"kind":"person","name":"OrbiMed Genesis GP LLC","position":4,"cik":"0001808744","reported_name":"OrbiMed Genesis GP LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53131,"kind":"organization","name":"OrbiMed Advisors Israel II Ltd","position":5,"cik":"0001682093","reported_name":"OrbiMed Advisors Israel II Ltd","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53132,"kind":"organization","name":"OrbiMed Israel GP II, L.P.","position":6,"cik":"0001682090","reported_name":"OrbiMed Israel GP II, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53133,"kind":"organization","name":"OrbiMed Israel GP Ltd.","position":7,"cik":"0001569590","reported_name":"OrbiMed Israel GP Ltd.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53134,"kind":"organization","name":"OrbiMed Israel BioFund GP Limited Partnership","position":8,"cik":"0001569821","reported_name":"OrbiMed Israel BioFund GP Limited Partnership","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-12-14T23:41:26.000Z","date":"2021-12-10","kind":"grant","acquired":true,"shares":214285,"price":14,"value":2999990.0,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"These shares of the Issuer's common stock were purchased in the Issuer's underwritten public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"These shares of the Issuer's common stock are held of record by OrbiMed Genesis Master Fund, L.P. (\"Genesis\"). OrbiMed Genesis GP LLC (\"Genesis GP\") is the general partner of Genesis, and OrbiMed Advisors is the managing member of Genesis. By virtue of such relationships, Genesis GP and OrbiMed Advisors may be deemed to have voting and investment power with respect to the securities held by Genesis noted above and as a result may be deemed to beneficially own such securities for purposes of Rule 13d-3 under the Exchange Act. OrbiMed Advisors exercises this investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the Shares held by Genesis."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"This report is being jointly filed by OrbiMed Advisors, GP V, GP VI, Genesis, OrbiMed Israel GP II, OrbiMed Israel II, OrbiMed BioFund, and OrbiMed Israel GP. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Exchange Act, except to the extent of its pecuniary interest therein, if any. OrbiMed Advisors, GP V, GP VI, OrbiMed Israel GP II, OrbiMed Israel II, OrbiMed BioFund, and OrbiMed Israel GP have designated Carl L. Gordon (\"Gordon\") to serve on the Issuer's board of directors. This report shall not be deemed an admission that any of the Reporting Persons or Gordon is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":242285,"source":{"system":"sec-edgar","filing":"0000947871-21-001280","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787121001280/ownership.xml","form_type":"4"}},{"id":2851473,"issuer":{"id":6860,"kind":"organization","name":"Adicet Bio, Inc."},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53130,"kind":"organization","name":"OrbiMed Capital GP V LLC","position":2,"cik":"0001615374","reported_name":"OrbiMed Capital GP V LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51517,"kind":"person","name":"OrbiMed Capital GP VI LLC","position":3,"cik":"0001682115","reported_name":"OrbiMed Capital GP VI LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53131,"kind":"organization","name":"OrbiMed Advisors Israel II Ltd","position":4,"cik":"0001682093","reported_name":"OrbiMed Advisors Israel II Ltd","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53132,"kind":"organization","name":"OrbiMed Israel GP II, L.P.","position":5,"cik":"0001682090","reported_name":"OrbiMed Israel GP II, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53133,"kind":"organization","name":"OrbiMed Israel GP Ltd.","position":6,"cik":"0001569590","reported_name":"OrbiMed Israel GP Ltd.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53134,"kind":"organization","name":"OrbiMed Israel BioFund GP Limited Partnership","position":7,"cik":"0001569821","reported_name":"OrbiMed Israel BioFund GP Limited Partnership","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-02-19T02:38:27.000Z","date":"2021-02-12","kind":"grant","acquired":true,"shares":104050,"price":13,"value":1352650.0,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"These shares of the Issuer's common stock were purchased in a private placement exempt from the registration requirements of the Securities Act of 1933, as amended."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"These shares of the Issuer's common stock are held of record by OrbiMed Israel Partners II, L.P. (\"OIP II\"). OrbiMed Israel GP II, L.P. (\"OrbiMed Israel GP II\") is the general partner of OIP II, and OrbiMed Advisors Israel II Limited (\"OrbiMed Israel II\") is the general partner of OrbiMed Israel GP II. By virtue of such relationships, OrbiMed Israel GP II and OrbiMed Israel II may be deemed to have voting and investment power with respect to the shares held directly by OIP II noted above and, as a result, may be deemed to beneficially own such securities for purposes of Rule 13d-3 under the Exchange Act. OrbiMed Israel II exercises this investment and voting power through a management committee comprised of Carl L. Gordon, Jonathan T. Silverstein, Nissim Darvish, Anat Naschitz, and Chimovits, each of whom disclaims beneficial ownership of the shares held by OIP II."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"This report is being jointly filed by OrbiMed Advisors, GP V, GP VI, OrbiMed Israel GP II, OrbiMed Israel II, OrbiMed BioFund. and OrbiMed Israel GP. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Exchange Act, except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Persons are a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose. The Reporting Persons have designated Carl L. Gordon (\"Gordon\") and Erez Chimovits (\"Chimovits\") to serve on the Issuer's board of directors. This report shall not be deemed an admission that any of the Reporting Persons, Gordon, or Chimovits is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":396657,"source":{"system":"sec-edgar","filing":"0000947871-21-000240","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787121000240/ownership.xml","form_type":"4"}},{"id":2851472,"issuer":{"id":6860,"kind":"organization","name":"Adicet Bio, Inc."},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53130,"kind":"organization","name":"OrbiMed Capital GP V LLC","position":2,"cik":"0001615374","reported_name":"OrbiMed Capital GP V LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51517,"kind":"person","name":"OrbiMed Capital GP VI LLC","position":3,"cik":"0001682115","reported_name":"OrbiMed Capital GP VI LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53131,"kind":"organization","name":"OrbiMed Advisors Israel II Ltd","position":4,"cik":"0001682093","reported_name":"OrbiMed Advisors Israel II Ltd","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53132,"kind":"organization","name":"OrbiMed Israel GP II, L.P.","position":5,"cik":"0001682090","reported_name":"OrbiMed Israel GP II, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53133,"kind":"organization","name":"OrbiMed Israel GP Ltd.","position":6,"cik":"0001569590","reported_name":"OrbiMed Israel GP Ltd.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53134,"kind":"organization","name":"OrbiMed Israel BioFund GP Limited Partnership","position":7,"cik":"0001569821","reported_name":"OrbiMed Israel BioFund GP Limited Partnership","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-02-19T02:38:27.000Z","date":"2021-02-12","kind":"grant","acquired":true,"shares":420299,"price":13,"value":5463887.0,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"These shares of the Issuer's common stock were purchased in a private placement exempt from the registration requirements of the Securities Act of 1933, as amended."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These shares of the Issuer's common stock are held of record by OrbiMed Private Investments V, LP (\"OPI V\"). OrbiMed Capital GP V LLC (\"GP V\") is the general partner of OPI V, and OrbiMed Advisors is the managing member of GP V. By virtue of such relationships, GP V and OrbiMed Advisors may be deemed to have voting and investment power with respect to the securities held by OPI V noted above and as a result may be deemed to beneficially own such securities for purposes of Rule 13d-3 under the Exchange Act. OrbiMed Advisors exercises this investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and Jonathan T. Silverstein, each of whom disclaims beneficial ownership of the Shares held by OPI V."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"This report is being jointly filed by OrbiMed Advisors, GP V, GP VI, OrbiMed Israel GP II, OrbiMed Israel II, OrbiMed BioFund. and OrbiMed Israel GP. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Exchange Act, except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Persons are a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose. The Reporting Persons have designated Carl L. Gordon (\"Gordon\") and Erez Chimovits (\"Chimovits\") to serve on the Issuer's board of directors. This report shall not be deemed an admission that any of the Reporting Persons, Gordon, or Chimovits is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":5243259,"source":{"system":"sec-edgar","filing":"0000947871-21-000240","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787121000240/ownership.xml","form_type":"4"}},{"id":2993186,"issuer":{"id":4602,"kind":"organization","name":"Damora Therapeutics, Inc.","symbol":"DMRA"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53131,"kind":"organization","name":"OrbiMed Advisors Israel II Ltd","position":2,"cik":"0001682093","reported_name":"OrbiMed Advisors Israel II Ltd","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53132,"kind":"organization","name":"OrbiMed Israel GP II, L.P.","position":3,"cik":"0001682090","reported_name":"OrbiMed Israel GP II, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35791,"kind":"organization","name":"OrbiMed Capital GP VII LLC","position":4,"cik":"0001760648","reported_name":"OrbiMed Capital GP VII LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24740,"kind":"person","name":"OrbiMed Genesis GP LLC","position":5,"cik":"0001808744","reported_name":"OrbiMed Genesis GP LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series D Preferred Stock","published_at":"2020-11-05T01:00:18.000Z","date":"2020-11-02","kind":"exercise","acquired":false,"shares":73773,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The Series C-2 Preferred Stock, Series C-4 Preferred Stock, Series C-5 Preferred Stock, and Series D Preferred Stock (collectively, the \"Preferred Stock\") was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock converted into Common Stock at a ratio of 2.59970:1 upon the closing of the Issuer's initial public offering without payment of additional consideration. The Preferred Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The Series C-2 Preferred Stock, Series C-4 Preferred Stock, Series C-5 Preferred Stock, and Series D Preferred Stock (collectively, the \"Preferred Stock\") was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock converted into Common Stock at a ratio of 2.59970:1 upon the closing of the Issuer's initial public offering without payment of additional consideration. The Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Series C-2 Preferred Stock, Series C-4 Preferred Stock, Series C-5 Preferred Stock, and Series D Preferred Stock (collectively, the \"Preferred Stock\") was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock converted into Common Stock at a ratio of 2.59970:1 upon the closing of the Issuer's initial public offering without payment of additional consideration. The Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The Series C-2 Preferred Stock, Series C-4 Preferred Stock, Series C-5 Preferred Stock, and Series D Preferred Stock (collectively, the \"Preferred Stock\") was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock converted into Common Stock at a ratio of 2.59970:1 upon the closing of the Issuer's initial public offering without payment of additional consideration. The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"This report on Form 4 is jointly filed by OrbiMed Advisors, GP VII, OrbiMed Advisors Israel II Limited (\"OrbiMed Limited\"), OrbiMed Israel GP II, L.P. (\"OrbiMed Israel\"), and OrbiMed Genesis GP LLC (\"Genesis GP\"). Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its or his pecuniary interest therein, if any. The Reporting Persons have designated a representative, Chau Khuong, an employee of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any of the reporting persons is a beneficial owner of such securities for the purposes of Section 16 of the Exchange Act, or for any other purposes."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"These securities are held of record by OrbiMed Genesis Master Fund, L.P. (\"Genesis Master Fund\"). Genesis GP is the general partner of Genesis Master Fund and OrbiMed Advisors is the managing member of Genesis GP. By virtue of such relationships, Genesis GP and OrbiMed Advisors may be deemed to have voting and investment power over the securities held by Genesis Master Fund and as a result may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises its investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and Jonathan T. Silverstein, each of whom disclaims beneficial ownership of the securities held by Genesis Master Fund."}],"balance_after":0,"derivative":{"underlying":"Common Shares","underlying_shares":191787},"source":{"system":"sec-edgar","filing":"0000899243-20-030414","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":17,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000089924320030414/doc4.xml","form_type":"4"}},{"id":2993185,"issuer":{"id":4602,"kind":"organization","name":"Damora Therapeutics, Inc.","symbol":"DMRA"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53131,"kind":"organization","name":"OrbiMed Advisors Israel II Ltd","position":2,"cik":"0001682093","reported_name":"OrbiMed Advisors Israel II Ltd","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53132,"kind":"organization","name":"OrbiMed Israel GP II, L.P.","position":3,"cik":"0001682090","reported_name":"OrbiMed Israel GP II, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35791,"kind":"organization","name":"OrbiMed Capital GP VII LLC","position":4,"cik":"0001760648","reported_name":"OrbiMed Capital GP VII LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24740,"kind":"person","name":"OrbiMed Genesis GP LLC","position":5,"cik":"0001808744","reported_name":"OrbiMed Genesis GP LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series D Preferred Stock","published_at":"2020-11-05T01:00:18.000Z","date":"2020-11-02","kind":"exercise","acquired":false,"shares":59350,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The Series C-2 Preferred Stock, Series C-4 Preferred Stock, Series C-5 Preferred Stock, and Series D Preferred Stock (collectively, the \"Preferred Stock\") was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock converted into Common Stock at a ratio of 2.59970:1 upon the closing of the Issuer's initial public offering without payment of additional consideration. The Preferred Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The Series C-2 Preferred Stock, Series C-4 Preferred Stock, Series C-5 Preferred Stock, and Series D Preferred Stock (collectively, the \"Preferred Stock\") was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock converted into Common Stock at a ratio of 2.59970:1 upon the closing of the Issuer's initial public offering without payment of additional consideration. The Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Series C-2 Preferred Stock, Series C-4 Preferred Stock, Series C-5 Preferred Stock, and Series D Preferred Stock (collectively, the \"Preferred Stock\") was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock converted into Common Stock at a ratio of 2.59970:1 upon the closing of the Issuer's initial public offering without payment of additional consideration. The Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The Series C-2 Preferred Stock, Series C-4 Preferred Stock, Series C-5 Preferred Stock, and Series D Preferred Stock (collectively, the \"Preferred Stock\") was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock converted into Common Stock at a ratio of 2.59970:1 upon the closing of the Issuer's initial public offering without payment of additional consideration. The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"This report on Form 4 is jointly filed by OrbiMed Advisors, GP VII, OrbiMed Advisors Israel II Limited (\"OrbiMed Limited\"), OrbiMed Israel GP II, L.P. (\"OrbiMed Israel\"), and OrbiMed Genesis GP LLC (\"Genesis GP\"). Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its or his pecuniary interest therein, if any. The Reporting Persons have designated a representative, Chau Khuong, an employee of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any of the reporting persons is a beneficial owner of such securities for the purposes of Section 16 of the Exchange Act, or for any other purposes."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"These securities are held of record by OrbiMed Israel Partners II, L.P. (\"OIP II\"). OrbiMed Israel is the general partner of OIP II, and OrbiMed Limited is the managing member of OrbiMed Israel. By virtue of such relationships, OrbiMed Israel and OrbiMed Limited may be deemed to have voting and investment power over the securities held by OIP II and as a result may be deemed to have beneficial ownership over such securities. OrbiMed Limited exercises its investment and voting power through a management committee comprised of Carl L. Gordon, Jonathan Silverstein, Nissim Darvish, Anat Naschitz, and Erez Chimovits, each of whom disclaims beneficial ownership of the securities held by OIP II."}],"balance_after":0,"derivative":{"underlying":"Common Shares","underlying_shares":154292},"source":{"system":"sec-edgar","filing":"0000899243-20-030414","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":16,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000089924320030414/doc4.xml","form_type":"4"}},{"id":2993184,"issuer":{"id":4602,"kind":"organization","name":"Damora Therapeutics, Inc.","symbol":"DMRA"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53131,"kind":"organization","name":"OrbiMed Advisors Israel II Ltd","position":2,"cik":"0001682093","reported_name":"OrbiMed Advisors Israel II Ltd","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53132,"kind":"organization","name":"OrbiMed Israel GP II, L.P.","position":3,"cik":"0001682090","reported_name":"OrbiMed Israel GP II, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35791,"kind":"organization","name":"OrbiMed Capital GP VII LLC","position":4,"cik":"0001760648","reported_name":"OrbiMed Capital GP VII LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24740,"kind":"person","name":"OrbiMed Genesis GP LLC","position":5,"cik":"0001808744","reported_name":"OrbiMed Genesis GP LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series D Preferred Stock","published_at":"2020-11-05T01:00:18.000Z","date":"2020-11-02","kind":"exercise","acquired":false,"shares":148395,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The Series C-2 Preferred Stock, Series C-4 Preferred Stock, Series C-5 Preferred Stock, and Series D Preferred Stock (collectively, the \"Preferred Stock\") was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock converted into Common Stock at a ratio of 2.59970:1 upon the closing of the Issuer's initial public offering without payment of additional consideration. The Preferred Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The Series C-2 Preferred Stock, Series C-4 Preferred Stock, Series C-5 Preferred Stock, and Series D Preferred Stock (collectively, the \"Preferred Stock\") was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock converted into Common Stock at a ratio of 2.59970:1 upon the closing of the Issuer's initial public offering without payment of additional consideration. The Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Series C-2 Preferred Stock, Series C-4 Preferred Stock, Series C-5 Preferred Stock, and Series D Preferred Stock (collectively, the \"Preferred Stock\") was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock converted into Common Stock at a ratio of 2.59970:1 upon the closing of the Issuer's initial public offering without payment of additional consideration. The Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The Series C-2 Preferred Stock, Series C-4 Preferred Stock, Series C-5 Preferred Stock, and Series D Preferred Stock (collectively, the \"Preferred Stock\") was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock converted into Common Stock at a ratio of 2.59970:1 upon the closing of the Issuer's initial public offering without payment of additional consideration. The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held of record by OrbiMed Private Investments VII, LP (\"OPI VII\"). OrbiMed Capital GP VII LLC (\"GP VII\") is the general partner of OPI VII and OrbiMed Advisors LLC (\"OrbiMed Advisors\") is the managing member of GP VII. By virtue of such relationships, GP VII and OrbiMed Advisors may be deemed to have voting and investment power over the securities held by OPI VII and as a result may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises its investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and Jonathan T. Silverstein, each of whom disclaims beneficial ownership of the securities held by OPI VII."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"This report on Form 4 is jointly filed by OrbiMed Advisors, GP VII, OrbiMed Advisors Israel II Limited (\"OrbiMed Limited\"), OrbiMed Israel GP II, L.P. (\"OrbiMed Israel\"), and OrbiMed Genesis GP LLC (\"Genesis GP\"). Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its or his pecuniary interest therein, if any. The Reporting Persons have designated a representative, Chau Khuong, an employee of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any of the reporting persons is a beneficial owner of such securities for the purposes of Section 16 of the Exchange Act, or for any other purposes."}],"balance_after":0,"derivative":{"underlying":"Common Shares","underlying_shares":385782},"source":{"system":"sec-edgar","filing":"0000899243-20-030414","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":15,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000089924320030414/doc4.xml","form_type":"4"}},{"id":2993183,"issuer":{"id":4602,"kind":"organization","name":"Damora Therapeutics, Inc.","symbol":"DMRA"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53131,"kind":"organization","name":"OrbiMed Advisors Israel II Ltd","position":2,"cik":"0001682093","reported_name":"OrbiMed Advisors Israel II Ltd","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53132,"kind":"organization","name":"OrbiMed Israel GP II, L.P.","position":3,"cik":"0001682090","reported_name":"OrbiMed Israel GP II, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35791,"kind":"organization","name":"OrbiMed Capital GP VII LLC","position":4,"cik":"0001760648","reported_name":"OrbiMed Capital GP VII LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24740,"kind":"person","name":"OrbiMed Genesis GP LLC","position":5,"cik":"0001808744","reported_name":"OrbiMed Genesis GP LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series C-5 Preferred Stock","published_at":"2020-11-05T01:00:18.000Z","date":"2020-11-02","kind":"exercise","acquired":false,"shares":31147,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The Series C-2 Preferred Stock, Series C-4 Preferred Stock, Series C-5 Preferred Stock, and Series D Preferred Stock (collectively, the \"Preferred Stock\") was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock converted into Common Stock at a ratio of 2.59970:1 upon the closing of the Issuer's initial public offering without payment of additional consideration. The Preferred Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The Series C-2 Preferred Stock, Series C-4 Preferred Stock, Series C-5 Preferred Stock, and Series D Preferred Stock (collectively, the \"Preferred Stock\") was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock converted into Common Stock at a ratio of 2.59970:1 upon the closing of the Issuer's initial public offering without payment of additional consideration. The Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Series C-2 Preferred Stock, Series C-4 Preferred Stock, Series C-5 Preferred Stock, and Series D Preferred Stock (collectively, the \"Preferred Stock\") was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock converted into Common Stock at a ratio of 2.59970:1 upon the closing of the Issuer's initial public offering without payment of additional consideration. The Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The Series C-2 Preferred Stock, Series C-4 Preferred Stock, Series C-5 Preferred Stock, and Series D Preferred Stock (collectively, the \"Preferred Stock\") was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock converted into Common Stock at a ratio of 2.59970:1 upon the closing of the Issuer's initial public offering without payment of additional consideration. The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"This report on Form 4 is jointly filed by OrbiMed Advisors, GP VII, OrbiMed Advisors Israel II Limited (\"OrbiMed Limited\"), OrbiMed Israel GP II, L.P. (\"OrbiMed Israel\"), and OrbiMed Genesis GP LLC (\"Genesis GP\"). Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its or his pecuniary interest therein, if any. The Reporting Persons have designated a representative, Chau Khuong, an employee of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any of the reporting persons is a beneficial owner of such securities for the purposes of Section 16 of the Exchange Act, or for any other purposes."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"These securities are held of record by OrbiMed Israel Partners II, L.P. (\"OIP II\"). OrbiMed Israel is the general partner of OIP II, and OrbiMed Limited is the managing member of OrbiMed Israel. By virtue of such relationships, OrbiMed Israel and OrbiMed Limited may be deemed to have voting and investment power over the securities held by OIP II and as a result may be deemed to have beneficial ownership over such securities. OrbiMed Limited exercises its investment and voting power through a management committee comprised of Carl L. Gordon, Jonathan Silverstein, Nissim Darvish, Anat Naschitz, and Erez Chimovits, each of whom disclaims beneficial ownership of the securities held by OIP II."}],"balance_after":0,"derivative":{"underlying":"Common Shares","underlying_shares":80972},"source":{"system":"sec-edgar","filing":"0000899243-20-030414","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000089924320030414/doc4.xml","form_type":"4"}},{"id":2993182,"issuer":{"id":4602,"kind":"organization","name":"Damora Therapeutics, Inc.","symbol":"DMRA"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53131,"kind":"organization","name":"OrbiMed Advisors Israel II Ltd","position":2,"cik":"0001682093","reported_name":"OrbiMed Advisors Israel II Ltd","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53132,"kind":"organization","name":"OrbiMed Israel GP II, L.P.","position":3,"cik":"0001682090","reported_name":"OrbiMed Israel GP II, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35791,"kind":"organization","name":"OrbiMed Capital GP VII LLC","position":4,"cik":"0001760648","reported_name":"OrbiMed Capital GP VII LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24740,"kind":"person","name":"OrbiMed Genesis GP LLC","position":5,"cik":"0001808744","reported_name":"OrbiMed Genesis GP LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series C-5 Preferred Stock","published_at":"2020-11-05T01:00:18.000Z","date":"2020-11-02","kind":"exercise","acquired":false,"shares":77866,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The Series C-2 Preferred Stock, Series C-4 Preferred Stock, Series C-5 Preferred Stock, and Series D Preferred Stock (collectively, the \"Preferred Stock\") was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock converted into Common Stock at a ratio of 2.59970:1 upon the closing of the Issuer's initial public offering without payment of additional consideration. The Preferred Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The Series C-2 Preferred Stock, Series C-4 Preferred Stock, Series C-5 Preferred Stock, and Series D Preferred Stock (collectively, the \"Preferred Stock\") was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock converted into Common Stock at a ratio of 2.59970:1 upon the closing of the Issuer's initial public offering without payment of additional consideration. The Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Series C-2 Preferred Stock, Series C-4 Preferred Stock, Series C-5 Preferred Stock, and Series D Preferred Stock (collectively, the \"Preferred Stock\") was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock converted into Common Stock at a ratio of 2.59970:1 upon the closing of the Issuer's initial public offering without payment of additional consideration. The Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The Series C-2 Preferred Stock, Series C-4 Preferred Stock, Series C-5 Preferred Stock, and Series D Preferred Stock (collectively, the \"Preferred Stock\") was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock converted into Common Stock at a ratio of 2.59970:1 upon the closing of the Issuer's initial public offering without payment of additional consideration. The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held of record by OrbiMed Private Investments VII, LP (\"OPI VII\"). OrbiMed Capital GP VII LLC (\"GP VII\") is the general partner of OPI VII and OrbiMed Advisors LLC (\"OrbiMed Advisors\") is the managing member of GP VII. By virtue of such relationships, GP VII and OrbiMed Advisors may be deemed to have voting and investment power over the securities held by OPI VII and as a result may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises its investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and Jonathan T. Silverstein, each of whom disclaims beneficial ownership of the securities held by OPI VII."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"This report on Form 4 is jointly filed by OrbiMed Advisors, GP VII, OrbiMed Advisors Israel II Limited (\"OrbiMed Limited\"), OrbiMed Israel GP II, L.P. (\"OrbiMed Israel\"), and OrbiMed Genesis GP LLC (\"Genesis GP\"). Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its or his pecuniary interest therein, if any. The Reporting Persons have designated a representative, Chau Khuong, an employee of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any of the reporting persons is a beneficial owner of such securities for the purposes of Section 16 of the Exchange Act, or for any other purposes."}],"balance_after":0,"derivative":{"underlying":"Common Shares","underlying_shares":202428},"source":{"system":"sec-edgar","filing":"0000899243-20-030414","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000089924320030414/doc4.xml","form_type":"4"}},{"id":2993181,"issuer":{"id":4602,"kind":"organization","name":"Damora Therapeutics, Inc.","symbol":"DMRA"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53131,"kind":"organization","name":"OrbiMed Advisors Israel II Ltd","position":2,"cik":"0001682093","reported_name":"OrbiMed Advisors Israel II Ltd","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53132,"kind":"organization","name":"OrbiMed Israel GP II, L.P.","position":3,"cik":"0001682090","reported_name":"OrbiMed Israel GP II, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35791,"kind":"organization","name":"OrbiMed Capital GP VII LLC","position":4,"cik":"0001760648","reported_name":"OrbiMed Capital GP VII LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24740,"kind":"person","name":"OrbiMed Genesis GP LLC","position":5,"cik":"0001808744","reported_name":"OrbiMed Genesis GP LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series C-4 Preferred Stock","published_at":"2020-11-05T01:00:18.000Z","date":"2020-11-02","kind":"exercise","acquired":false,"shares":109013,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The Series C-2 Preferred Stock, Series C-4 Preferred Stock, Series C-5 Preferred Stock, and Series D Preferred Stock (collectively, the \"Preferred Stock\") was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock converted into Common Stock at a ratio of 2.59970:1 upon the closing of the Issuer's initial public offering without payment of additional consideration. The Preferred Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The Series C-2 Preferred Stock, Series C-4 Preferred Stock, Series C-5 Preferred Stock, and Series D Preferred Stock (collectively, the \"Preferred Stock\") was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock converted into Common Stock at a ratio of 2.59970:1 upon the closing of the Issuer's initial public offering without payment of additional consideration. The Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Series C-2 Preferred Stock, Series C-4 Preferred Stock, Series C-5 Preferred Stock, and Series D Preferred Stock (collectively, the \"Preferred Stock\") was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock converted into Common Stock at a ratio of 2.59970:1 upon the closing of the Issuer's initial public offering without payment of additional consideration. The Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The Series C-2 Preferred Stock, Series C-4 Preferred Stock, Series C-5 Preferred Stock, and Series D Preferred Stock (collectively, the \"Preferred Stock\") was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock converted into Common Stock at a ratio of 2.59970:1 upon the closing of the Issuer's initial public offering without payment of additional consideration. The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"This report on Form 4 is jointly filed by OrbiMed Advisors, GP VII, OrbiMed Advisors Israel II Limited (\"OrbiMed Limited\"), OrbiMed Israel GP II, L.P. (\"OrbiMed Israel\"), and OrbiMed Genesis GP LLC (\"Genesis GP\"). Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its or his pecuniary interest therein, if any. The Reporting Persons have designated a representative, Chau Khuong, an employee of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any of the reporting persons is a beneficial owner of such securities for the purposes of Section 16 of the Exchange Act, or for any other purposes."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"These securities are held of record by OrbiMed Israel Partners II, L.P. (\"OIP II\"). OrbiMed Israel is the general partner of OIP II, and OrbiMed Limited is the managing member of OrbiMed Israel. By virtue of such relationships, OrbiMed Israel and OrbiMed Limited may be deemed to have voting and investment power over the securities held by OIP II and as a result may be deemed to have beneficial ownership over such securities. OrbiMed Limited exercises its investment and voting power through a management committee comprised of Carl L. Gordon, Jonathan Silverstein, Nissim Darvish, Anat Naschitz, and Erez Chimovits, each of whom disclaims beneficial ownership of the securities held by OIP II."}],"balance_after":0,"derivative":{"underlying":"Common Shares","underlying_shares":283402},"source":{"system":"sec-edgar","filing":"0000899243-20-030414","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000089924320030414/doc4.xml","form_type":"4"}},{"id":2993180,"issuer":{"id":4602,"kind":"organization","name":"Damora Therapeutics, Inc.","symbol":"DMRA"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53131,"kind":"organization","name":"OrbiMed Advisors Israel II Ltd","position":2,"cik":"0001682093","reported_name":"OrbiMed Advisors Israel II Ltd","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53132,"kind":"organization","name":"OrbiMed Israel GP II, L.P.","position":3,"cik":"0001682090","reported_name":"OrbiMed Israel GP II, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35791,"kind":"organization","name":"OrbiMed Capital GP VII LLC","position":4,"cik":"0001760648","reported_name":"OrbiMed Capital GP VII LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24740,"kind":"person","name":"OrbiMed Genesis GP LLC","position":5,"cik":"0001808744","reported_name":"OrbiMed Genesis GP LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series C-4 Preferred Stock","published_at":"2020-11-05T01:00:18.000Z","date":"2020-11-02","kind":"exercise","acquired":false,"shares":272533,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The Series C-2 Preferred Stock, Series C-4 Preferred Stock, Series C-5 Preferred Stock, and Series D Preferred Stock (collectively, the \"Preferred Stock\") was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock converted into Common Stock at a ratio of 2.59970:1 upon the closing of the Issuer's initial public offering without payment of additional consideration. The Preferred Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The Series C-2 Preferred Stock, Series C-4 Preferred Stock, Series C-5 Preferred Stock, and Series D Preferred Stock (collectively, the \"Preferred Stock\") was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock converted into Common Stock at a ratio of 2.59970:1 upon the closing of the Issuer's initial public offering without payment of additional consideration. The Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Series C-2 Preferred Stock, Series C-4 Preferred Stock, Series C-5 Preferred Stock, and Series D Preferred Stock (collectively, the \"Preferred Stock\") was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock converted into Common Stock at a ratio of 2.59970:1 upon the closing of the Issuer's initial public offering without payment of additional consideration. The Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The Series C-2 Preferred Stock, Series C-4 Preferred Stock, Series C-5 Preferred Stock, and Series D Preferred Stock (collectively, the \"Preferred Stock\") was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock converted into Common Stock at a ratio of 2.59970:1 upon the closing of the Issuer's initial public offering without payment of additional consideration. The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held of record by OrbiMed Private Investments VII, LP (\"OPI VII\"). OrbiMed Capital GP VII LLC (\"GP VII\") is the general partner of OPI VII and OrbiMed Advisors LLC (\"OrbiMed Advisors\") is the managing member of GP VII. By virtue of such relationships, GP VII and OrbiMed Advisors may be deemed to have voting and investment power over the securities held by OPI VII and as a result may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises its investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and Jonathan T. Silverstein, each of whom disclaims beneficial ownership of the securities held by OPI VII."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"This report on Form 4 is jointly filed by OrbiMed Advisors, GP VII, OrbiMed Advisors Israel II Limited (\"OrbiMed Limited\"), OrbiMed Israel GP II, L.P. (\"OrbiMed Israel\"), and OrbiMed Genesis GP LLC (\"Genesis GP\"). Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its or his pecuniary interest therein, if any. The Reporting Persons have designated a representative, Chau Khuong, an employee of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any of the reporting persons is a beneficial owner of such securities for the purposes of Section 16 of the Exchange Act, or for any other purposes."}],"balance_after":0,"derivative":{"underlying":"Common Shares","underlying_shares":708504},"source":{"system":"sec-edgar","filing":"0000899243-20-030414","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000089924320030414/doc4.xml","form_type":"4"}},{"id":2993179,"issuer":{"id":4602,"kind":"organization","name":"Damora Therapeutics, Inc.","symbol":"DMRA"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53131,"kind":"organization","name":"OrbiMed Advisors Israel II Ltd","position":2,"cik":"0001682093","reported_name":"OrbiMed Advisors Israel II Ltd","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53132,"kind":"organization","name":"OrbiMed Israel GP II, L.P.","position":3,"cik":"0001682090","reported_name":"OrbiMed Israel GP II, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35791,"kind":"organization","name":"OrbiMed Capital GP VII LLC","position":4,"cik":"0001760648","reported_name":"OrbiMed Capital GP VII LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24740,"kind":"person","name":"OrbiMed Genesis GP LLC","position":5,"cik":"0001808744","reported_name":"OrbiMed Genesis GP LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series C-2 Preferred Stock","published_at":"2020-11-05T01:00:18.000Z","date":"2020-11-02","kind":"exercise","acquired":false,"shares":116800,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The Series C-2 Preferred Stock, Series C-4 Preferred Stock, Series C-5 Preferred Stock, and Series D Preferred Stock (collectively, the \"Preferred Stock\") was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock converted into Common Stock at a ratio of 2.59970:1 upon the closing of the Issuer's initial public offering without payment of additional consideration. The Preferred Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The Series C-2 Preferred Stock, Series C-4 Preferred Stock, Series C-5 Preferred Stock, and Series D Preferred Stock (collectively, the \"Preferred Stock\") was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock converted into Common Stock at a ratio of 2.59970:1 upon the closing of the Issuer's initial public offering without payment of additional consideration. The Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Series C-2 Preferred Stock, Series C-4 Preferred Stock, Series C-5 Preferred Stock, and Series D Preferred Stock (collectively, the \"Preferred Stock\") was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock converted into Common Stock at a ratio of 2.59970:1 upon the closing of the Issuer's initial public offering without payment of additional consideration. The Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The Series C-2 Preferred Stock, Series C-4 Preferred Stock, Series C-5 Preferred Stock, and Series D Preferred Stock (collectively, the \"Preferred Stock\") was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock converted into Common Stock at a ratio of 2.59970:1 upon the closing of the Issuer's initial public offering without payment of additional consideration. The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"This report on Form 4 is jointly filed by OrbiMed Advisors, GP VII, OrbiMed Advisors Israel II Limited (\"OrbiMed Limited\"), OrbiMed Israel GP II, L.P. (\"OrbiMed Israel\"), and OrbiMed Genesis GP LLC (\"Genesis GP\"). Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its or his pecuniary interest therein, if any. The Reporting Persons have designated a representative, Chau Khuong, an employee of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any of the reporting persons is a beneficial owner of such securities for the purposes of Section 16 of the Exchange Act, or for any other purposes."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"These securities are held of record by OrbiMed Israel Partners II, L.P. (\"OIP II\"). OrbiMed Israel is the general partner of OIP II, and OrbiMed Limited is the managing member of OrbiMed Israel. By virtue of such relationships, OrbiMed Israel and OrbiMed Limited may be deemed to have voting and investment power over the securities held by OIP II and as a result may be deemed to have beneficial ownership over such securities. OrbiMed Limited exercises its investment and voting power through a management committee comprised of Carl L. Gordon, Jonathan Silverstein, Nissim Darvish, Anat Naschitz, and Erez Chimovits, each of whom disclaims beneficial ownership of the securities held by OIP II."}],"balance_after":0,"derivative":{"underlying":"Common Shares","underlying_shares":303645},"source":{"system":"sec-edgar","filing":"0000899243-20-030414","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000089924320030414/doc4.xml","form_type":"4"}},{"id":2993178,"issuer":{"id":4602,"kind":"organization","name":"Damora Therapeutics, Inc.","symbol":"DMRA"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53131,"kind":"organization","name":"OrbiMed Advisors Israel II Ltd","position":2,"cik":"0001682093","reported_name":"OrbiMed Advisors Israel II Ltd","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53132,"kind":"organization","name":"OrbiMed Israel GP II, L.P.","position":3,"cik":"0001682090","reported_name":"OrbiMed Israel GP II, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35791,"kind":"organization","name":"OrbiMed Capital GP VII LLC","position":4,"cik":"0001760648","reported_name":"OrbiMed Capital GP VII LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24740,"kind":"person","name":"OrbiMed Genesis GP LLC","position":5,"cik":"0001808744","reported_name":"OrbiMed Genesis GP LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series C-2 Preferred Stock","published_at":"2020-11-05T01:00:18.000Z","date":"2020-11-02","kind":"exercise","acquired":false,"shares":291999,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The Series C-2 Preferred Stock, Series C-4 Preferred Stock, Series C-5 Preferred Stock, and Series D Preferred Stock (collectively, the \"Preferred Stock\") was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock converted into Common Stock at a ratio of 2.59970:1 upon the closing of the Issuer's initial public offering without payment of additional consideration. The Preferred Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The Series C-2 Preferred Stock, Series C-4 Preferred Stock, Series C-5 Preferred Stock, and Series D Preferred Stock (collectively, the \"Preferred Stock\") was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock converted into Common Stock at a ratio of 2.59970:1 upon the closing of the Issuer's initial public offering without payment of additional consideration. The Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Series C-2 Preferred Stock, Series C-4 Preferred Stock, Series C-5 Preferred Stock, and Series D Preferred Stock (collectively, the \"Preferred Stock\") was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock converted into Common Stock at a ratio of 2.59970:1 upon the closing of the Issuer's initial public offering without payment of additional consideration. The Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The Series C-2 Preferred Stock, Series C-4 Preferred Stock, Series C-5 Preferred Stock, and Series D Preferred Stock (collectively, the \"Preferred Stock\") was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock converted into Common Stock at a ratio of 2.59970:1 upon the closing of the Issuer's initial public offering without payment of additional consideration. The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held of record by OrbiMed Private Investments VII, LP (\"OPI VII\"). OrbiMed Capital GP VII LLC (\"GP VII\") is the general partner of OPI VII and OrbiMed Advisors LLC (\"OrbiMed Advisors\") is the managing member of GP VII. By virtue of such relationships, GP VII and OrbiMed Advisors may be deemed to have voting and investment power over the securities held by OPI VII and as a result may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises its investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and Jonathan T. Silverstein, each of whom disclaims beneficial ownership of the securities held by OPI VII."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"This report on Form 4 is jointly filed by OrbiMed Advisors, GP VII, OrbiMed Advisors Israel II Limited (\"OrbiMed Limited\"), OrbiMed Israel GP II, L.P. (\"OrbiMed Israel\"), and OrbiMed Genesis GP LLC (\"Genesis GP\"). Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its or his pecuniary interest therein, if any. The Reporting Persons have designated a representative, Chau Khuong, an employee of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any of the reporting persons is a beneficial owner of such securities for the purposes of Section 16 of the Exchange Act, or for any other purposes."}],"balance_after":0,"derivative":{"underlying":"Common Shares","underlying_shares":759110},"source":{"system":"sec-edgar","filing":"0000899243-20-030414","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000089924320030414/doc4.xml","form_type":"4"}},{"id":2993177,"issuer":{"id":4602,"kind":"organization","name":"Damora Therapeutics, Inc.","symbol":"DMRA"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53131,"kind":"organization","name":"OrbiMed Advisors Israel II Ltd","position":2,"cik":"0001682093","reported_name":"OrbiMed Advisors Israel II Ltd","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53132,"kind":"organization","name":"OrbiMed Israel GP II, L.P.","position":3,"cik":"0001682090","reported_name":"OrbiMed Israel GP II, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35791,"kind":"organization","name":"OrbiMed Capital GP VII LLC","position":4,"cik":"0001760648","reported_name":"OrbiMed Capital GP VII LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24740,"kind":"person","name":"OrbiMed Genesis GP LLC","position":5,"cik":"0001808744","reported_name":"OrbiMed Genesis GP LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series D Preferred Stock","published_at":"2020-11-05T01:00:18.000Z","date":"2020-09-25","kind":"grant","acquired":false,"shares":73773,"price":27.11,"value":1999986.03,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The Series C-2 Preferred Stock, Series C-4 Preferred Stock, Series C-5 Preferred Stock, and Series D Preferred Stock (collectively, the \"Preferred Stock\") was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock converted into Common Stock at a ratio of 2.59970:1 upon the closing of the Issuer's initial public offering without payment of additional consideration. The Preferred Stock had no expiration date."},{"field":"kind","element":"transactionCoding","label":"F6","text":"This transaction occurred prior to the Issuer's initial public offering and is being reported on Form 4 solely for purposes of compliance with Rule 16a-2(a) under the Securities Exchange Act of 1934, as amended. The securities covered by such transaction were previously included on the Reporting Persons' Form 3."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Series C-2 Preferred Stock, Series C-4 Preferred Stock, Series C-5 Preferred Stock, and Series D Preferred Stock (collectively, the \"Preferred Stock\") was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock converted into Common Stock at a ratio of 2.59970:1 upon the closing of the Issuer's initial public offering without payment of additional consideration. The Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The Series C-2 Preferred Stock, Series C-4 Preferred Stock, Series C-5 Preferred Stock, and Series D Preferred Stock (collectively, the \"Preferred Stock\") was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock converted into Common Stock at a ratio of 2.59970:1 upon the closing of the Issuer's initial public offering without payment of additional consideration. The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"This report on Form 4 is jointly filed by OrbiMed Advisors, GP VII, OrbiMed Advisors Israel II Limited (\"OrbiMed Limited\"), OrbiMed Israel GP II, L.P. (\"OrbiMed Israel\"), and OrbiMed Genesis GP LLC (\"Genesis GP\"). Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its or his pecuniary interest therein, if any. The Reporting Persons have designated a representative, Chau Khuong, an employee of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any of the reporting persons is a beneficial owner of such securities for the purposes of Section 16 of the Exchange Act, or for any other purposes."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"These securities are held of record by OrbiMed Genesis Master Fund, L.P. (\"Genesis Master Fund\"). Genesis GP is the general partner of Genesis Master Fund and OrbiMed Advisors is the managing member of Genesis GP. By virtue of such relationships, Genesis GP and OrbiMed Advisors may be deemed to have voting and investment power over the securities held by Genesis Master Fund and as a result may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises its investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and Jonathan T. Silverstein, each of whom disclaims beneficial ownership of the securities held by Genesis Master Fund."}],"balance_after":73773,"derivative":{"underlying":"Common Shares","underlying_shares":191787},"source":{"system":"sec-edgar","filing":"0000899243-20-030414","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000089924320030414/doc4.xml","form_type":"4"}},{"id":2993176,"issuer":{"id":4602,"kind":"organization","name":"Damora Therapeutics, Inc.","symbol":"DMRA"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53131,"kind":"organization","name":"OrbiMed Advisors Israel II Ltd","position":2,"cik":"0001682093","reported_name":"OrbiMed Advisors Israel II Ltd","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53132,"kind":"organization","name":"OrbiMed Israel GP II, L.P.","position":3,"cik":"0001682090","reported_name":"OrbiMed Israel GP II, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35791,"kind":"organization","name":"OrbiMed Capital GP VII LLC","position":4,"cik":"0001760648","reported_name":"OrbiMed Capital GP VII LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24740,"kind":"person","name":"OrbiMed Genesis GP LLC","position":5,"cik":"0001808744","reported_name":"OrbiMed Genesis GP LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series D Preferred Stock","published_at":"2020-11-05T01:00:18.000Z","date":"2020-09-25","kind":"grant","acquired":false,"shares":59350,"price":27.11,"value":1608978.5,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The Series C-2 Preferred Stock, Series C-4 Preferred Stock, Series C-5 Preferred Stock, and Series D Preferred Stock (collectively, the \"Preferred Stock\") was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock converted into Common Stock at a ratio of 2.59970:1 upon the closing of the Issuer's initial public offering without payment of additional consideration. The Preferred Stock had no expiration date."},{"field":"kind","element":"transactionCoding","label":"F6","text":"This transaction occurred prior to the Issuer's initial public offering and is being reported on Form 4 solely for purposes of compliance with Rule 16a-2(a) under the Securities Exchange Act of 1934, as amended. The securities covered by such transaction were previously included on the Reporting Persons' Form 3."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Series C-2 Preferred Stock, Series C-4 Preferred Stock, Series C-5 Preferred Stock, and Series D Preferred Stock (collectively, the \"Preferred Stock\") was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock converted into Common Stock at a ratio of 2.59970:1 upon the closing of the Issuer's initial public offering without payment of additional consideration. The Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The Series C-2 Preferred Stock, Series C-4 Preferred Stock, Series C-5 Preferred Stock, and Series D Preferred Stock (collectively, the \"Preferred Stock\") was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock converted into Common Stock at a ratio of 2.59970:1 upon the closing of the Issuer's initial public offering without payment of additional consideration. The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"This report on Form 4 is jointly filed by OrbiMed Advisors, GP VII, OrbiMed Advisors Israel II Limited (\"OrbiMed Limited\"), OrbiMed Israel GP II, L.P. (\"OrbiMed Israel\"), and OrbiMed Genesis GP LLC (\"Genesis GP\"). Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its or his pecuniary interest therein, if any. The Reporting Persons have designated a representative, Chau Khuong, an employee of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any of the reporting persons is a beneficial owner of such securities for the purposes of Section 16 of the Exchange Act, or for any other purposes."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"These securities are held of record by OrbiMed Israel Partners II, L.P. (\"OIP II\"). OrbiMed Israel is the general partner of OIP II, and OrbiMed Limited is the managing member of OrbiMed Israel. By virtue of such relationships, OrbiMed Israel and OrbiMed Limited may be deemed to have voting and investment power over the securities held by OIP II and as a result may be deemed to have beneficial ownership over such securities. OrbiMed Limited exercises its investment and voting power through a management committee comprised of Carl L. Gordon, Jonathan Silverstein, Nissim Darvish, Anat Naschitz, and Erez Chimovits, each of whom disclaims beneficial ownership of the securities held by OIP II."}],"balance_after":59350,"derivative":{"underlying":"Common Shares","underlying_shares":154292},"source":{"system":"sec-edgar","filing":"0000899243-20-030414","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000089924320030414/doc4.xml","form_type":"4"}},{"id":2993175,"issuer":{"id":4602,"kind":"organization","name":"Damora Therapeutics, Inc.","symbol":"DMRA"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53131,"kind":"organization","name":"OrbiMed Advisors Israel II Ltd","position":2,"cik":"0001682093","reported_name":"OrbiMed Advisors Israel II Ltd","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53132,"kind":"organization","name":"OrbiMed Israel GP II, L.P.","position":3,"cik":"0001682090","reported_name":"OrbiMed Israel GP II, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35791,"kind":"organization","name":"OrbiMed Capital GP VII LLC","position":4,"cik":"0001760648","reported_name":"OrbiMed Capital GP VII LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24740,"kind":"person","name":"OrbiMed Genesis GP LLC","position":5,"cik":"0001808744","reported_name":"OrbiMed Genesis GP LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series D Preferred Stock","published_at":"2020-11-05T01:00:18.000Z","date":"2020-09-25","kind":"grant","acquired":false,"shares":148395,"price":27.11,"value":4022988.45,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The Series C-2 Preferred Stock, Series C-4 Preferred Stock, Series C-5 Preferred Stock, and Series D Preferred Stock (collectively, the \"Preferred Stock\") was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock converted into Common Stock at a ratio of 2.59970:1 upon the closing of the Issuer's initial public offering without payment of additional consideration. The Preferred Stock had no expiration date."},{"field":"kind","element":"transactionCoding","label":"F6","text":"This transaction occurred prior to the Issuer's initial public offering and is being reported on Form 4 solely for purposes of compliance with Rule 16a-2(a) under the Securities Exchange Act of 1934, as amended. The securities covered by such transaction were previously included on the Reporting Persons' Form 3."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Series C-2 Preferred Stock, Series C-4 Preferred Stock, Series C-5 Preferred Stock, and Series D Preferred Stock (collectively, the \"Preferred Stock\") was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock converted into Common Stock at a ratio of 2.59970:1 upon the closing of the Issuer's initial public offering without payment of additional consideration. The Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The Series C-2 Preferred Stock, Series C-4 Preferred Stock, Series C-5 Preferred Stock, and Series D Preferred Stock (collectively, the \"Preferred Stock\") was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock converted into Common Stock at a ratio of 2.59970:1 upon the closing of the Issuer's initial public offering without payment of additional consideration. The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held of record by OrbiMed Private Investments VII, LP (\"OPI VII\"). OrbiMed Capital GP VII LLC (\"GP VII\") is the general partner of OPI VII and OrbiMed Advisors LLC (\"OrbiMed Advisors\") is the managing member of GP VII. By virtue of such relationships, GP VII and OrbiMed Advisors may be deemed to have voting and investment power over the securities held by OPI VII and as a result may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises its investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and Jonathan T. Silverstein, each of whom disclaims beneficial ownership of the securities held by OPI VII."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"This report on Form 4 is jointly filed by OrbiMed Advisors, GP VII, OrbiMed Advisors Israel II Limited (\"OrbiMed Limited\"), OrbiMed Israel GP II, L.P. (\"OrbiMed Israel\"), and OrbiMed Genesis GP LLC (\"Genesis GP\"). Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its or his pecuniary interest therein, if any. The Reporting Persons have designated a representative, Chau Khuong, an employee of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any of the reporting persons is a beneficial owner of such securities for the purposes of Section 16 of the Exchange Act, or for any other purposes."}],"balance_after":148395,"derivative":{"underlying":"Common Shares","underlying_shares":385782},"source":{"system":"sec-edgar","filing":"0000899243-20-030414","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000089924320030414/doc4.xml","form_type":"4"}},{"id":2993174,"issuer":{"id":4602,"kind":"organization","name":"Damora Therapeutics, Inc.","symbol":"DMRA"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53131,"kind":"organization","name":"OrbiMed Advisors Israel II Ltd","position":2,"cik":"0001682093","reported_name":"OrbiMed Advisors Israel II Ltd","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53132,"kind":"organization","name":"OrbiMed Israel GP II, L.P.","position":3,"cik":"0001682090","reported_name":"OrbiMed Israel GP II, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35791,"kind":"organization","name":"OrbiMed Capital GP VII LLC","position":4,"cik":"0001760648","reported_name":"OrbiMed Capital GP VII LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24740,"kind":"person","name":"OrbiMed Genesis GP LLC","position":5,"cik":"0001808744","reported_name":"OrbiMed Genesis GP LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares","published_at":"2020-11-05T01:00:18.000Z","date":"2020-11-02","kind":"purchase","acquired":true,"shares":209500,"price":15,"value":3142500.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"This report on Form 4 is jointly filed by OrbiMed Advisors, GP VII, OrbiMed Advisors Israel II Limited (\"OrbiMed Limited\"), OrbiMed Israel GP II, L.P. (\"OrbiMed Israel\"), and OrbiMed Genesis GP LLC (\"Genesis GP\"). Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its or his pecuniary interest therein, if any. The Reporting Persons have designated a representative, Chau Khuong, an employee of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any of the reporting persons is a beneficial owner of such securities for the purposes of Section 16 of the Exchange Act, or for any other purposes."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"These securities are held of record by OrbiMed Israel Partners II, L.P. (\"OIP II\"). OrbiMed Israel is the general partner of OIP II, and OrbiMed Limited is the managing member of OrbiMed Israel. By virtue of such relationships, OrbiMed Israel and OrbiMed Limited may be deemed to have voting and investment power over the securities held by OIP II and as a result may be deemed to have beneficial ownership over such securities. OrbiMed Limited exercises its investment and voting power through a management committee comprised of Carl L. Gordon, Jonathan Silverstein, Nissim Darvish, Anat Naschitz, and Erez Chimovits, each of whom disclaims beneficial ownership of the securities held by OIP II."}],"balance_after":1031811,"source":{"system":"sec-edgar","filing":"0000899243-20-030414","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000089924320030414/doc4.xml","form_type":"4"}},{"id":2993173,"issuer":{"id":4602,"kind":"organization","name":"Damora Therapeutics, Inc.","symbol":"DMRA"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53131,"kind":"organization","name":"OrbiMed Advisors Israel II Ltd","position":2,"cik":"0001682093","reported_name":"OrbiMed Advisors Israel II Ltd","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53132,"kind":"organization","name":"OrbiMed Israel GP II, L.P.","position":3,"cik":"0001682090","reported_name":"OrbiMed Israel GP II, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35791,"kind":"organization","name":"OrbiMed Capital GP VII LLC","position":4,"cik":"0001760648","reported_name":"OrbiMed Capital GP VII LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24740,"kind":"person","name":"OrbiMed Genesis GP LLC","position":5,"cik":"0001808744","reported_name":"OrbiMed Genesis GP LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares","published_at":"2020-11-05T01:00:18.000Z","date":"2020-11-02","kind":"purchase","acquired":true,"shares":523833,"price":15,"value":7857495.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held of record by OrbiMed Private Investments VII, LP (\"OPI VII\"). OrbiMed Capital GP VII LLC (\"GP VII\") is the general partner of OPI VII and OrbiMed Advisors LLC (\"OrbiMed Advisors\") is the managing member of GP VII. By virtue of such relationships, GP VII and OrbiMed Advisors may be deemed to have voting and investment power over the securities held by OPI VII and as a result may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises its investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and Jonathan T. Silverstein, each of whom disclaims beneficial ownership of the securities held by OPI VII."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"This report on Form 4 is jointly filed by OrbiMed Advisors, GP VII, OrbiMed Advisors Israel II Limited (\"OrbiMed Limited\"), OrbiMed Israel GP II, L.P. (\"OrbiMed Israel\"), and OrbiMed Genesis GP LLC (\"Genesis GP\"). Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its or his pecuniary interest therein, if any. The Reporting Persons have designated a representative, Chau Khuong, an employee of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any of the reporting persons is a beneficial owner of such securities for the purposes of Section 16 of the Exchange Act, or for any other purposes."}],"balance_after":2579657,"source":{"system":"sec-edgar","filing":"0000899243-20-030414","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000089924320030414/doc4.xml","form_type":"4"}},{"id":2993172,"issuer":{"id":4602,"kind":"organization","name":"Damora Therapeutics, Inc.","symbol":"DMRA"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53131,"kind":"organization","name":"OrbiMed Advisors Israel II Ltd","position":2,"cik":"0001682093","reported_name":"OrbiMed Advisors Israel II Ltd","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53132,"kind":"organization","name":"OrbiMed Israel GP II, L.P.","position":3,"cik":"0001682090","reported_name":"OrbiMed Israel GP II, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35791,"kind":"organization","name":"OrbiMed Capital GP VII LLC","position":4,"cik":"0001760648","reported_name":"OrbiMed Capital GP VII LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24740,"kind":"person","name":"OrbiMed Genesis GP LLC","position":5,"cik":"0001808744","reported_name":"OrbiMed Genesis GP LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares","published_at":"2020-11-05T01:00:18.000Z","date":"2020-11-02","kind":"exercise","acquired":true,"shares":191787,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The Series C-2 Preferred Stock, Series C-4 Preferred Stock, Series C-5 Preferred Stock, and Series D Preferred Stock (collectively, the \"Preferred Stock\") was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock converted into Common Stock at a ratio of 2.59970:1 upon the closing of the Issuer's initial public offering without payment of additional consideration. The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"This report on Form 4 is jointly filed by OrbiMed Advisors, GP VII, OrbiMed Advisors Israel II Limited (\"OrbiMed Limited\"), OrbiMed Israel GP II, L.P. (\"OrbiMed Israel\"), and OrbiMed Genesis GP LLC (\"Genesis GP\"). Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its or his pecuniary interest therein, if any. The Reporting Persons have designated a representative, Chau Khuong, an employee of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any of the reporting persons is a beneficial owner of such securities for the purposes of Section 16 of the Exchange Act, or for any other purposes."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"These securities are held of record by OrbiMed Genesis Master Fund, L.P. (\"Genesis Master Fund\"). Genesis GP is the general partner of Genesis Master Fund and OrbiMed Advisors is the managing member of Genesis GP. By virtue of such relationships, Genesis GP and OrbiMed Advisors may be deemed to have voting and investment power over the securities held by Genesis Master Fund and as a result may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises its investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and Jonathan T. Silverstein, each of whom disclaims beneficial ownership of the securities held by Genesis Master Fund."}],"balance_after":191787,"source":{"system":"sec-edgar","filing":"0000899243-20-030414","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000089924320030414/doc4.xml","form_type":"4"}},{"id":2993171,"issuer":{"id":4602,"kind":"organization","name":"Damora Therapeutics, Inc.","symbol":"DMRA"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53131,"kind":"organization","name":"OrbiMed Advisors Israel II Ltd","position":2,"cik":"0001682093","reported_name":"OrbiMed Advisors Israel II Ltd","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53132,"kind":"organization","name":"OrbiMed Israel GP II, L.P.","position":3,"cik":"0001682090","reported_name":"OrbiMed Israel GP II, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35791,"kind":"organization","name":"OrbiMed Capital GP VII LLC","position":4,"cik":"0001760648","reported_name":"OrbiMed Capital GP VII LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24740,"kind":"person","name":"OrbiMed Genesis GP LLC","position":5,"cik":"0001808744","reported_name":"OrbiMed Genesis GP LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares","published_at":"2020-11-05T01:00:18.000Z","date":"2020-11-02","kind":"exercise","acquired":true,"shares":822311,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The Series C-2 Preferred Stock, Series C-4 Preferred Stock, Series C-5 Preferred Stock, and Series D Preferred Stock (collectively, the \"Preferred Stock\") was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock converted into Common Stock at a ratio of 2.59970:1 upon the closing of the Issuer's initial public offering without payment of additional consideration. The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"This report on Form 4 is jointly filed by OrbiMed Advisors, GP VII, OrbiMed Advisors Israel II Limited (\"OrbiMed Limited\"), OrbiMed Israel GP II, L.P. (\"OrbiMed Israel\"), and OrbiMed Genesis GP LLC (\"Genesis GP\"). Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its or his pecuniary interest therein, if any. The Reporting Persons have designated a representative, Chau Khuong, an employee of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any of the reporting persons is a beneficial owner of such securities for the purposes of Section 16 of the Exchange Act, or for any other purposes."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"These securities are held of record by OrbiMed Israel Partners II, L.P. (\"OIP II\"). OrbiMed Israel is the general partner of OIP II, and OrbiMed Limited is the managing member of OrbiMed Israel. By virtue of such relationships, OrbiMed Israel and OrbiMed Limited may be deemed to have voting and investment power over the securities held by OIP II and as a result may be deemed to have beneficial ownership over such securities. OrbiMed Limited exercises its investment and voting power through a management committee comprised of Carl L. Gordon, Jonathan Silverstein, Nissim Darvish, Anat Naschitz, and Erez Chimovits, each of whom disclaims beneficial ownership of the securities held by OIP II."}],"balance_after":822311,"source":{"system":"sec-edgar","filing":"0000899243-20-030414","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000089924320030414/doc4.xml","form_type":"4"}},{"id":2993170,"issuer":{"id":4602,"kind":"organization","name":"Damora Therapeutics, Inc.","symbol":"DMRA"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53131,"kind":"organization","name":"OrbiMed Advisors Israel II Ltd","position":2,"cik":"0001682093","reported_name":"OrbiMed Advisors Israel II Ltd","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53132,"kind":"organization","name":"OrbiMed Israel GP II, L.P.","position":3,"cik":"0001682090","reported_name":"OrbiMed Israel GP II, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35791,"kind":"organization","name":"OrbiMed Capital GP VII LLC","position":4,"cik":"0001760648","reported_name":"OrbiMed Capital GP VII LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24740,"kind":"person","name":"OrbiMed Genesis GP LLC","position":5,"cik":"0001808744","reported_name":"OrbiMed Genesis GP LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares","published_at":"2020-11-05T01:00:18.000Z","date":"2020-11-02","kind":"exercise","acquired":true,"shares":2055824,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The Series C-2 Preferred Stock, Series C-4 Preferred Stock, Series C-5 Preferred Stock, and Series D Preferred Stock (collectively, the \"Preferred Stock\") was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock converted into Common Stock at a ratio of 2.59970:1 upon the closing of the Issuer's initial public offering without payment of additional consideration. The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held of record by OrbiMed Private Investments VII, LP (\"OPI VII\"). OrbiMed Capital GP VII LLC (\"GP VII\") is the general partner of OPI VII and OrbiMed Advisors LLC (\"OrbiMed Advisors\") is the managing member of GP VII. By virtue of such relationships, GP VII and OrbiMed Advisors may be deemed to have voting and investment power over the securities held by OPI VII and as a result may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises its investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and Jonathan T. Silverstein, each of whom disclaims beneficial ownership of the securities held by OPI VII."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"This report on Form 4 is jointly filed by OrbiMed Advisors, GP VII, OrbiMed Advisors Israel II Limited (\"OrbiMed Limited\"), OrbiMed Israel GP II, L.P. (\"OrbiMed Israel\"), and OrbiMed Genesis GP LLC (\"Genesis GP\"). Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its or his pecuniary interest therein, if any. The Reporting Persons have designated a representative, Chau Khuong, an employee of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any of the reporting persons is a beneficial owner of such securities for the purposes of Section 16 of the Exchange Act, or for any other purposes."}],"balance_after":2055824,"source":{"system":"sec-edgar","filing":"0000899243-20-030414","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000089924320030414/doc4.xml","form_type":"4"}}],"next_cursor":"2020-11-05T01:00:18.000000Z,2993170"}